

HealthSun

HEALTH PLANS

FORMULARY

(List of Covered Drugs)

FÒMILÈ

(Lis Medikaman ki kouvri yo)

2025

Medicare_{Rx}
Prescription Drug Coverage

PLEASE READ: THIS DOCUMENT CONTAINS INFORMATION ABOUT THE DRUGS WE COVER IN THIS PLAN. TANPRI LI: DOKIMAN SA A GENYEN ENFÒMASYON SOU MEDIKAMAN NOU KOUVRI NAN PLAN SA A.

HPMS Approved Formulary ID 25102, Version 10

This formulary was updated on 9/23/2024. For more recent information or other questions, please contact our HealthSun Health Plans Member Services at 1-877-336-2069 / TTY: 711, Monday through Friday from 8 a.m. to 8 p.m. (EST), or visit www.healthsun.com. From October 1 through March 31, we are open seven days a week from 8 a.m. to 8 p.m. (our office will be closed on Thanksgiving and Christmas Day). From April 1 through September 30, we are available Monday through Friday from 8 a.m. to 8 p.m. (our office will be closed on federal holidays). Fòmilè sa a te fè mizajou nan dat 9/23/2024. Pou enfòmasyon ki pi resan oswa lòt kesyon, tanpri kontakte Sèvis Manm HealthSun Health Plans nou an nan 1-877-336-2069 / TTY: 711, Lendi jiska Vandredi soti 8 am jiska 8 pm (LÈS), oswa vizite www.healthsun.com. Soti 1ye oktòb jiska 31 mas, nou ouvri sèt jou pa semèn soti 8 am jiska 8 pm (biwo nou an ap fèmen jou Aksyon de Gras ak Jou Nwèl). Soti 1ye avril jiska 30 septanm, nou disponib Lendi jiska Vandredi de 8 am jiska 8 pm (biwo nou an ap fèmen nan jou ferye federal yo).

HealthSun Health Plans

2025 Formulary List of Covered Drugs

**PLEASE READ: THIS DOCUMENT CONTAINS INFORMATION
ABOUT THE DRUGS WE COVER IN THIS PLAN**

HPMS Approved Formulary File Submission 25102, Version 10

This formulary was updated on **09/23/2024**. For more recent information or other questions, please contact HealthSun Health Plans Member Services at 1-877-336-2069 (TTY users should call 1-877-206-0500), from 8am to 8pm, EST., or visit www.healthsun.com. Ours hours of operations during October 1st through March 31st, we are open seven days a week (our office will be closed on Thanksgiving and Christmas Day). From April 1st until September 30th, we are available Monday through Friday from 8am to 8pm (our office will be closed on federal holidays).

Note to existing members: This Formulary has changed since last year. Please review this document to make sure that it still contains the drugs you take.

When this Drug List (Formulary) refers to “we,” “us”, or “our,” it means HealthSun Health Plans. When it refers to “plan” or “our plan,” it means HealthSun Health Plans.

This document includes the Drug List (formulary) for our plan which is current as of **09/23/2024**. For an updated Drug Lis (formulary), please contact us. Our contact information, along with the date we last updated the Drug List (formulary), appears on the front and back cover pages.

You must generally use network pharmacies to use your prescription drug benefit. Benefits, formulary, pharmacy network, and/or copayments/coinsurance may change on January 1, 2026, and from time to time during the year.

What is the HealthSun Health Plans formulary?

In this document, we use the terms Drug List and formulary to mean the same thing. A formulary is a list of covered drugs selected by HealthSun Health Plans in consultation with a team of health care providers, which represents the prescription therapies believed to be a necessary part of a quality treatment program. HealthSun Health Plans will generally cover the drugs listed in our formulary as long as the drug is medically necessary, the prescription is filled at a HealthSun Health Plans network pharmacy, and other plan rules are followed. For more information on how to fill your prescriptions, please review your Evidence of Coverage.

For a complete listing of all prescription drugs covered by HealthSun Health Plans, please visit our website or call us. Our contact information, along with the date we last updated the formulary, appears on the front and back cover pages.

Can the formulary change?

Most changes in drug coverage happen on January 1, but we may add or remove drugs on the formulary during the year, move them to different cost-sharing tiers, or add new restrictions. We must follow the Medicare rules in making these changes. Updates to the formulary are posted monthly to our website here:

<https://healthsun.com/plans-coverage/prescription-drug-benefits/>

Y0114_25_3014545_0000_T_C

Changes that can affect you this year: In the below cases, you will be affected by coverage changes during the year:

- **Immediate substitutions of certain new versions of brand name drugs and original biological products.** We may immediately remove a drug from our formulary if we are replacing it with a certain new version of that drug that will appear on the same or lower cost-sharing tier and with the same or fewer restrictions. When we add a new version of a drug to our formulary, we may decide to keep the brand name drug or original biological product on our formulary, but immediately move it to a different cost-sharing tier or add new restrictions.

We can make these immediate changes only if we are adding a new generic version of a brand name drug or adding certain new biosimilar versions of an original biological product, that was already on the formulary (for example, adding an interchangeable biosimilar that can be substituted for an original biological product by a pharmacy without a new prescription).

If you are currently taking the brand name drug or original biological product, we may not tell you in advance before we make an immediate change, but we will later provide you with information about the specific change(s) we have made.

If we make such a change, you or your prescriber can ask us to make an exception and continue to cover for you the drug that is being changed. For more information, see the section below titled “How do I request an exception to HealthSun Health Plans’ Formulary?”

Some of these drug types may be new to you. For more information, see the section below titled “What are original biological products and how are they related to biosimilars?”

- **Drugs removed from the market.** If a drug is withdrawn from sale by the manufacturer or the Food and Drug Administration (FDA) determines to be withdrawn for safety or effectiveness reasons, we may immediately remove the drug from our formulary and later provide notice to members who take the drug.
- **Other changes.** We may make other changes that affect members currently taking a drug. For instance, we may remove a brand name drug from the formulary when adding a generic equivalent or remove an original biological product when adding a biosimilar. We may also apply new restrictions to the brand name drug or original biological product or move it to a different cost-sharing tier, or both. We may make changes based on new clinical guidelines. If we remove drugs from our formulary, add prior authorization, quantity limits and/or step therapy restrictions on a drug, or move a drug to a higher cost-sharing tier, we must notify affected members of the change at least 30 days before the change becomes effective. Alternatively, when a member requests a refill of the drug, they may receive a 30-day supply of the drug and notice of the change.

If we make these other changes, you or your prescriber can ask us to make an exception for you and continue to cover the drug you have been taking. The notice we provide you will also include information on how to request an exception, and you can also find information in the section below entitled “How do I request an exception to the HealthSun Health Plans’ Formulary?”

Changes that will not affect you if you are currently taking the drug. Generally, if you are taking a drug on our 2025 formulary that was covered at the beginning of the year, we will not discontinue or reduce coverage of the drug during the 2025 coverage year except as described above. This means these drugs will remain available at the same cost sharing and with no new restrictions for those members taking them for the remainder of the coverage year. You will not get direct notice this year about changes that do not affect you. However, on January 1 of the next year, such changes would affect you, and it is important to check the formulary for the new benefit year for any changes to drugs.

The enclosed formulary is current as of **09/23/2024**. To get updated information about the drugs covered by HealthSun Health Plans please contact us. Our contact information appears on the front and back cover pages

How do I use the Formulary?

There are two ways to find your drug within the formulary:

Medical Condition

The formulary begins on page 20. The drugs in this formulary are grouped into categories depending on the type of medical conditions that they are used to treat. For example, drugs used to treat a heart condition are listed under the category, “cardiovascular agents.” If you know what your drug is used for, look for the category name in the list that begins on 20. Then look under the category name for your drug.

Alphabetical Listing

If you are not sure what category to look under, you should look for your drug in the Index that begins on page 118. The Index provides an alphabetical list of all of the drugs included in this document. Both brand name drugs and generic drugs are listed in the Index. Look in the Index and find your drug. Next to your drug, you will see the page number where you can find coverage information. Turn to the page listed in the Index and find the name of your drug in the first column of the list.

What are generic drugs?

HealthSun Health Plans covers both brand name drugs and generic drugs. A generic drug is approved by the FDA as having the same active ingredient as the brand name drug. Generally, generic drugs work just as well as and usually cost less than brand name drugs. There are generic drug substitutes available for many brand name drugs. Generic drugs usually can be substituted for the brand name drug at the pharmacy without needing a new prescription, depending on state laws.

What are original biological products and how are they related to biosimilars?

On the formulary, when we refer to drugs, this could mean a drug or a biological product. Biological products are drugs that are more complex than typical drugs. Since biological products are more complex than typical drugs, instead of having a generic form, they have alternatives that are called biosimilars. Generally, biosimilars work just as well as the original biological product and may cost less. There are biosimilar alternatives for some original biological products. Some biosimilars are interchangeable biosimilars and, depending on state laws, may be substituted for the original biological product at the pharmacy without needing a new prescription, just like generic drugs can be substituted for brand name drugs.

- For discussion of drug types, please see the Evidence of Coverage, Chapter 5, Section 3.1, “The ‘Drug List’ tells which Part D drugs are covered.

Are there any restrictions on my coverage?

Some covered drugs may have additional requirements or limits on coverage. These requirements and limits may include:

- **Prior Authorization:** HealthSun Health Plans requires you or your prescriber to get prior authorization for certain drugs. This means that you will need to get approval from HealthSun Health Plans before you fill your prescriptions. If you don't get approval, HealthSun Health Plans may not cover the drug.
- **Quantity Limits:** For certain drugs, HealthSun Health Plans limits the amount of the drug that HealthSun Health Plans will cover. For example, HealthSun Health Plans provides 30 tabs per prescription for TRADJENTA. This may be in addition to a standard one-month or three-month supply.
- **Step Therapy:** In some cases, HealthSun Health Plans requires you to first try certain drugs to treat your medical condition before we will cover another drug for that condition. For example, if Drug A and Drug B both treat your medical condition HealthSun Health Plans may not cover Drug B unless you try Drug A first. If Drug A does not work for you, HealthSun Health Plans will then cover Drug B.

You can find out if your drug has any additional requirements or limits by looking in the formulary that begins on page 20. You can also get more information about the restrictions applied to specific covered drugs by visiting our website. We have posted online documents that explain our prior authorization and step therapy restrictions. You may also ask us to send you a copy. Our contact information, along with the date we last updated the formulary, appears on the front and back cover pages.

You can ask HealthSun Health Plans to make an exception to these restrictions or limits or for a list of other, similar drugs that may treat your health condition. See the section, "How do I request an exception to the HealthSun Health Plans' formulary?" on this page for information about how to request an exception.

What if my drug is not on the Formulary?

If your drug is not included in this formulary (list of covered drugs), you should first contact Member Services and ask if your drug is covered. For more information, please contact us. Our contact information, along with the date we last updated the formulary, appears on the front and back cover pages.

If you learn that HealthSun Health Plans does not cover your drug, you have two options:

- You can ask Member Services for a list of similar drugs that are covered by HealthSun Health Plans. When you receive the list, show it to your doctor and ask them to prescribe a similar drug that is covered by HealthSun Health Plans.
- You can ask HealthSun Health Plans to make an exception and cover your drug. See below for information about how to request an exception.

How do I request an exception to HealthSun Health Plans' Formulary?

You can ask HealthSun Health Plans to make an exception to our coverage rules. There are several types of exceptions that you can ask us to make.

- You can ask us to cover a drug even if it is not on our formulary. If approved, this drug will be covered at a pre-determined cost-sharing level, and you would not be able to ask us to provide the drug at a lower cost-sharing level.

- You can ask us to waive a coverage restriction including prior authorization, step therapy, or a quantity limit on your drug. For example, for certain drugs, HealthSun Health Plans limits the amount of the drug that we will cover. If your drug has a quantity limit, you can ask us to waive the limit and cover a greater amount.
- You can ask us to cover a formulary drug at lower cost-sharing level unless the drug is on the specialty tier. If approved, this would lower the amount you must pay for your drug.

Generally, HealthSun Health Plans will only approve your request for an exception if the alternative drugs included on the plan's formulary, the lower cost-sharing drug, or applying the restriction would not be as effective for you and/or would cause you to have adverse effects.

You or your prescriber should contact us to ask for a tiering or formulary exception, including an exception to a coverage restriction. **When you request an exception, your prescriber will need to explain the medical reasons why you need the exception.** Generally, we must make our decision within 72 hours of getting your prescriber's supporting statement. You can ask for an expedited (fast) decision if you believe, and we agree, that your health could be seriously harmed by waiting up to 72 hours for a decision. If we agree, or if your prescriber asks for a fast decision, we must give you a decision no later than 24 hours after we get your prescriber's supporting statement.

What can I do if my drug is not on the formulary or has a restriction?

As a new or continuing member in our plan you may be taking drugs that are not on our formulary. Or, you may be taking a drug that is on our formulary but has a coverage restriction, such as prior authorization. You should talk to your prescriber about requesting a coverage decision to show that you meet the criteria for approval, switching to an alternative drug that we cover, or requesting a formulary exception so that we will cover the drug you take. While you and your doctor determine the right course of action for you, we may cover your drug in certain cases during the first 90 days you are a member of our plan.

For each of your drugs that is not on our formulary or has a coverage restriction, we will cover a temporary 30-day supply. If your prescription is written for fewer days, we'll allow refills to provide up to a maximum 30-day supply of medication. If coverage is not approved, after your first 30-day supply, we will not pay for these drugs, even if you have been a member of the plan less than 90 days.

If you are a resident of a long-term care facility and you need a drug that is not on our formulary or if your ability to get your drugs is limited, but you are past the first 90 days of membership in our plan, we will cover a 34-day emergency supply of that drug while you pursue a formulary exception.

HealthSun Health Plans transition process will be maintained with respect to the following: **(1)** the transition of new members into the plan during the annual election period; **(2)** the transition of newly eligible Medicare members from other coverage into our plan; **(3)** the transition of individuals who switch from one Plan to another after the start of the contract year; **(4)** members residing in a Long Term care (LTC) Facility; **(5)** current members affected by negative formulary changes from one contract year to the next contract year; **(6)** members who request an exception but there is a failure to issue a timely decision on the request by the end of the transition period; **(7)** members who remain in the same plan for the new plan year and are on a drug that was the result of an exception that was granted in the previous year; **(8)** current members experiencing a level of care change; **(9)** current members entering the LTC setting from other care settings; and **(10)** current members in a LTC setting requiring an emergency supply of a nonformulary drug.

For more information

For more detailed information about your HealthSun Health Plans prescription drug coverage, please review your Evidence of Coverage and other plan materials.

If you have questions about HealthSun Health Plans, please contact us. Our contact information, along with the date we last updated the formulary, appears on the front and back cover pages.

If you have general questions about Medicare prescription drug coverage, please call Medicare at 1-800-MEDICARE (1-800-633-4227) 24 hours a day/7 days a week. TTY users should call 1-877-486-2048. Or, visit <http://www.medicare.gov>.

HealthSun Health Plans Formulary

The formulary that begins on page 20 provides coverage information about the drugs covered by HealthSun Health Plans. If you have trouble finding your drug in the list, turn to the Index that begins on page 118.

The first column of the chart lists the drug name. Brand name drugs are capitalized (e.g., ENTRESTO and generic drugs are listed in lower-case italics (e.g., *simvastatin tab*).

The information in the Requirements/Limits column tells you if HealthSun Health Plans has any special requirements for coverage of your drug.

Certain drugs throughout the formulary will be marked with one or more symbols to indicate their application, such as utilization management restrictions and requirements, mail order availability, drugs limited to a one month supply (even when the drug is on a tier that allows for an extended day supply), excluded Part D drugs covered by the plan, limited access, mail order drugs, tier names, and other coverage information.

The Drug Table starting on page 22 includes a column titled, “Drug Tier”. This column indicates what tier each drug is listed under. The table starting on page 8 provides the copayments/coinsurances associated with the corresponding tiers if you receive the drug at an in-network pharmacy. These copayments/coinsurances apply during the initial coverage phase. Please refer to your *Evidence of Coverage* for what you pay during the catastrophic coverage stage. If you receive “Extra Help”, some information about the costs for Part D prescription drugs may not apply to you. Refer to your *Evidence of Coverage Rider for People Who Get "Extra Help" Paying for Prescription Drugs* (also known as the Low-Income Subsidy Rider or the LIS Rider), which tells you about your drug coverage.

| Tier | Drug Tier Name |
|------|--|
| 1 | Preferred Generic |
| 2 | Generic |
| 3 | Preferred Brand |
| 4 | Non-Preferred Drug |
| 5 | Specialty Tier |
| 6 | Supplemental Drugs (enhanced drug coverage) |

Preferred Retail Pharmacy / Mail Order Pharmacy

| HealthSun Plan Name | Tier 1 30-day supply (up to a 100-day supply for some medications) | Ter 2 30-day supply (up to a 90-day supply for some medications) | Tier 3 30-day supply | Insulin Drugs Tier 3 30-day supply | Tier 4 30-day supply | Tier 5 30-day supply | Tier 6 30-day supply |
|--|---|---|-------------------------------------|---|-------------------------------------|-------------------------------------|-------------------------------------|
| HealthAdvantage Plan (HMO) Miami-Dade 001 | \$0 | \$0 | \$0 | \$0 | \$30 | 33% | \$0 |
| HealthAdvantage Plan (HMO) Broward 012 | \$0 | \$0 | \$5 | \$5 | \$30 | 33% | \$0 |
| HealthAdvantage Plan (HMO) Palm Beach 013 | \$0 | \$0 | \$15 | \$15 | \$30 | 33% | \$0 |
| HealthAdvantage Plus (HMO) Miami-Dade 017 | \$0 | \$0 | \$10 | \$10 | \$30 | 33% | \$0 |
| HealthAdvantage Plus (HMO) Broward 018 | \$0 | \$0 | \$5 | \$5 | \$50 | 33% | \$0 |
| HealthAdvantage Plus (HMO) Palm Beach 020 | \$0 | \$0 | \$42 | \$35 | \$95 | 33% | \$0 |
| *MediMax (HMO) Miami-Dade/Broward 006 | \$0 | \$0 | \$25* | \$25* | 25%* | 25%* | \$0 |
| * MediSun Plus (HMO D-SNP) Palm Beach 016 | \$0 | \$0 | \$0 | \$0 | \$0 | \$0 | \$0 |
| * MediSun Extra (HMO D-SNP) Miami-Dade/Broward 019 | \$0 | \$0 | \$0 | \$0 | \$0 | \$0 | \$0 |
| VitalCare (HMO C-SNP) Miami-Dade/Broward 021 | \$0 | \$0 | \$37 | \$35 | \$85 | 33% | \$0 |
| VitalCare (HMO C-SNP) Palm Beach 022 | \$0 | \$0 | \$37 | \$35 | \$85 | 33% | \$0 |

Standard Retail Pharmacy

| HealthSun Plan Name | Tier 1 30-day supply (up to a 100-day supply for some medications) | Tier 2 30-day supply (up to a 90-day supply for some medications) | Tier 3 30-day supply | Insulin Drugs Tier 3 30-day supply | Tier 4 30-day supply | Tier 5 30-day supply | Tier 6 30-day supply |
|--|---|--|-------------------------------------|---|-------------------------------------|-------------------------------------|-------------------------------------|
| HealthAdvantage Plan (HMO) Miami-Dade 001 | \$0 | \$0 | \$20 | \$0 | \$35 | 33% | \$0 |
| HealthAdvantage Plan (HMO) Broward 012 | \$0 | \$0 | \$20 | \$5 | \$35 | 33% | \$0 |
| HealthAdvantage Plan (HMO) Palm Beach 013 | \$0 | \$0 | \$20 | \$15 | \$35 | 33% | \$0 |
| HealthAdvantage Plus (HMO) Miami-Dade 017 | \$0 | \$0 | \$10 | \$10 | \$35 | 33% | \$0 |
| HealthAdvantage Plus (HMO) Broward 018 | \$0 | \$0 | \$5 | \$5 | \$55 | 33% | \$0 |
| HealthAdvantage Plus (HMO) Palm Beach 020 | \$0 | \$0 | \$47 | \$35 | \$100 | 33% | \$0 |
| *MediMax (HMO) Miami-Dade/Broward 006 | \$0 | \$0 | \$25* | \$25* | 25%* | 25%* | \$0 |
| * MediSun Plus (HMO D-SNP) Palm Beach 016 | \$0 | \$0 | \$0 | \$0 | \$0 | \$0 | \$0 |
| * MediSun Extra (HMO D-SNP) Miami-Dade/Broward 019 | \$0 | \$0 | \$0 | \$0 | \$0 | \$0 | \$0 |
| VitalCare (HMO C-SNP) Miami-Dade/Broward 021 | \$0 | \$0 | \$42 | \$35 | \$90 | 33% | \$0 |
| VitalCare (HMO C-SNP) Palm Beach 022 | \$0 | \$0 | \$42 | \$35 | \$90 | 33% | \$0 |

**Members enrolled in HealthSun MediMax (HMO) / PBP 006, MediSun Plus (HMO D-NSP) / PBP 016 or MediSun Extra (HMO D-NSP) / PBP 019 If you receive “Extra Help”, this plan will cover all of your Medicare-covered Part D drugs included on the plan formulary at a \$0.00 copay during the Deductible, Initial, and Catastrophic coverage stages.*

Please refer to your plan's *Evidence of Coverage* for details on what you pay at a long-term care pharmacy or at an out-of-network pharmacy when approved by the plan.

Abbreviations

| SYMBOL | NAME | ABBREVIATION DESCRIPTION |
|---------------|--|---|
| 90D | 90 Day Benefit | This drug is approved for a 90-day supply. |
| 100D | 100 Day Benefit | This drug is approved for a 100-day supply. |
| B/D PA | Part B vs. Part D Prior Authorization Review | This drug may be covered under Medicare Part B or Medicare Part D depending upon the circumstances. |
| ED | Enhanced Drug Coverage | Coverage for excluded Medicare Part D Drugs. This prescription drug is not normally covered in a Medicare Prescription Drug Plan. The amount you pay when you fill a prescription for this drug does not count towards your total drug costs (that is, the amount you pay does not help you qualify for catastrophic coverage). In addition, if you are receiving extra help to pay for your prescriptions, you will not get any extra help to pay for this drug. |
| HRM | High Risk Medication | PA required for ages 65 or over. |
| LA | Limited Access | This prescription may be available only at certain pharmacies. For more information consult your Pharmacy Directory or call Member Services at 1-877-336-2069 (TTY users should call 1-877-206-0500), from 8 am to 8 pm, or visit www.HealthSun.com . From October 1st through March 31st, we are open seven days a week (our office will be closed on Thanksgiving and Christmas Day). From April 1st until September 30th, we are available Monday through Friday from 8 am to 8 pm (our office will be closed on federal holidays). |
| NEDS | Non-Extended Days Supply | This drug is approved for no more than a 30-day supply. |
| MO | Mail-Order | This drug is available at our mail order pharmacies. |
| PA | Prior Authorization | You (or your physician) are required to get prior authorization before you fill your prescription for this drug; without prior approval, we may not cover this drug. |
| QL | Quantity Limit | There is a limit on the amount of this drug that is covered per prescription, or within a specific timeframe. Certain drugs marked “QL” for quantity limit will indicate the amount (days’ supply or amount dispensed). |
| ST | Step Therapy | In some cases, you may be required to first try certain drugs to treat your medical condition before we will cover another drug for that condition. |

HealthSun Health Plans

2025 fòmilè Lis Medikaman ki Kouvri yo

TANPRI LI: DOKIMAN SA GENYEN ENFÒMASYON

SOU MEDIKAMAN NOU KOVRI NAN PLAN SA A

HPMS Apwouve Fòmilè Soumisyon Dosye 25102, Version 10

Fòmilè sa a te fè mizajou nan dat **09/23/2024**. Pou plis enfòmasyon resan oswa lòt kesyon, tanpri kontakte Sèvis Manm HealthSun Health Plans nan 1-877-336-2069 (itilizatè TTY yo ta dwe rele 1-877-206-0500), soti 8am jiska 8pm, EST., oswa vizite www.healthsun.com. Orè operasyon nou yo pandan 1ye oktòb jiska 31 mas, nou ouvri sèt jou pa semèn (biwo nou an ap fèmen jou Aksyon de Gras ak Jou Nwèl). Soti 1ye avril jiska 30 septanm, nou disponib Lendi jiska Vandredi soti 8am jiska 8pm (biwo nou an ap fèmen nan jou ferye federal yo).

Avi pou manm ki deja egziste yo: Fòmilè sa a te chanje depi ane pase. Tanpri revize dokiman sa a pou asire w ke li toujou genyen medikaman w ap pran yo.

Lè Lis Medikaman sa a (Fòmilè) refere a “nou”, “nou menm”, oswa “pa nou”, sa vle di HealthSun Health Plans. Lè li refere a "plan" oswa "plan nou an," sa vle di HealthSun Health Plans.

Dokiman sa a gen ladann Lis Medikaman an (fòmilè) pou plan nou an ki aktyèl apati **09/23/2024**. Pou yon Lis Medikaman aktyalize (fòmilè), tanpri kontakte nou. Enfòmasyon kontak nou yo, ansanm ak dènye dat nou te mete ajou Lis Medikaman an (fòmilè), parèt sou paj devan ak dèyè yo.

Ou dwe jeneralman itilize famasi rezo yo pou itilize avantaj medikaman sou preskripsyon ou. Avantaj, fòmilè, rezo famasi, ak/oswa kopeman/koasirans ka chanje apati 1ye janvyè 2026, epi detanzantan pandan ane a.

Kisa fòmilè HealthSun Health Plans la ye?

Nan dokiman sa a, nou itilize tèms Lis Medikaman ak fòmilè ki vle di menm bagay. Yon fòmilè se yon lis medikaman ki kouvri HealthSun Health Plans chwazi an konsiltasyon ak yon ekip pwofesyonèl swen sante, ki reprezante terapi sou preskripsyon yo kwè ke se yon pati nesèsè nan yon pwogram tretman kalite. Anjeneral, HealthSun Health Plans pral kouvri medikaman ki endike nan fòmilè nou an toutotan medikaman an nesèsè sou plan medikal, preskripsyon an ranpli nan yon famasi rezo HealthSun Health Plans, epi yo swiv lòt règ plan an. Pou plis enfòmasyon sou fason pou ranpli preskripsyon ou yo, tanpri revize Prèk Kouvèti ou a.

Pou jwenn yon lis konplè sou tout medikaman sou preskripsyon HealthSun Health Plans kouvri, tanpri vizite sit entènèt nou an oswa rele nou. Enfòmasyon kontak nou yo, ansanm ak dènye dat nou te fè mizajou fòmilè a, parèt sou paj devan ak dèyè yo.

Èske fòmilè a ka chanje?

Pifò chanjman nan kouvèti medikaman fèt sou 1ye janvyè, men nou ka ajoute oswa retire medikaman nan fòmilè a pandan ane a, deplase yo nan diferan nivo pataj pri, oswa ajoute nouvo restriksyon. Nou dwe suiv règ Medicare yo lè nou fè chanjman sa yo. Mizajou nan fòmilè a afiche chak mwa sou sit entènèt nou an isit la:

<https://healthsun.com/plans-coverage/prescription-drug-benefits/>

Chanjman ki ka afekte ou ane sa a: Nan ka sa yo ki anba a, chanjman kouvèti asirans yo pral afekte w pandan ane a:

- **Ranplasman imedyat sèten nouvo vèsyon medikaman mak ak pwodwi byolojik orijinal yo.** Nou ka retire imedyatman yon medikaman nan fòmilè nou an si n ap ranplase li ak yon sèten nouvo vèsyon medikaman sa a ki pral parèt sou menm nivo oswa pi ba pri pataje epi avèk menm restriksyon oswa mwens. Lè nou ajoute yon nouvo vèsyon yon medikaman nan fòmilè nou an, nou ka deside kenbe medikaman mak la oswa pwodwi byolojik orijinal la sou fòmilè nou an, men imedyatman deplase li nan yon nivo pataj pri diferan oswa ajoute nouvo restriksyon.

Nou ka fè chanjman imedyat sa yo sèlman si nou ajoute yon nouvo vèsyon jenerik yon medikaman mak oswa ajoute sèten nouvo vèsyon byosimilè nan plas yon pwodwi byolojik orijinal, ki te deja sou fòmilè a (pa egzanp, ajoute yon byosimilè ki ka ranplase yon pwodwi byolojik orijinal pa yon famasi san yon nouvo preskripsyon).

Si w ap pran medikaman mak oswa pwodwi byolojik orijinal la kounye a, nou ka pa di w alavans anvan nou fè yon chanjman imedyat, men pita n ap ba w enfòmasyon sou chanjman espesifik nou te fè a.

Si nou fè yon chanjman konsa, oumenm oswa moun k ap preskri w la ka mande nou pou nou fè yon eksepsyon epi pou nou kontinye kouvri medikaman k ap chanje a pou ou. Pou plis enfòmasyon, gade seksyon ki anba a ki gen tit "Kijan pou mwen mande yon eksepsyon nan Fòmilè HealthSun Health Plans?"

Kèk nan kalite medikaman sa yo ka nouvo pou ou. Pou plis enfòmasyon, gade seksyon ki anba a ki rele "Kisa ki pwodwi byolojik orijinal e ki rapò yo genyen ak byosimilè?"

- **Medikaman yo retire sou mache a.** Si fabrikan an retire yon medikaman sou mache a oswa Administrasyon Manje ak Medikaman (FDA) deside retire l pou rezon sekirite oswa efikasite, nou ka retire medikaman an imedyatman nan fòmilè nou an epi pita bay manm ki pran medikaman an avètisman.
- **Lòt chanjman.** Nou ka fè lòt chanjman ki afekte manm k ap pran yon medikaman nan moman an. Pa egzanp, nou ka retire yon medikaman ki gen mak nan fòmilè a epi nou ajoute yon ekivalan jenerik oswa retire yon pwodwi byolojik orijinal epi nou ajoute yon byosimilè. Nou ka aplike tou nouvo restriksyon sou medikaman mak oswa pwodwi byolojik orijinal la oswa deplase li nan yon nivo pataj pri diferan, oswa fè toude. Nou ka fè chanjman ki baze sou nouvo gid klinik. Si nou retire medikaman nan fòmilè nou an, ajoute otorizasyon alavans, limit kantite ak/oswa restriksyon etap terapi sou yon medikaman, oswa deplase yon medikaman nan yon nivo pi wo pataj pri, nou dwe notifye manm ki afekte yo sou chanjman an omwen 30 jou anvan chanjman vin efektif. Altènativman, lè yon manm mande yon renouvèlman medikaman an, yo ka resevwa yon rezèv pou 30 jou medikaman an ak yon avi sou chanjman an.

Si nou fè lòt chanjman sa yo, oumenm oswa moun k ap preskri w la ka mande nou pou fè yon eksepsyon pou ou epi kontinye kouvri medikaman w ap pran an. Avi nou ba ou a pral genyen tou

enfòmasyon sou fason pou mande yon eksepsyon, epi ou ka jwenn enfòmasyon tou nan seksyon ki anba a ki rele “Kijan pou mwen mande yon eksepsyon nan Fòmilè HealthSun Health Plans?”

Chanjman ki pap afekte w si w ap pran medikaman an nan moman sa a. Anjeneral, si w ap pran yon medikaman ki sou fòmilè 2025 nou an ki te kouvri nan kòmansman ane a, nou p ap sispann oswa redwi kouvèti medikaman an pandan ane kouvèti 2025 la eksepte jan sa dekri pi wo a. Sa vle di medikaman sa yo ap rete disponib nan menm pataj pri epi yo pa gen okenn nouvo restriksyon pou manm sa yo k ap pran yo pandan rès ane kouvèti asirans lan. Ou p ap resevwa avi dirèk ane sa a sou chanjman ki pa afekte w. Sepandan, nan dat 1ye janvye ane kap vini an, chanjman sa yo ka pral afekte w, e li enpòtan pou verifye fòmilè a pou nouvo ane avantaj la pou nenpòt chanjman nan medikaman yo.

Fòmilè ki nan anvlòp la ajou apati **09/23/2024**. Pou jwenn enfòmasyon ajou sou medikaman ki kouvri yo nan HealthSun Health Plans tanpri kontakte nou. Enfòmasyon kontak nou yo parèt sou paj kouvèti devan ak dèyè yo

Kouman pou m itilize fòmilè a?

Gen de fason pou jwenn medikaman ou nan fòmilè a:

Kondisyon Medikal

Fòmilè a kòmanse nan paj 20. Medikaman ki nan fòmilè sa a gwoupe an kategori selon kalite kondisyon medikal ki itilize yo pou tretman. Pa egzanp, medikaman yo itilize pou trete yon maladi kè nan lis ki anba kategori, "ajan kadyovaskilè." Si ou konnen pou kisa medikaman ou a itilize, chèche non kategori a nan lis ki kòmanse sou 20 la. Apre sa a, gade anba non kategori a pou medikaman ou a.

Lis Alfabetik

Si w pa sèten ki kategori pou w gade, ou ta dwe chèche medikaman w lan nan Endèks ki kòmanse nan paj 118 la. Endèks la bay yon lis alfabetik tout medikaman ki enkli nan dokiman sa a. Toude medikaman mak ak medikaman jenerik yo nan lis Endèks la. Gade nan endèks la epi jwenn medikaman ou a. Akote medikaman w la, w ap wè nimewo paj la kote w ka jwenn enfòmasyon sou kouvèti a. Ale nan paj ki nan Endèks la epi jwenn non medikaman w lan nan premye kolòn lis la.

Kisa ki medikaman jenerik?

HealthSun Health Plans kouvri toude medikaman mak ak medikaman jenerik. Yon medikaman jenerik apwouve pa FDA kòm kwa li gen menm engredyan aktif ak medikaman non mak la. Anjeneral, medikaman jenerik travay menm jan e anjeneral yo koute mwens pase medikaman ki gen mak. Gen ranplasan medikaman jenerik ki disponib pou anpil medikaman mak. Anjeneral, medikaman jenerik yo ka ranplase medikaman mak la nan famasi san yo pa bezwen yon nouvo preskripsyon, selon lwa eta a..

Kisa ki pwodwi byolojik orijinal e ki rapò yo genyen ak byosimilè yo?

Sou fòmilè a, lè nou refere a medikaman, sa ka vle di yon medikaman oswa yon pwodwi byolojik. Pwodwi byolojik yo se medikaman ki pi konplèks pase medikaman tipik yo. Kòm pwodwi byolojik yo pi konplèks pase medikaman tipik yo, olye pou yo gen yon fòm jenerik, yo gen altènativ ki rele byosimilè. Anjeneral, byosimilè travay menm jan ak pwodwi byolojik orijinal la epi yo ka koute mwens. Gen altènativ byosimilè pou kèk pwodwi byolojik orijinal. Gen kèk byosimilè ki ka ranplase lòt byosimilè epi, selon lwa eta a, yo ka ranplase pwodwi byolojik orijinal la nan famasi a san yo pa bezwen yon nouvo preskripsyon, menm jan medikaman jenerik yo ka ranplase medikaman mak yo.

- Pou diskisyon sou kalite medikaman yo, tanpri gade Prèv Kouvèti a, Chapit 5, Seksyon 3.1, “Lis Medikaman an' di ki medikaman Pati D ki kouvri.

Èske gen okenn restriksyon sou kouvèti mwen an?

Gen kèk medikaman ki kouvri ki ka gen lòt kondisyon oswa limit sou kouvèti asirans. Kondisyon ak limit sa yo ka enkli:

- **Otorizasyon Davans:** HealthSun Health Plans mande oumenm oswa moun k ap preskri w la pou jwenn otorizasyon davans pou sèten medikaman. Sa vle di w ap bezwen jwenn apwobasyon HealthSun Health Plans anvan ou ranpli preskripsyon w yo. Si w pa jwenn apwobasyon, HealthSun Health Plans ka pa kouvri medikaman an.
- **Limit Kantite:** Pou sèten medikaman, HealthSun Health Plans limite kantite medikaman HealthSun Health Plans pral kouvri. Pa egzanp, HealthSun Health Plans bay 30 tab pa preskripsyon pou TRADJENTA. Sa a ka anplis de yon rezèv estanda yon mwa oswa twa mwa.
- **Etap Terapi:** Nan kèk ka, HealthSun Health Plans mande pou w eseye an premye sèten medikaman pou trete kondisyon medikal ou anvan nou pral kouvri yon lòt medikaman pou kondisyon sa a. Pa egzanp, si Medikaman A ak Medikaman B tou de trete kondisyon medikal ou HealthSun Health Plans ka pa kouvri Medikaman B sof si ou eseye Medikaman A dabò. Si Medikaman A pa travay pou ou, HealthSun Health Plans pral kouvri Medikaman B.

Ou ka chèche konnen si medikaman ou a gen nenpòt lòt kondisyon oswa limit lè w gade nan fòmilè ki kòmanse nan paj 20 la. Ou ka jwenn plis enfòmasyon tou sou restriksyon ki aplike pou medikaman espesifik ki kouvri yo lè w vizite sit entènèt nou an. Nou afiche dokiman sou Entènèt ki eksplike restriksyon otorizasyon davans ak etap terapi nou yo. Ou ka mande nou tou pou voye yon kopi ba ou. Enfòmasyon kontak nou yo, ansanm ak dènye dat nou te fè mizajou fòmilè a, parèt sou paj devan ak dèyè yo.

Ou ka mande HealthSun Health Plans pou fè yon eksepsyon nan restriksyon oswa limit sa yo oswa pou yon lis lòt medikaman analogik ki ka trete kondisyon sante ou. Gade seksyon, "Kijan pou mwen mande yon eksepsyon nan fòmilè HealthSun Health Plans an?" nan paj 15 pou enfòmasyon sou fason pou mande yon eksepsyon.

E si medikaman mwen an pa nan fòmilè a?

Si medikaman ou a pa enkli nan fòmilè sa a (lis medikaman ki kouvri), ou ta dwe kontakte Sèvis Manm yo dabò epi mande si medikaman ou an kouvri. Pou plis enfòmasyon, tanpri kontakte nou. Enfòmasyon kontak nou yo, ansanm ak dènye dat nou te fè mizajou fòmilè a, parèt sou paj devan ak dèyè yo.

Si w aprann HealthSun Health Plans pa kouvri medikaman w la, ou gen de opsyon:

- Ou ka mande Sèvis Manm yo yon lis medikaman ki analogik ke HealthSun Health Plans kouvri. Lè w resevwa lis la, montre doktè w la epi mande l pou li preskri yon medikaman ki sanble HealthSun Health Plans kouvri.
- Ou ka mande HealthSun Health Plans pou fè yon eksepsyon epi kouvri medikaman w lan. Gade pi ba a pou enfòmasyon sou fason pou mande yon eksepsyon.

Kouman pou mwen mande yon eksepsyon nan Fòmilè HealthSun Health Plans?

Ou ka mande HealthSun Health Plans pou fè yon eksepsyon nan règ kouvèti asirans nou an. Gen plizyè kalite eksepsyon ou ka mande nou fè.

- Ou ka mande nou pou kouvri yon medikaman menm si li pa nan fòmilè nou an. Si yo apwouve, medikaman sa a pral kouvri nan yon nivo pataj pri yo te detèmine davans, epi ou p ap kapab mande nou bay medikaman an nan yon nivo pataj pri ki pi ba.
- Ou ka mande nou pou nou anile yon restriksyon sou kouvèti ki gen ladan otorizasyon davans, terapi pa etap, oswa yon limit kantite sou medikaman ou a. Pa egzanp, pou sèten medikaman, HealthSun Health Plans limite kantite medikaman n ap kouvri a. Si medikaman ou a gen yon limit kantite, ou ka mande nou anile limit la epi kouvri yon pi gwo kantite.
- Ou ka mande nou pou nou kouvri yon medikaman fòmilè nan nivo pataj pri ki pi ba sof si medikaman an nan nivo espesyalite. Si yo apwouve li, sa t ap diminye kantite lajan ou dwe peye pou medikaman w la.

Anjeneral, HealthSun Health Plans pral sèlman apwouve demann ou an pou yon eksepsyon si medikaman altènatif ki enkli nan fòmilè plan an, gen pri pataje ki pi ba a, oswa si aplike restriksyon an pa t ap osi efikas pou ou epi/oswa ta ka lakòz ou gen yon efè negatif.

Oumenm oswa moun k ap preskri w la ta dwe kontakte nou pou mande yon eksepsyon nan nivo oswa fòmilè, ki gen ladan yon eksepsyon nan yon restriksyon sou kouvèti. **Lè w mande yon eksepsyon, moun k ap preskri w la ap bezwen eksplike rezon medikal ki fè w bezwen eksepsyon an.** Anjeneral, nou dwe pran desizyon nou an nan lespas 72 èdtan apre nou resevwa deklarasyon sipò doktè w la. Ou ka mande pou yon desizyon rapid (akselere) si ou kwè, epi nou dakò, ke sante ou ka vin gravman andomaje lè w tann jiska 72 èdtan pou yon desizyon. Si nou dakò, oswa si moun k ap preskri w la mande pou yon desizyon rapid, nou dwe ba w yon desizyon pa pita pase 24 èdtan apre nou resevwa deklarasyon sipò doktè w la.

Kisa mwen ka fè si medikaman mwen an pa sou fòmilè a oswa si gen yon restriksyon?

Antanke yon nouvo manm oswa w ap kontinye nan plan nou an, ou kapab ap pran medikaman ki pa nan fòmilè nou an. Oswa, ou kapab ap pran yon medikaman ki sou fòmilè nou an men ki gen yon restriksyon sou kouvèti, tankou otorizasyon davans. Ou ta dwe pale ak moun k ap preskri w la pou w mande yon desizyon sou kouvèti pou montre w satisfè kritè pou apwobasyon an, pou w chanje nan yon medikaman altènatif ke nou kouvri, oswa pou w mande yon eksepsyon nan fòmilè pou nou ka kouvri medikaman w ap pran an. Pandan ke oumenm ak doktè ou ap detèmine bon jan aksyon pou ou, nou ka kouvri medikaman ou nan sèten ka pandan premye 90 jou ou manm nan plan nou an.

Pou chak medikaman ou yo ki pa nan fòmilè nou an oswa ki gen yon restriksyon sou kouvèti, nou pral kouvri yon rezèv tanporè pou 30 jou. Si preskripsyon ou ekri pou mwens jou, nou pral pèmèt renouvèlman medikaman yo pou nou bay jiska yon maksimòm Rezèv pou 30 jou medikaman. Si yo pa apwouve kouvèti, apre premye rezèv pou 30 jou ou a, nou p ap peye pou medikaman sa yo, menm si ou te manm plan an pou mwens pase 90 jou. Si w abite nan yon etablisman swen alontèm epi w bezwen yon medikaman ki pa nan fòmilè nou an oswa si kapasite w genyen pou w jwenn medikaman w yo limite, men ou deja pase premye 90 jou manm nan plan nou an, n ap kouvri yon pwovizyon ijans pou 34 jou medikaman sa a pandan w ap chèche yon eksepsyon nan fòmilè.

Pwosesis tranzisyon HealthSun Health Plans pral mentni parapò ak sa ki annapre yo: **(1)** tranzisyon nouvo manm nan plan an pandan peryòd eleksyon anyèl la; **(2)** tranzisyon manm Medicare ki fèk elijib ki soti nan lòt kouvèti vini nan plan nou an; **(3)** tranzisyon moun ki chanje soti nan yon Plan ale nan yon lòt apre kòmansman ane kontra a; **(4)** manm ki abite nan yon etablisman swen alontèm (LTC); **(5)** manm aktyèl ki afekte pa chanjman fòmilè negatif yo soti nan yon ane kontra pou rive nan pwochen ane kontra a; **(6)** manm ki mande yon eksepsyon men ki pa jwenn yon desizyon ki pran alè sou demann lan nan fen peryòd tranzisyon an; **(7)** manm ki rete nan menm

plan an pou nouvo ane plan an epi ki pran yon medikaman ki te rezilta yon eksepsyon ki te akòde nan ane anvan an; **(8)** manm aktyèl ki gen yon chanjman nan nivo swen; **(9)** manm aktyèl k ap antre nan anviwònman LTC a soti nan lòt anviwònman swen; epi **(10)** manm aktyèl ki nan yon anviwònman LTC ki mande yon rezèv ijans nan yon medikaman ki pa nan fòmilè.

Pou plis enfòmasyon:

Pou jwenn plis enfòmasyon detaye sou kouvèti medikaman sou preskripsyon HealthSun Health Plans ou a, tanpri revize Prèv Kouvèti ou ak lòt materyèl plan an.

Si w gen kesyon sou HealthSun Health Plans, tanpri kontakte nou. Enfòmasyon kontak nou yo, ansanm ak dènye dat nou te fè mizajou fòmilè a, parèt sou paj devan ak dèye yo.

Si w gen kesyon jeneral sou kouvèti Medicare pou medikaman sou preskripsyon, tanpri rele Medicare nan 1-800-MEDICARE (1-800-633-4227) 24 èdtan pa jou/7 jou pa semèn. Itilizatè TTY yo ta dwe rele 1-877-486-2048.

Oswa, vizite <http://www.medicare.gov>.

HealthSun Health Plans Fòmilè

Fòmilè ki kòmanse nan paj 20 a bay enfòmasyon sou kouvèti medikaman HealthSun Health Plans kouvri yo. Si w gen pwoblèm pou w jwenn medikaman w lan nan lis la, ale nan Endèks ki kòmanse nan paj 118 la.

Premye kolòn nan tablo a bay non medikaman an. Medikaman mak yo ekri an majiskil (egzanp, ENTRESTO ak medikaman jenerik yo ekri an italik miniskil (egzanp, *tab simvastatin*).

Enfòmasyon ki nan kolòn Kondisyon/Limit yo fè w konnen si HealthSun Health Plans gen nenpòt kondisyon espesyal pou kouvri medikaman w lan.

Sèten medikaman nan fòmilè a pral make ak youn oswa plizyè senbòl pou endike aplikasyon yo, tankou restriksyon ak egzijans jesyon itilizasyon, disponiblite kòmman pa lapòs, medikaman limite a yon rezèv pou yon mwa (menm lè medikaman an nan yon nivo ki pèmèt pwovizyon pou jou pwolonje), medikaman Pati D ki ekskli nan kouvri plan an, aksè limite, medikaman pa lapòs, non nivo, ak lòt enfòmasyon sou kouvèti a.

Tablo Medikaman an ki kòmanse nan paj 21 gen ladann yon kolòn ki gen tit, “Nivo Medikaman,” Kolòn sa a endike anba ki nivo chak medikaman ki nan lis la ye. Tablo ki kòmanse nan paj 17 bay kopeman/koasirans ki asosye ak nivo ki koresponn yo si w resevwa medikaman an nan yon famasi ki nan rezo a. Kopeman/koasirans sa yo aplike pandan premye faz kouvèti asirans lan. Tanpri, al gade nan *Prèv Kouvèti ou a* pou konnen sa ou peye pandan etap kouvèti asirans katastwofik la. Si w resevwa “Èd Siplemantè”, kèk enfòmasyon sou depans pou medikaman sou preskripsyon Pati D yo ka pa aplike pou ou. Al gade nan *Sipleman Prèv Kouvèti ou pou Moun ki jwenn "Èd Siplemantè" pou Peye Medikaman sou Preskripsyon* (ki rele tou Sipleman Sibvansyon pou Revni Fèb oswa Sipleman LIS), ki fè w konnen sou kouvèti medikaman ou.

| Nivo | Non Nivo Medikaman |
|-------------|--|
| 1 | Jenerik Prefere |
| 2 | Jenerik |
| 3 | Mak Prefere |
| 4 | Medikaman ki pa Prefere |
| 5 | Nivo Espesyalite |
| 6 | Medikaman siplemantè (kouvèti medikaman amelyore) |

Famasi ki Vann an Detay Prefere / Famasi Kòmman Postal

| Non HealthSun Plan | Nivo 1 Rezèv pou 30 jou (jiska yon rezèv pou 100 jou pou kèk medikaman) | Nivo 2 Rezèv pou 30 jou (jiska yon rezèv 90 jou pou kèk medikaman) | Nivo 3 Rezèv pou 30 jou | Medikaman ensilin Nivo 3 Rezèv pou 30 jou | Nivo 4 Rezèv pou 30 jou | Nivo 5 Rezèv pou 30 jou | Nivo 6 Rezèv pou 30 jou |
|--|--|---|--|--|--|--|--|
| HealthAdvantage Plan (HMO) Miami-Dade 001 | \$0 | \$0 | \$0 | \$0 | \$30 | 33% | \$0 |
| HealthAdvantage Plan (HMO) Broward 012 | \$0 | \$0 | \$5 | \$5 | \$30 | 33% | \$0 |
| HealthAdvantage Plan (HMO) Palm Beach 013 | \$0 | \$0 | \$15 | \$15 | \$30 | 33% | \$0 |
| HealthAdvantage Plus (HMO) Miami-Dade 017 | \$0 | \$0 | \$10 | \$10 | \$30 | 33% | \$0 |
| HealthAdvantage Plus (HMO) Broward 018 | \$0 | \$0 | \$5 | \$5 | \$50 | 33% | \$0 |
| HealthAdvantage Plus (HMO) Palm Beach 020 | \$0 | \$0 | \$42 | \$35 | \$95 | 33% | \$0 |
| *MediMax (HMO) Miami-Dade/Broward 006 | \$0 | \$0 | \$25* | \$25* | 25%* | 25%* | \$0 |
| * MediSun Plus (HMO D-SNP) Palm Beach 016 | \$0 | \$0 | \$0 | \$0 | \$0 | \$0 | \$0 |
| * MediSun Extra (HMO D-SNP) Miami-Dade/Broward 019 | \$0 | \$0 | \$0 | \$0 | \$0 | \$0 | \$0 |
| VitalCare (HMO C-SNP) Miami-Dade/Broward 021 | \$0 | \$0 | \$37 | \$35 | \$85 | 33% | \$0 |
| VitalCare (HMO C-SNP) Palm Beach 022 | \$0 | \$0 | \$37 | \$35 | \$85 | 33% | \$0 |

Famasi ki Vann an Detay Estanda

| Non HealthSun Plan | Nivo 1 Rezè v pou 30 jou (jiska yon rezè v pou 100 jou pou kèk medikaman) | Nivo 2 Rezè v pou 30 jou (jiska yon rezè v 90 jou pou kèk medikaman) | Nivo 3 Rezè v pou 30 jou | Medikaman Ensilin Nivo 3 Rezè v pou 30 jou | Nivo 4 Rezè v pou 30 jou | Nivo 5 Rezè v pou 30 jou | Nivo 6 Rezè v pou 30 jou |
|--|--|---|---|---|---|---|---|
| HealthAdvantage Plan (HMO) Miami-Dade 001 | \$0 | \$0 | \$20 | \$0 | \$35 | 33% | \$0 |
| HealthAdvantage Plan (HMO) Broward 012 | \$0 | \$0 | \$20 | \$5 | \$35 | 33% | \$0 |
| HealthAdvantage Plan (HMO) Palm Beach 013 | \$0 | \$0 | \$20 | \$15 | \$35 | 33% | \$0 |
| HealthAdvantage Plus (HMO) Miami-Dade 017 | \$0 | \$0 | \$10 | \$10 | \$35 | 33% | \$0 |
| HealthAdvantage Plus (HMO) Broward 018 | \$0 | \$0 | \$5 | \$5 | \$55 | 33% | \$0 |
| HealthAdvantage Plus (HMO) Palm Beach 020 | \$0 | \$0 | \$47 | \$35 | \$100 | 33% | \$0 |
| *MediMax (HMO) Miami-Dade/Broward 006 | \$0 | \$0 | \$25* | \$25* | 25%* | 25%* | \$0 |
| * MediSun Plus (HMO D-SNP) Palm Beach 016 | \$0 | \$0 | \$0 | \$0 | \$0 | \$0 | \$0 |
| * MediSun Extra (HMO D-SNP) Miami-Dade/Broward 019 | \$0 | \$0 | \$0 | \$0 | \$0 | \$0 | \$0 |
| VitalCare (HMO C-SNP) Miami-Dade/Broward 021 | \$0 | \$0 | \$42 | \$35 | \$90 | 33% | \$0 |
| VitalCare (HMO C-SNP) Palm Beach 022 | \$0 | \$0 | \$42 | \$35 | \$90 | 33% | \$0 |

**Manm ki enskri nan HealthSun MediMax (HMO) / PBP 006, MediSun Plus (HMO D-NSP) / PBP 016 oswa MediSun Extra (HMO D-NSP) / PBP 019 Si w resevwa “Èd Sipleman tè”, plan sa a pral kouvri tout Medicare Pati D ki kouvri nan Medicare e ki enkli nan fòmilè plan an avèk yon kopeman \$0.00 pandan Dediktib, Inisyal, ak etap Katastwofik kouvèti yo.*

Tanpri, al gade nan *Prè v Kouvèti* plan ou a pou plis detay sou sa ou peye nan yon famasi swen alontèm oswa nan yon famasi andeyò rezo lè plan an apwouve.

Abreviyasyon yo

| Senbòl | NON | DESKRIPSYON ABREVIYASYON |
|---------------|--|--|
| 90D | Avantaj 90 Jou | Medikaman sa a apwouve pou yon rezèv 90 jou. |
| 100D | Avantaj 100 Jou | Medikaman sa a apwouve pou yon rezèv 100 jou. |
| B/D PA | Pati B kont Pati D Revizyon Otorizasyon Davans | Medicare sa a ka kouvri anba Medicare Pati B oswa Medicare Pati D selon sikonstans yo. |
| ED | Kouvèti Medikaman Amelyore | Kouvèti pou Medicare Pati D ki eskli yo. Medikaman sou preskripsyon sa a pa nòmalman kouvri nan yon Plan Medicare sou Preskripsyon. Kantite lajan ou peye lè w ranpli yon preskripsyon pou medikaman sa a pa konte nan depans total medikaman w yo (sa vle di, montan w peye a pa ede w kalifye pou kouvèti asirans katastwofik). Anplis de sa, si w ap resevwa èd siplemantè pou peye pou preskripsyon ou yo, ou p ap jwenn okenn èd siplemantè pou peye medikaman sa a. |
| HRM | Medikaman ki gen gwo risk | PA obligatwa pou laj 65 oswa plis. |
| LA | Aksè limite | Preskripsyon sa a ka disponib sèlman nan sèten famasi. Pou plis enfòmasyon konsilte Anyè Famasi w la oswa rele Sèvis Manm yo nan 1-877-336-2069 (itilizatè TTY yo ta dwe rele 1-877-206-0500), soti 8 am jiska 8 pm, oswa vizite www.HealthSun.com . Soti 1ye oktòb jiska 31 mas, nou ouvri sèt jou pa semèn (biwo nou an ap fèmen nan Jou Aksyon de Gras ak Nwèl). Soti 1ye avril jiska 30 septanm, nou disponib Lendi jiska Vandredi de 8 am jiska 8 pm (biwo nou an ap fèmen nan jou ferye federal). |
| NEDS | Rezèv pou jou ki pa pwolonje | Medikaman sa a apwouve pou pa plis pase yon rezèv 30 jou. |
| MO | Kòmman Postal | Medikaman sa a disponib nan famasi pa lapòs nou yo. |
| PA | Otorizasyon davans | Oumenm (oswa doktè ou) oblije jwenn otorizasyon davans anvan ou ranpli preskripsyon ou pou medikaman sa a; san apwobasyon alavans, nou ka pa kouvri medikaman sa a. |
| QL | Limit Kantite | Gen yon limit sou kantite medikaman sa a ki kouvri pou chak preskripsyon, oswa nan yon delè espesifik. Sèten medikaman ki make “QL” pou limit kantite pral endike kantite an (pwovizyon pou plizyè jou oswa kantite ki te bay). |
| ST | Terapi Etap | Nan kèk ka, ou ka oblije eseye an premye sèten medikaman pou trete kondisyon medikal ou anvan nou pral kouvri yon lòt medikaman pou kondisyon sa a. |

List of Covered Drugs Lis Medikaman ki Kouvri yo

Table of Contents (Tab matyè)

| | |
|---|-----|
| ANALGESICS AND ANTI-INFLAMMATORY AGENTS / ANALJEZIK AK AJAN ANTI-ENFLAMATWA ... | 21 |
| ANTINEOPLASTICS / ANTINEYOPLAZIK | 24 |
| BLOOD PRODUCTS AND MODIFIERS / PWODUI SAN AK MODIFIKATÈ..... | 33 |
| CARDIOVASCULAR AGENTS / AJAN ADYOVASKILÈ..... | 36 |
| CENTRAL NERVOUS SYSTEM AGENTS / AJAN SISTÈM NÈVE SANTRAL | 43 |
| DERMATOLOGICAL AGENTS / AJAN DÈMATOLOJIK..... | 64 |
| ELECTROLYTES / MINERALS / METALS / VITAMINS / ELEKTWOLIT / MINERAL / METAL / VITAMIN ... | 69 |
| ENDOCRINE AND METABOLIC DISORDER AGENTS / AJAN MALADI ANDOKRIN AK METABOLIS... | 72 |
| GASTROINTESTINAL AGENTS / AJAN GASTROENTESTINAL..... | 78 |
| GENETIC OR ENZYME OR PROTEIN DISORDER: REPLACEMENT, MODIFIERS, TREATMENT / MALADI JÈN, ANZIM, OSWA PWOTEYIN: RANPLASMAN, MODIFIKATÈ, TRETMAN | 82 |
| GENITOURINARY AGENTS / AJAN JENITOURINÈ..... | 82 |
| HORMONAL AGENTS / AJAN ÒMONAL..... | 83 |
| IMMUNOLOGICAL AGENTS / AJAN IMINOLOJIK..... | 90 |
| INFECTIOUS DISEASE AGENTS / AJAN MALADI ENFEKTYE..... | 96 |
| MISCELLANEOUS THERAPEUTIC AGENTS / AJAN TERAPI DIVÈS | 109 |
| OPHTHALMIC AGENTS / AJAN OFTALMIK..... | 109 |
| OTIC AGENTS / AJAN OTIK | 112 |
| RESPIRATORY TRACT/PULMONARY AGENTS / AJAN RESPIRATWA/PILMONÈ | 113 |

| DRUG NAME / NON MEDIKAMAN | DRUG TIER / NIVO MEDIKAMAN | REQUIREMENTS / LIMITS KONDISYON / LIMIT |
|--|----------------------------|---|
| ANALGESICS AND ANTI-INFLAMMATORY AGENTS / ANALJEZIK AK AJAN ANTI-ENFLAMATWA | | |
| <i>acetaminophen-codeine oral solution</i> | 2 | QL (900 per 30 days); NEDS |
| <i>acetaminophen-codeine oral tablet</i> | 3 | QL (180 per 30 days); NEDS |
| <i>allopurinol oral tablet 100 mg, 300 mg</i> | 1 | MO; 100D |
| <i>buprenorphine transdermal</i> | 2 | PA; QL (4 per 28 days); NEDS |
| <i>butorphanol tartrate nasal</i> | 2 | QL (5 per 30 days); NEDS |
| <i>celecoxib oral capsule 100 mg, 200 mg, 50 mg</i> | 2 | QL (60 per 30 days); MO; 90D |
| <i>celecoxib oral capsule 400 mg</i> | 2 | QL (30 per 30 days); MO; 90D |
| <i>colchicine oral capsule</i> | 3 | |
| <i>colchicine oral tablet</i> | 2 | |
| <i>colchicine-probenecid</i> | 1 | MO; 100D |
| <i>diclofenac potassium oral tablet 50 mg</i> | 1 | MO; 100D |
| <i>diclofenac sodium er</i> | 1 | MO; 100D |
| <i>diclofenac sodium external gel 1 %</i> | 2 | QL (1000 per 30 days) |
| <i>diclofenac sodium external solution 1.5 %</i> | 4 | QL (300 per 30 days) |
| <i>diclofenac sodium oral</i> | 1 | MO; 100D |
| <i>diclofenac-misoprostol oral tablet delayed release</i> | 2 | MO; 90D |
| <i>diflunisal oral</i> | 2 | MO; 90D |
| <i>duramorph</i> | 4 | |
| <i>ec-naproxen</i> | 2 | MO; 90D |
| ENDOCET ORAL TABLET 10-325 MG, 2.5-325 MG, 5-325 MG, 7.5-325 MG | 2 | QL (180 per 30 days); NEDS |
| <i>etodolac er</i> | 2 | MO; 90D |
| <i>etodolac oral</i> | 1 | MO; 100D |
| <i>febuxostat</i> | 2 | ST; MO; 90D |
| <i>fenoprofen calcium oral tablet</i> | 2 | MO; 90D |
| <i>fentanyl</i> | 2 | PA; QL (15 per 30 days); NEDS |

You can find information on what the symbols and abbreviations in this table mean by going to page 10 of this document. Ou ka jwenn enfòmasyon sou sa senbòl ak abrevyasyon yo nan tablo sa a vle di lè w ale nan paj 19 dokiman sa a.

| DRUG NAME / NON MEDIKAMAN | DRUG TIER / NIVO MEDIKAMAN | REQUIREMENTS / LIMITS KONDISYON / LIMIT |
|---|----------------------------|---|
| <i>fentanyl citrate buccal tablet</i> | 5 | PA; QL (120 per 30 days); NEDS |
| <i>flurbiprofen oral tablet 100 mg</i> | 1 | MO; 100D |
| GLYDO EXTERNAL PREFILLED SYRINGE | 2 | |
| <i>hydrocodone-acetaminophen oral solution 2.5-108 mg/5ml, 5-217 mg/10ml, 7.5-325 mg/15ml</i> | 2 | QL (2700 per 30 days); NEDS |
| <i>hydrocodone-acetaminophen oral tablet 10-300 mg, 5-300 mg, 7.5-300 mg</i> | 2 | QL (180 per 30 days); NEDS |
| <i>hydrocodone-acetaminophen oral tablet 10-325 mg, 5-325 mg, 7.5-325 mg</i> | 3 | QL (180 per 30 days); NEDS |
| <i>hydrocodone-ibuprofen oral tablet 10-200 mg, 5-200 mg, 7.5-200 mg</i> | 4 | QL (50 per 10 days); NEDS |
| <i>hydromorphone hcl injection solution 2 mg/ml</i> | 2 | |
| <i>hydromorphone hcl oral liquid</i> | 2 | QL (720 per 30 days); NEDS |
| <i>hydromorphone hcl oral tablet</i> | 2 | QL (180 per 30 days); NEDS |
| IBU ORAL TABLET 600 MG, 800 MG | 1 | MO; 100D |
| <i>ibuprofen oral suspension</i> | 1 | |
| <i>ibuprofen oral tablet 400 mg, 600 mg, 800 mg</i> | 1 | MO; 100D |
| <i>indomethacin oral capsule 25 mg, 50 mg</i> | 1 | PA; MO; 100D; HRM |
| <i>ketoprofen oral capsule 50 mg</i> | 4 | MO |
| <i>ketorolac tromethamine oral</i> | 2 | PA; HRM |
| <i>lidocaine external ointment 5 %</i> | 2 | PA; QL (150 per 30 days) |
| <i>lidocaine external patch 5 %</i> | 2 | PA; QL (90 per 30 days) |
| <i>lidocaine hcl external solution</i> | 2 | PA; QL (300 per 30 days) |
| <i>lidocaine hcl urethral/mucosal</i> | 2 | |
| <i>lidocaine viscous hcl</i> | 1 | |
| <i>lidocaine-prilocaine external cream</i> | 2 | QL (30 per 30 days) |
| <i>meloxicam oral tablet</i> | 1 | MO; 100D |
| <i>meperidine hcl injection solution 100 mg/ml, 25 mg/ml, 50 mg/ml</i> | 2 | PA; HRM |

You can find information on what the symbols and abbreviations in this table mean by going to page 10 of this document. Ou ka jwenn enfòmasyon sou sa senbòl ak abrevyasyon yo nan tablo sa a vle di lè w ale nan paj 19 dokiman sa a.

| DRUG NAME / NON MEDIKAMAN | DRUG TIER / NIVO MEDIKAMAN | REQUIREMENTS / LIMITS KONDISYON / LIMIT |
|--|-----------------------------------|--|
| <i>meperidine hcl oral solution</i> | 2 | PA; QL (900 per 30 days); NEDS; HRM |
| <i>meperidine hcl oral tablet 50 mg</i> | 5 | PA; QL (180 per 30 days); NEDS; HRM |
| <i>methadone hcl oral solution</i> | 3 | QL (900 per 30 days); NEDS |
| <i>methadone hcl oral tablet</i> | 3 | PA; QL (180 per 30 days); NEDS |
| <i>morphine sulfate (concentrate) oral solution 100 mg/5ml, 20 mg/ml</i> | 2 | QL (180 per 30 days); NEDS |
| <i>morphine sulfate (pf) injection solution 0.5 mg/ml, 1 mg/ml</i> | 4 | |
| <i>morphine sulfate er oral tablet extended release 100 mg, 200 mg</i> | 2 | PA; QL (60 per 30 days); NEDS |
| <i>morphine sulfate er oral tablet extended release 15 mg, 30 mg, 60 mg</i> | 2 | PA; QL (90 per 30 days); NEDS |
| <i>morphine sulfate oral solution</i> | 2 | QL (900 per 30 days); NEDS |
| <i>morphine sulfate oral tablet 15 mg</i> | 2 | QL (180 per 30 days); NEDS |
| <i>morphine sulfate oral tablet 30 mg</i> | 1 | QL (180 per 30 days); NEDS |
| <i>nabumetone oral</i> | 1 | MO; 100D |
| <i>naproxen dr oral tablet delayed release 500 mg</i> | 2 | MO; 90D |
| <i>naproxen oral suspension</i> | 2 | MO; 90D |
| <i>naproxen oral tablet</i> | 1 | MO; 100D |
| <i>naproxen oral tablet delayed release</i> | 2 | MO; 90D |
| <i>naproxen sodium oral tablet 275 mg, 550 mg</i> | 2 | MO; 90D |
| <i>oxaprozin oral tablet</i> | 2 | MO; 90D |
| <i>oxycodone hcl oral capsule</i> | 2 | QL (180 per 30 days); NEDS |
| <i>oxycodone hcl oral concentrate 100 mg/5ml</i> | 2 | QL (180 per 30 days); NEDS |
| <i>oxycodone hcl oral tablet</i> | 3 | QL (180 per 30 days); NEDS |
| <i>oxycodone-acetaminophen oral tablet 10-325 mg, 2.5-325 mg, 5-325 mg, 7.5-325 mg</i> | 2 | QL (180 per 30 days); NEDS |
| <i>oxymorphone hcl</i> | 2 | QL (180 per 30 days); NEDS |

You can find information on what the symbols and abbreviations in this table mean by going to page 10 of this document. Ou ka jwenn enfòmasyon sou sa senbòl ak abrevyasyon yo nan tablo sa a vle di lè w ale nan paj 19 dokiman sa a.

| DRUG NAME / NON MEDIKAMAN | DRUG TIER / NIVO MEDIKAMAN | REQUIREMENTS / LIMITS KONDISYON / LIMIT |
|--|----------------------------|---|
| <i>pentazocine-naloxone hcl</i> | 2 | PA; QL (360 per 30 days); NEDS; HRM |
| <i>piroxicam oral</i> | 2 | MO; 90D |
| <i>probenecid oral</i> | 1 | MO; 100D |
| <i>sulindac oral</i> | 1 | MO; 100D |
| <i>tolmetin sodium oral tablet 600 mg</i> | 2 | MO; 90D |
| <i>tramadol hcl (er biphasic) oral tablet extended release 24 hour</i> | 2 | PA; QL (30 per 30 days); NEDS |
| <i>tramadol hcl er</i> | 2 | PA; QL (30 per 30 days); NEDS |
| <i>tramadol hcl oral tablet 50 mg</i> | 1 | QL (240 per 30 days); NEDS |
| <i>tramadol-acetaminophen</i> | 2 | QL (40 per 5 days); NEDS |
| ANTINEOPLASTICS / ANTINEYOPLAZIK | | |
| <i>abiraterone acetate oral tablet 250 mg</i> | 5 | PA; QL (120 per 30 days) |
| <i>abiraterone acetate oral tablet 500 mg</i> | 5 | PA; QL (60 per 30 days) |
| AKEEGA | 5 | PA; QL (60 per 30 days) |
| ALECENSA | 5 | PA; QL (240 per 30 days); LA |
| ALUNBRIG ORAL TABLET 180 MG | 5 | PA; QL (30 per 30 days); LA |
| ALUNBRIG ORAL TABLET 30 MG | 5 | PA; QL (180 per 30 days); LA |
| ALUNBRIG ORAL TABLET 90 MG | 5 | PA; QL (60 per 30 days); LA |
| ALUNBRIG ORAL TABLET THERAPY PACK | 5 | PA; QL (30 per 180 days); LA |
| <i>anastrozole oral</i> | 2 | QL (30 per 30 days); MO; 90D |
| AUGTYRO | 5 | PA; QL (240 per 30 days) |
| AYVAKIT | 5 | PA; QL (30 per 30 days); LA |
| BALVERSA ORAL TABLET 3 MG | 5 | PA; QL (90 per 30 days); LA |
| BALVERSA ORAL TABLET 4 MG | 5 | PA; QL (60 per 30 days); LA |
| BALVERSA ORAL TABLET 5 MG | 5 | PA; QL (30 per 30 days); LA |
| BAVENCIO | 5 | PA; LA |
| BESREMI | 5 | PA; LA |
| <i>bexarotene oral</i> | 5 | PA; QL (300 per 30 days) |

You can find information on what the symbols and abbreviations in this table mean by going to page 10 of this document. Ou ka jwenn enfòmasyon sou sa senbòl ak abrevyasyon yo nan tablo sa a vle di lè w ale nan paj 19 dokiman sa a.

| DRUG NAME / NON MEDIKAMAN | DRUG TIER / NIVO MEDIKAMAN | REQUIREMENTS / LIMITS KONDISYON / LIMIT |
|---|----------------------------|---|
| <i>bicalutamide</i> | 2 | QL (30 per 30 days) |
| BOSULIF ORAL CAPSULE 100 MG | 5 | PA; QL (180 per 30 days); LA |
| BOSULIF ORAL CAPSULE 50 MG | 5 | PA; QL (30 per 30 days); LA |
| BOSULIF ORAL TABLET 100 MG | 5 | PA; QL (120 per 30 days) |
| BOSULIF ORAL TABLET 400 MG, 500 MG | 5 | PA; QL (30 per 30 days) |
| BRAFTOVI ORAL CAPSULE 75 MG | 5 | PA; QL (180 per 30 days); LA |
| BRUKINSA | 5 | PA; QL (120 per 30 days); LA |
| CABOMETYX | 5 | PA; QL (30 per 30 days); LA |
| CALQUENCE | 5 | PA; QL (60 per 30 days); LA |
| CAPRELSA ORAL TABLET 100 MG | 5 | PA; QL (90 per 30 days); LA |
| CAPRELSA ORAL TABLET 300 MG | 5 | PA; QL (30 per 30 days); LA |
| COMETRIQ (100 MG DAILY DOSE) ORAL KIT 80 & 20 MG | 5 | PA; QL (56 per 28 days); LA |
| COMETRIQ (140 MG DAILY DOSE) ORAL KIT 3 X 20 MG & 80 MG | 5 | PA; QL (112 per 28 days); LA |
| COMETRIQ (60 MG DAILY DOSE) | 5 | PA; QL (84 per 28 days); LA |
| COPIKTRA | 5 | PA; QL (60 per 30 days); LA |
| COTELLIC | 5 | PA; QL (90 per 30 days); LA |
| <i>cyclophosphamide intravenous solution 500 mg/2.5ml</i> | 5 | |
| <i>cyclophosphamide oral capsule</i> | 3 | B/D PA |
| CYRAMZA | 5 | PA; LA |
| DARZALEX FASPRO | 5 | PA |
| DARZALEX INTRAVENOUS SOLUTION 400 MG/20ML | 5 | PA; LA |
| DAURISMO ORAL TABLET 100 MG | 5 | PA; QL (30 per 30 days); LA |
| DAURISMO ORAL TABLET 25 MG | 5 | PA; QL (60 per 30 days); LA |
| ELIGARD | 4 | PA |
| EMCYT | 4 | |
| ENHERTU | 5 | PA |

You can find information on what the symbols and abbreviations in this table mean by going to page 10 of this document. Ou ka jwenn enfòmasyon sou sa senbòl ak abrevyasyon yo nan tablo sa a vle di lè w ale nan paj 19 dokiman sa a.

| DRUG NAME / NON MEDIKAMAN | DRUG TIER / NIVO MEDIKAMAN | REQUIREMENTS / LIMITS KONDISYON / LIMIT |
|---|----------------------------|---|
| ERIVEDGE | 5 | PA; QL (30 per 30 days); LA |
| ERLEADA ORAL TABLET 240 MG | 5 | PA; QL (30 per 30 days); LA |
| ERLEADA ORAL TABLET 60 MG | 5 | PA; QL (120 per 30 days); LA |
| <i>erlotinib hcl oral tablet 100 mg, 150 mg</i> | 5 | PA; QL (30 per 30 days) |
| <i>erlotinib hcl oral tablet 25 mg</i> | 5 | PA; QL (90 per 30 days) |
| <i>everolimus oral tablet 10 mg, 2.5 mg, 5 mg, 7.5 mg</i> | 5 | PA |
| <i>everolimus oral tablet soluble</i> | 5 | PA |
| <i>exemestane</i> | 2 | QL (60 per 30 days); MO; 90D |
| EXKIVITY | 5 | PA; QL (120 per 30 days); LA |
| FIRMAGON (240 MG DOSE) | 5 | PA |
| FIRMAGON SUBCUTANEOUS SOLUTION RECONSTITUTED 80 MG | 4 | PA |
| FOTIVDA | 5 | PA; QL (21 per 28 days) |
| FRUZAQLA ORAL CAPSULE 1 MG | 5 | PA; QL (84 per 28 days); LA |
| FRUZAQLA ORAL CAPSULE 5 MG | 5 | PA; QL (21 per 28 days); LA |
| GAVRETO | 5 | PA; QL (120 per 30 days); LA |
| GAZYVA | 5 | PA; LA |
| <i>gefitinib</i> | 5 | PA; QL (60 per 30 days) |
| GILOTRIF | 5 | PA; QL (30 per 30 days); LA |
| GLEOSTINE ORAL CAPSULE 10 MG, 40 MG | 4 | PA |
| GLEOSTINE ORAL CAPSULE 100 MG | 5 | PA |
| HERCEPTIN HYLECTA | 5 | B/D PA |
| <i>hydroxyurea oral</i> | 1 | |
| IBRANCE | 5 | PA; QL (21 per 28 days); LA |
| ICLUSIG | 5 | PA; QL (30 per 30 days); LA |
| IDHIFA ORAL TABLET 100 MG | 5 | PA; QL (30 per 30 days); LA |
| IDHIFA ORAL TABLET 50 MG | 5 | PA; QL (60 per 30 days); LA |
| <i>imatinib mesylate oral tablet 100 mg</i> | 5 | PA; QL (90 per 30 days) |
| <i>imatinib mesylate oral tablet 400 mg</i> | 5 | PA; QL (60 per 30 days) |

You can find information on what the symbols and abbreviations in this table mean by going to page 10 of this document. Ou ka jwenn enfòmasyon sou sa senbòl ak abrevyasyon yo nan tablo sa a vle di lè w ale nan paj 19 dokiman sa a.

| DRUG NAME / NON MEDIKAMAN | DRUG TIER / NIVO MEDIKAMAN | REQUIREMENTS / LIMITS KONDISYON / LIMIT |
|--|----------------------------|---|
| IMBRUVICA ORAL CAPSULE 140 MG | 5 | PA; QL (90 per 30 days); LA |
| IMBRUVICA ORAL CAPSULE 70 MG | 5 | PA; QL (30 per 30 days); LA |
| IMBRUVICA ORAL SUSPENSION | 5 | PA; QL (216 per 27 days); LA |
| IMBRUVICA ORAL TABLET 420 MG, 560 MG | 5 | PA; QL (30 per 30 days); LA |
| INLYTA ORAL TABLET 1 MG | 5 | PA; QL (180 per 30 days); LA |
| INLYTA ORAL TABLET 5 MG | 5 | PA; QL (120 per 30 days); LA |
| INQOVI | 5 | PA; QL (5 per 28 days); LA |
| INREBIC | 5 | PA; QL (120 per 30 days); LA |
| IWILFIN | 5 | PA; QL (240 per 30 days) |
| JAKAFI | 5 | PA; QL (60 per 30 days); LA |
| JAYPIRCA ORAL TABLET 100 MG | 5 | PA; QL (60 per 30 days) |
| JAYPIRCA ORAL TABLET 50 MG | 5 | PA; QL (30 per 30 days) |
| KADCYLA | 5 | PA |
| KISQALI (200 MG DOSE) | 5 | PA; QL (21 per 28 days) |
| KISQALI (400 MG DOSE) | 5 | PA; QL (42 per 28 days) |
| KISQALI (600 MG DOSE) | 5 | PA; QL (63 per 28 days) |
| KISQALI FEMARA (200 MG DOSE) | 5 | PA; QL (49 per 28 days) |
| KISQALI FEMARA (400 MG DOSE) | 5 | PA; QL (70 per 28 days) |
| KISQALI FEMARA (600 MG DOSE) | 5 | PA; QL (91 per 28 days) |
| KRAZATI | 5 | PA; QL (180 per 30 days) |
| <i>lapatinib ditosylate</i> | 5 | PA; QL (180 per 30 days) |
| <i>lenalidomide oral capsule 10 mg</i> | 5 | PA; QL (60 per 30 days); LA |
| <i>lenalidomide oral capsule 15 mg, 2.5 mg, 20 mg, 25 mg</i> | 5 | PA; QL (30 per 30 days); LA |
| <i>lenalidomide oral capsule 5 mg</i> | 5 | PA; QL (150 per 30 days); LA |
| LENVIMA (10 MG DAILY DOSE) | 5 | PA; QL (30 per 30 days); LA |
| LENVIMA (12 MG DAILY DOSE) | 5 | PA; QL (90 per 30 days); LA |
| LENVIMA (14 MG DAILY DOSE) | 5 | PA; QL (60 per 30 days); LA |
| LENVIMA (18 MG DAILY DOSE) | 5 | PA; QL (90 per 30 days); LA |

You can find information on what the symbols and abbreviations in this table mean by going to page 10 of this document. Ou ka jwenn enfòmasyon sou sa senbòl ak abrevyasyon yo nan tablo sa a vle di lè w ale nan paj 19 dokiman sa a.

| DRUG NAME / NON MEDIKAMAN | DRUG TIER / NIVO MEDIKAMAN | REQUIREMENTS / LIMITS KONDISYON / LIMIT |
|---|----------------------------|---|
| LENVIMA (20 MG DAILY DOSE) | 5 | PA; QL (60 per 30 days); LA |
| LENVIMA (24 MG DAILY DOSE) | 5 | PA; QL (90 per 30 days); LA |
| LENVIMA (4 MG DAILY DOSE) | 5 | PA; QL (30 per 30 days); LA |
| LENVIMA (8 MG DAILY DOSE) | 5 | PA; QL (60 per 30 days); LA |
| <i>letrozole oral</i> | 2 | QL (30 per 30 days); MO; 90D |
| <i>leucovorin calcium oral tablet 10 mg, 15 mg, 25 mg</i> | 2 | |
| <i>leucovorin calcium oral tablet 5 mg</i> | 1 | |
| LEUKERAN | 4 | |
| <i>leuprolide acetate (3 month)</i> | 4 | PA |
| <i>leuprolide acetate injection</i> | 2 | PA |
| LONSURF | 5 | PA |
| LORBRENA ORAL TABLET 100 MG | 5 | PA; QL (30 per 30 days); LA |
| LORBRENA ORAL TABLET 25 MG | 5 | PA; QL (90 per 30 days); LA |
| LUMAKRAS ORAL TABLET 120 MG | 5 | PA; QL (240 per 30 days); LA |
| LUMAKRAS ORAL TABLET 320 MG | 5 | PA; QL (90 per 30 days) |
| LUPRON DEPOT (1-MONTH) | 5 | PA; QL (1 per 28 days) |
| LUPRON DEPOT (3-MONTH) | 5 | PA; QL (1 per 84 days) |
| LUPRON DEPOT (4-MONTH) | 5 | PA; QL (1 per 112 days) |
| LUPRON DEPOT (6-MONTH) | 5 | PA; QL (1 per 168 days) |
| LYNPARZA ORAL TABLET | 5 | PA; QL (120 per 30 days); LA |
| LYSODREN | 5 | |
| LYTGOBI (12 MG DAILY DOSE) | 5 | PA |
| LYTGOBI (16 MG DAILY DOSE) | 5 | PA |
| LYTGOBI (20 MG DAILY DOSE) | 5 | PA |
| MATULANE | 5 | LA |
| <i>megestrol acetate oral suspension 40 mg/ml, 400 mg/10ml, 800 mg/20ml</i> | 1 | PA; HRM |
| <i>megestrol acetate oral tablet</i> | 1 | PA; HRM |

You can find information on what the symbols and abbreviations in this table mean by going to page 10 of this document. Ou ka jwenn enfòmasyon sou sa senbòl ak abrevyasyon yo nan tablo sa a vle di lè w ale nan paj 19 dokiman sa a.

| DRUG NAME / NON MEDIKAMAN | DRUG TIER / NIVO MEDIKAMAN | REQUIREMENTS / LIMITS KONDISYON / LIMIT |
|---|----------------------------|---|
| MEKINIST ORAL SOLUTION RECONSTITUTED | 5 | PA; QL (1200 per 30 days) |
| MEKINIST ORAL TABLET 0.5 MG | 5 | PA; QL (90 per 30 days); LA |
| MEKINIST ORAL TABLET 2 MG | 5 | PA; QL (30 per 30 days); LA |
| MEKTOVI | 5 | PA; QL (180 per 30 days); LA |
| <i>mercaptapurine oral</i> | 2 | |
| MESNEX ORAL | 5 | |
| NERLYNX | 5 | PA; QL (180 per 30 days); LA |
| <i>nilutamide</i> | 5 | QL (30 per 30 days) |
| NINLARO | 5 | PA; QL (3 per 28 days) |
| NUBEQA | 5 | PA; QL (120 per 30 days); LA |
| ODOMZO | 5 | PA; QL (30 per 30 days); LA |
| OGSIVEO ORAL TABLET 100 MG, 150 MG | 5 | PA; QL (60 per 30 days) |
| OGSIVEO ORAL TABLET 50 MG | 5 | PA; QL (180 per 30 days) |
| OJEMDA ORAL SUSPENSION RECONSTITUTED | 5 | PA; QL (96 per 28 days) |
| OJEMDA ORAL TABLET | 5 | PA; QL (24 per 28 days) |
| OJJAARA | 5 | PA; QL (30 per 30 days); LA |
| ONUREG | 5 | PA; QL (14 per 28 days); LA |
| ORGOVYX | 5 | PA; QL (30 per 28 days); LA |
| ORSERDU ORAL TABLET 345 MG | 5 | PA; QL (30 per 30 days) |
| ORSERDU ORAL TABLET 86 MG | 5 | PA; QL (90 per 30 days) |
| <i>oxaliplatin intravenous solution 200 mg/40ml</i> | 4 | B/D PA |
| <i>pazopanib hcl</i> | 5 | PA; QL (120 per 30 days) |
| PEMAZYRE | 5 | PA; QL (30 per 30 days); LA |
| PHESGO | 5 | PA |
| PIQRAY (200 MG DAILY DOSE) | 5 | PA; QL (28 per 28 days) |
| PIQRAY (250 MG DAILY DOSE) | 5 | PA; QL (56 per 28 days) |
| PIQRAY (300 MG DAILY DOSE) | 5 | PA; QL (56 per 28 days) |
| POMALYST | 5 | PA; QL (21 per 28 days); LA |

You can find information on what the symbols and abbreviations in this table mean by going to page 10 of this document. Ou ka jwenn enfòmasyon sou sa senbòl ak abrevyasyon yo nan tablo sa a vle di lè w ale nan paj 19 dokiman sa a.

| DRUG NAME / NON MEDIKAMAN | DRUG TIER / NIVO MEDIKAMAN | REQUIREMENTS / LIMITS KONDISYON / LIMIT |
|--|----------------------------|---|
| PURIXAN | 5 | PA |
| QINLOCK | 5 | PA; QL (90 per 30 days) |
| RETEVMO ORAL CAPSULE 40 MG | 5 | PA; QL (180 per 30 days) |
| RETEVMO ORAL CAPSULE 80 MG | 5 | PA; QL (120 per 30 days) |
| RETEVMO ORAL TABLET 120 MG, 160 MG | 5 | PA; QL (60 per 30 days) |
| RETEVMO ORAL TABLET 40 MG | 5 | PA; QL (180 per 30 days) |
| RETEVMO ORAL TABLET 80 MG | 5 | PA; QL (120 per 30 days) |
| REZLIDHIA | 5 | PA; QL (60 per 30 days); LA |
| RIABNI | 5 | B/D PA |
| RITUXAN INTRAVENOUS SOLUTION 100 MG/10ML | 5 | B/D PA; LA |
| ROZLYTREK ORAL CAPSULE 100 MG | 5 | PA; QL (150 per 30 days); LA |
| ROZLYTREK ORAL CAPSULE 200 MG | 5 | PA; QL (90 per 30 days); LA |
| ROZLYTREK ORAL PACKET | 5 | PA; QL (360 per 30 days); LA |
| RUBRACA | 5 | PA; QL (120 per 30 days); LA |
| RYBREVANT | 5 | PA |
| RYDAPT | 5 | PA; QL (240 per 30 days) |
| RYLAZE | 5 | PA |
| SARCLISA | 5 | PA |
| SCEMBLIX ORAL TABLET 100 MG | 5 | PA; QL (120 per 30 days) |
| SCEMBLIX ORAL TABLET 20 MG | 5 | PA; QL (60 per 30 days) |
| SCEMBLIX ORAL TABLET 40 MG | 5 | PA; QL (300 per 30 days) |
| SOLTAMOX | 5 | MO |
| <i>sorafenib tosylate</i> | 5 | PA; QL (120 per 30 days) |
| SPRYCEL | 5 | PA; QL (30 per 30 days) |
| STIVARGA | 5 | PA; QL (84 per 28 days); LA |
| <i>sunitinib malate</i> | 5 | PA; QL (30 per 30 days) |
| TABLOID | 4 | |
| TABRECTA | 5 | PA; QL (120 per 30 days) |

You can find information on what the symbols and abbreviations in this table mean by going to page 10 of this document. Ou ka jwenn enfòmasyon sou sa senbòl ak abrevyasyon yo nan tablo sa a vle di lè w ale nan paj 19 dokiman sa a.

| DRUG NAME / NON MEDIKAMAN | DRUG TIER / NIVO MEDIKAMAN | REQUIREMENTS / LIMITS KONDISYON / LIMIT |
|--|----------------------------|---|
| TAFINLAR ORAL CAPSULE | 5 | PA; QL (120 per 30 days); LA |
| TAFINLAR ORAL TABLET SOLUBLE | 5 | PA; QL (900 per 30 days) |
| TAGRISSO | 5 | PA; QL (30 per 30 days); LA |
| TALZENNA ORAL CAPSULE 0.1 MG, 0.35 MG | 5 | PA; QL (30 per 30 days) |
| TALZENNA ORAL CAPSULE 0.25 MG, 0.5 MG, 0.75 MG, 1 MG | 5 | PA; QL (30 per 30 days); LA |
| <i>tamoxifen citrate oral</i> | 1 | MO; 100D |
| TASIGNA | 5 | PA; QL (112 per 28 days) |
| TAZVERIK | 5 | PA; QL (240 per 30 days); LA |
| TECENTRIQ INTRAVENOUS SOLUTION 1200 MG/20ML | 5 | PA; QL (20 per 21 days); LA |
| TECENTRIQ INTRAVENOUS SOLUTION 840 MG/14ML | 5 | PA; QL (28 per 28 days); LA |
| TECVAYLI | 5 | PA |
| TEPMETKO | 5 | PA; QL (60 per 30 days); LA |
| THALOMID ORAL CAPSULE 100 MG, 50 MG | 5 | PA; QL (30 per 30 days) |
| THALOMID ORAL CAPSULE 150 MG, 200 MG | 5 | PA; QL (60 per 30 days) |
| TIBSOVO | 5 | PA; QL (60 per 30 days); LA |
| <i>toremifene citrate</i> | 4 | QL (30 per 30 days) |
| TRELSTAR MIXJECT | 4 | PA |
| <i>tretinoin oral</i> | 5 | |
| TRODELVY | 5 | PA |
| TRUQAP | 5 | PA; QL (64 per 28 days) |
| TRUSELTIQ (100MG DAILY DOSE) | 5 | PA; QL (21 per 28 days); LA |
| TRUSELTIQ (125MG DAILY DOSE) | 5 | PA; QL (42 per 28 days); LA |
| TRUSELTIQ (50MG DAILY DOSE) | 5 | PA; QL (42 per 28 days); LA |
| TRUSELTIQ (75MG DAILY DOSE) | 5 | PA; QL (63 per 28 days); LA |
| TUKYSA | 5 | PA; QL (120 per 30 days); LA |
| TURALIO ORAL CAPSULE 125 MG | 5 | PA; QL (120 per 30 days); LA |
| VANFLYTA | 5 | PA; QL (56 per 28 days) |

You can find information on what the symbols and abbreviations in this table mean by going to page 10 of this document. Ou ka jwenn enfòmasyon sou sa senbòl ak abrevyasyon yo nan tablo sa a vle di lè w ale nan paj 19 dokiman sa a.

| DRUG NAME / NON MEDIKAMAN | DRUG TIER / NIVO MEDIKAMAN | REQUIREMENTS / LIMITS KONDISYON / LIMIT |
|--|-----------------------------------|--|
| VENCLEXTA ORAL TABLET 10 MG | 3 | PA; QL (60 per 30 days); LA |
| VENCLEXTA ORAL TABLET 100 MG | 5 | PA; QL (180 per 30 days); LA |
| VENCLEXTA ORAL TABLET 50 MG | 5 | PA; QL (30 per 30 days); LA |
| VENCLEXTA STARTING PACK | 5 | PA; LA |
| VERZENIO | 5 | PA; QL (56 per 28 days); LA |
| VITRAKVI ORAL CAPSULE 100 MG | 5 | PA; QL (60 per 30 days); LA |
| VITRAKVI ORAL CAPSULE 25 MG | 5 | PA; QL (180 per 30 days); LA |
| VITRAKVI ORAL SOLUTION | 5 | PA; QL (300 per 30 days); LA |
| VIZIMPRO | 5 | PA; QL (30 per 30 days); LA |
| VONJO | 5 | PA; QL (120 per 30 days); LA |
| WELIREG | 5 | PA; QL (90 per 30 days); LA |
| XALKORI ORAL CAPSULE | 5 | PA; QL (120 per 30 days); LA |
| XALKORI ORAL CAPSULE SPRINKLE 150 MG | 5 | PA; QL (180 per 30 days); LA |
| XALKORI ORAL CAPSULE SPRINKLE 20 MG | 5 | PA; QL (240 per 30 days); LA |
| XALKORI ORAL CAPSULE SPRINKLE 50 MG | 5 | PA; QL (120 per 30 days); LA |
| XOSPATA | 5 | PA; QL (90 per 30 days); LA |
| XPOVIO (100 MG ONCE WEEKLY) ORAL TABLET THERAPY PACK 50 MG | 5 | PA; QL (8 per 28 days); LA |
| XPOVIO (40 MG ONCE WEEKLY) ORAL TABLET THERAPY PACK 40 MG | 5 | PA; QL (4 per 28 days); LA |
| XPOVIO (40 MG TWICE WEEKLY) ORAL TABLET THERAPY PACK 40 MG | 5 | PA; QL (8 per 28 days); LA |
| XPOVIO (60 MG ONCE WEEKLY) ORAL TABLET THERAPY PACK 60 MG | 5 | PA; QL (4 per 28 days); LA |
| XPOVIO (60 MG TWICE WEEKLY) | 5 | PA; QL (24 per 28 days); LA |
| XPOVIO (80 MG ONCE WEEKLY) ORAL TABLET THERAPY PACK 40 MG | 5 | PA; QL (8 per 28 days); LA |
| XPOVIO (80 MG TWICE WEEKLY) | 5 | PA; QL (32 per 28 days); LA |
| XTANDI ORAL CAPSULE | 5 | PA; QL (120 per 30 days); LA |

You can find information on what the symbols and abbreviations in this table mean by going to page 10 of this document. Ou ka jwenn enfòmasyon sou sa senbòl ak abrevyasyon yo nan tablo sa a vle di lè w ale nan paj 19 dokiman sa a.

| DRUG NAME / NON MEDIKAMAN | DRUG TIER / NIVO MEDIKAMAN | REQUIREMENTS / LIMITS KONDISYON / LIMIT |
|---|----------------------------|---|
| XTANDI ORAL TABLET 40 MG | 5 | PA; QL (120 per 30 days) |
| XTANDI ORAL TABLET 80 MG | 5 | PA; QL (60 per 30 days) |
| ZEJULA ORAL TABLET 100 MG | 5 | PA; QL (90 per 30 days) |
| ZEJULA ORAL TABLET 200 MG, 300 MG | 5 | PA; QL (30 per 30 days) |
| ZELBORAF | 5 | PA; QL (240 per 30 days); LA |
| ZEPZELCA | 5 | PA |
| ZOLINZA | 5 | PA; QL (120 per 30 days) |
| ZYDELIG | 5 | PA; QL (60 per 30 days); LA |
| ZYKADIA ORAL TABLET | 5 | PA; QL (90 per 30 days); LA |
| BLOOD PRODUCTS AND MODIFIERS / PWODUI SAN AK MODIFIKATÈ | | |
| <i>anagrelide hcl</i> | 2 | MO; 90D |
| <i>aspirin-dipyridamole er</i> | 2 | QL (60 per 30 days); MO; 90D |
| BRILINTA | 3 | QL (60 per 30 days); MO |
| <i>cilostazol</i> | 2 | MO; 90D |
| <i>clopidogrel bisulfate oral tablet 75 mg</i> | 2 | QL (30 per 30 days); MO; 90D |
| <i>dabigatran etexilate mesylate</i> | 2 | QL (60 per 30 days); MO; 90D |
| <i>dipyridamole oral tablet 25 mg, 50 mg</i> | 1 | PA; MO; 100D; HRM |
| <i>dipyridamole oral tablet 75 mg</i> | 2 | PA; MO; 90D; HRM |
| DROXIA | 4 | MO |
| ELIQUIS | 3 | QL (60 per 30 days); MO |
| ELIQUIS DVT/PE STARTER PACK ORAL TABLET THERAPY PACK | 3 | QL (74 per 180 days) |
| <i>enoxaparin sodium injection solution prefilled syringe 100 mg/ml, 150 mg/ml</i> | 2 | QL (56 per 28 days) |
| <i>enoxaparin sodium injection solution prefilled syringe 120 mg/0.8ml, 80 mg/0.8ml</i> | 2 | QL (44.8 per 28 days) |
| <i>enoxaparin sodium injection solution prefilled syringe 30 mg/0.3ml</i> | 2 | QL (16.8 per 28 days) |

You can find information on what the symbols and abbreviations in this table mean by going to page 10 of this document. Ou ka jwenn enfòmasyon sou sa senbòl ak abrevyasyon yo nan tablo sa a vle di lè w ale nan paj 19 dokiman sa a.

| DRUG NAME / NON MEDIKAMAN | DRUG TIER / NIVO MEDIKAMAN | REQUIREMENTS / LIMITS KONDISYON / LIMIT |
|--|----------------------------|---|
| <i>enoxaparin sodium injection solution prefilled syringe 40 mg/0.4ml</i> | 2 | QL (22.4 per 28 days) |
| <i>enoxaparin sodium injection solution prefilled syringe 60 mg/0.6ml</i> | 2 | QL (33.6 per 28 days) |
| <i>fondaparinux sodium subcutaneous solution 10 mg/0.8ml</i> | 5 | QL (24 per 30 days) |
| <i>fondaparinux sodium subcutaneous solution 2.5 mg/0.5ml</i> | 2 | QL (15 per 30 days) |
| <i>fondaparinux sodium subcutaneous solution 5 mg/0.4ml</i> | 5 | QL (12 per 30 days) |
| <i>fondaparinux sodium subcutaneous solution 7.5 mg/0.6ml</i> | 5 | QL (18 per 30 days) |
| FRAGMIN SUBCUTANEOUS SOLUTION 10000 UNIT/4ML | 4 | |
| FRAGMIN SUBCUTANEOUS SOLUTION 95000 UNIT/3.8ML | 5 | |
| FRAGMIN SUBCUTANEOUS SOLUTION PREFILLED SYRINGE 10000 UNIT/ML, 12500 UNIT/0.5ML, 15000 UNIT/0.6ML, 18000 UNT/0.72ML, 7500 UNIT/0.3ML | 5 | |
| FRAGMIN SUBCUTANEOUS SOLUTION PREFILLED SYRINGE 2500 UNIT/0.2ML, 5000 UNIT/0.2ML | 4 | |
| <i>heparin sodium (porcine) injection solution 1000 unit/ml, 10000 unit/ml, 20000 unit/ml</i> | 2 | B/D PA |
| <i>heparin sodium (porcine) injection solution 5000 unit/ml</i> | 1 | B/D PA |
| <i>heparin sodium (porcine) pf injection solution 1000 unit/ml</i> | 2 | B/D PA |
| <i>icatibant acetate</i> | 5 | PA |
| <i>jantoven</i> | 1 | MO; 100D |
| LEUKINE INJECTION SOLUTION RECONSTITUTED | 5 | PA |
| <i>l-glutamine oral packet</i> | 5 | PA |

You can find information on what the symbols and abbreviations in this table mean by going to page 10 of this document. Ou ka jwenn enfòmasyon sou sa senbòl ak abrevyasyon yo nan tablo sa a vle di lè w ale nan paj 19 dokiman sa a.

| DRUG NAME / NON MEDIKAMAN | DRUG TIER / NIVO MEDIKAMAN | REQUIREMENTS / LIMITS KONDISYON / LIMIT |
|--|----------------------------|---|
| NEULASTA SUBCUTANEOUS SOLUTION PREFILLED SYRINGE | 5 | PA; QL (1.2 per 28 days) |
| NEUPOGEN INJECTION SOLUTION 300 MCG/ML, 480 MCG/1.6ML | 5 | PA |
| NEUPOGEN INJECTION SOLUTION PREFILLED SYRINGE | 5 | PA |
| <i>pentoxifylline er</i> | 1 | MO; 100D |
| <i>prasugrel hcl</i> | 2 | QL (30 per 30 days); MO; 90D |
| PROCRIT INJECTION SOLUTION 10000 UNIT/ML, 2000 UNIT/ML, 3000 UNIT/ML, 4000 UNIT/ML | 4 | PA |
| PROCRIT INJECTION SOLUTION 20000 UNIT/ML, 40000 UNIT/ML | 5 | PA |
| PROMACTA ORAL PACKET 12.5 MG | 5 | PA; QL (360 per 30 days); LA |
| PROMACTA ORAL PACKET 25 MG | 5 | PA; QL (180 per 30 days); LA |
| PROMACTA ORAL TABLET 12.5 MG, 25 MG | 5 | PA; QL (30 per 30 days); LA |
| PROMACTA ORAL TABLET 50 MG | 5 | PA; QL (90 per 30 days); LA |
| PROMACTA ORAL TABLET 75 MG | 5 | PA; QL (60 per 30 days); LA |
| RETACRIT INJECTION SOLUTION 10000 UNIT/ML, 10000 UNIT/ML(1ML), 2000 UNIT/ML, 20000 UNIT/ML, 3000 UNIT/ML, 4000 UNIT/ML | 4 | PA; QL (12 per 28 days) |
| RETACRIT INJECTION SOLUTION 40000 UNIT/ML | 5 | PA; QL (12 per 28 days) |
| SAJAZIR SUBCUTANEOUS SOLUTION PREFILLED SYRINGE | 5 | PA |
| TAKHZYRO SUBCUTANEOUS SOLUTION | 5 | PA; LA |
| TAKHZYRO SUBCUTANEOUS SOLUTION PREFILLED SYRINGE | 5 | PA |
| <i>tranexamic acid oral</i> | 2 | |
| UDENYCA | 5 | PA; QL (1.2 per 28 days) |
| <i>warfarin sodium oral</i> | 1 | MO; 100D |
| XARELTO ORAL SUSPENSION RECONSTITUTED | 3 | QL (600 per 30 days); MO |

You can find information on what the symbols and abbreviations in this table mean by going to page 10 of this document. Ou ka jwenn enfòmasyon sou sa senbòl ak abrevyasyon yo nan tablo sa a vle di lè w ale nan paj 19 dokiman sa a.

| DRUG NAME / NON MEDIKAMAN | DRUG TIER / NIVO MEDIKAMAN | REQUIREMENTS / LIMITS KONDISYON / LIMIT |
|---|-----------------------------------|--|
| XARELTO ORAL TABLET 10 MG, 20 MG | 3 | QL (30 per 30 days); MO |
| XARELTO ORAL TABLET 15 MG, 2.5 MG | 3 | QL (60 per 30 days); MO |
| XARELTO STARTER PACK | 3 | |
| ZARXIO | 5 | PA |
| CARDIOVASCULAR AGENTS / AJAN ADYOVASKILÈ | | |
| <i>acebutolol hcl oral</i> | 1 | MO; 100D |
| <i>acetazolamide oral</i> | 2 | MO; 90D |
| <i>aliskiren fumarate</i> | 2 | MO; 90D |
| <i>amiloride hcl oral</i> | 1 | MO; 100D |
| <i>amiloride-hydrochlorothiazide</i> | 1 | MO; 100D |
| <i>amiodarone hcl oral</i> | 2 | MO; 90D |
| <i>amlodipine besy-benazepril hcl oral capsule 10-20 mg, 10-40 mg, 5-20 mg, 5-40 mg</i> | 2 | QL (30 per 30 days); MO; 90D |
| <i>amlodipine besy-benazepril hcl oral capsule 2.5-10 mg, 5-10 mg</i> | 1 | QL (30 per 30 days); MO; 100D |
| <i>amlodipine besylate oral</i> | 1 | MO; 100D |
| <i>amlodipine besylate-valsartan</i> | 2 | QL (30 per 30 days); MO; 90D |
| <i>amlodipine-atorvastatin</i> | 2 | QL (30 per 30 days); MO; 90D |
| <i>amlodipine-olmesartan</i> | 2 | QL (30 per 30 days); MO; 90D |
| <i>amlodipine-valsartan-hctz</i> | 2 | QL (30 per 30 days); MO; 90D |
| <i>atenolol oral</i> | 1 | MO; 100D |
| <i>atenolol-chlorthalidone</i> | 1 | MO; 100D |
| <i>atorvastatin calcium oral</i> | 1 | QL (30 per 30 days); MO; 100D |
| <i>benazepril hcl oral</i> | 1 | MO; 100D |
| <i>benazepril-hydrochlorothiazide</i> | 2 | QL (30 per 30 days); MO; 90D |
| <i>betaxolol hcl oral</i> | 1 | MO; 100D |
| <i>bisoprolol fumarate oral</i> | 1 | MO; 100D |
| <i>bisoprolol-hydrochlorothiazide</i> | 1 | MO; 100D |
| <i>bumetanide injection</i> | 2 | |

You can find information on what the symbols and abbreviations in this table mean by going to page 10 of this document. Ou ka jwenn enfòmasyon sou sa senbòl ak abrevyasyon yo nan tablo sa a vle di lè w ale nan paj 19 dokiman sa a.

| DRUG NAME / NON MEDIKAMAN | DRUG TIER / NIVO MEDIKAMAN | REQUIREMENTS / LIMITS KONDISYON / LIMIT |
|--|----------------------------|---|
| <i>bumetanide oral</i> | 2 | MO; 90D |
| <i>candesartan cilexetil oral tablet 16 mg, 4 mg, 8 mg</i> | 2 | QL (60 per 30 days); MO; 90D |
| <i>candesartan cilexetil oral tablet 32 mg</i> | 2 | QL (30 per 30 days); MO; 90D |
| <i>candesartan cilexetil-hctz oral tablet 16-12.5 mg</i> | 2 | QL (60 per 30 days); MO; 90D |
| <i>candesartan cilexetil-hctz oral tablet 32-12.5 mg, 32-25 mg</i> | 2 | QL (30 per 30 days); MO; 90D |
| <i>captopril oral tablet 100 mg</i> | 1 | QL (120 per 30 days); MO; 100D |
| <i>captopril oral tablet 12.5 mg, 25 mg, 50 mg</i> | 1 | QL (90 per 30 days); MO; 100D |
| <i>captopril-hydrochlorothiazide</i> | 2 | QL (60 per 30 days); MO; 90D |
| CARTIA XT | 1 | MO; 100D |
| <i>carvedilol</i> | 1 | MO; 100D |
| <i>carvedilol phosphate er</i> | 2 | MO; 90D |
| <i>chlorthalidone oral tablet 25 mg, 50 mg</i> | 1 | MO; 100D |
| <i>cholestyramine light</i> | 2 | MO; 90D |
| <i>cholestyramine oral</i> | 2 | MO; 90D |
| <i>clonidine</i> | 2 | QL (4 per 28 days); MO; 90D |
| <i>clonidine hcl oral</i> | 1 | MO; 100D |
| <i>colesevelam hcl</i> | 2 | MO; 90D |
| <i>colestipol hcl</i> | 2 | MO; 90D |
| CORLANOR ORAL SOLUTION | 4 | PA; QL (560 per 28 days); MO |
| <i>digox oral tablet 125 mcg</i> | 1 | QL (30 per 30 days); MO; 100D |
| <i>digox oral tablet 250 mcg</i> | 1 | PA; QL (60 per 30 days); MO; 100D; HRM |
| <i>digoxin oral solution</i> | 2 | MO; 90D |
| <i>digoxin oral tablet 125 mcg</i> | 1 | QL (30 per 30 days); MO; 100D |
| <i>digoxin oral tablet 250 mcg</i> | 1 | PA; QL (60 per 30 days); MO; 100D; HRM |

You can find information on what the symbols and abbreviations in this table mean by going to page 10 of this document. Ou ka jwenn enfòmasyon sou sa senbòl ak abrevyasyon yo nan tablo sa a vle di lè w ale nan paj 19 dokiman sa a.

| DRUG NAME / NON MEDIKAMAN | DRUG TIER / NIVO MEDIKAMAN | REQUIREMENTS / LIMITS KONDISYON / LIMIT |
|---|----------------------------|---|
| <i>diltiazem hcl er beads oral capsule extended release 24 hour 120 mg, 180 mg, 240 mg, 300 mg</i> | 3 | MO |
| <i>diltiazem hcl er beads oral capsule extended release 24 hour 360 mg, 420 mg</i> | 2 | MO; 90D |
| <i>diltiazem hcl er coated beads oral capsule extended release 24 hour 120 mg, 180 mg, 300 mg</i> | 1 | MO; 100D |
| <i>diltiazem hcl er coated beads oral capsule extended release 24 hour 240 mg, 360 mg</i> | 2 | MO; 90D |
| <i>diltiazem hcl er oral capsule extended release 12 hour</i> | 2 | MO; 90D |
| <i>diltiazem hcl er oral capsule extended release 24 hour 120 mg, 180 mg, 240 mg</i> | 1 | MO; 100D |
| <i>diltiazem hcl er oral tablet extended release 24 hour 180 mg, 240 mg, 300 mg, 360 mg, 420 mg</i> | 2 | MO; 90D |
| <i>diltiazem hcl oral</i> | 1 | MO; 100D |
| <i>dilt-xr</i> | 1 | MO; 100D |
| <i>disopyramide phosphate oral</i> | 2 | PA; MO; 90D; HRM |
| <i>dofetilide</i> | 2 | 90D |
| <i>doxazosin mesylate oral</i> | 1 | MO; 100D |
| <i>droxidopa oral capsule 100 mg</i> | 2 | PA; QL (90 per 30 days) |
| <i>droxidopa oral capsule 200 mg, 300 mg</i> | 5 | PA; QL (180 per 30 days) |
| <i>enalapril maleate oral tablet</i> | 1 | MO; 100D |
| <i>enalapril-hydrochlorothiazide</i> | 1 | QL (60 per 30 days); MO; 100D |
| ENTRESTO ORAL CAPSULE SPRINKLE | 3 | QL (240 per 30 days); MO |
| ENTRESTO ORAL TABLET 24-26 MG | 3 | QL (180 per 30 days); MO |
| ENTRESTO ORAL TABLET 49-51 MG, 97-103 MG | 3 | QL (60 per 30 days); MO |
| <i>eplerenone</i> | 2 | MO; 90D |
| <i>ezetimibe</i> | 2 | QL (30 per 30 days); MO; 90D |
| <i>ezetimibe-simvastatin</i> | 2 | PA; QL (30 per 30 days); MO; 90D |

You can find information on what the symbols and abbreviations in this table mean by going to page 10 of this document. Ou ka jwenn enfòmasyon sou sa senbòl ak abrevyasyon yo nan tablo sa a vle di lè w ale nan paj 19 dokiman sa a.

| DRUG NAME / NON MEDIKAMAN | DRUG TIER / NIVO MEDIKAMAN | REQUIREMENTS / LIMITS KONDISYON / LIMIT |
|---|----------------------------|---|
| <i>felodipine er</i> | 1 | MO; 100D |
| <i>fenofibrate micronized oral capsule 130 mg, 134 mg, 200 mg, 43 mg, 67 mg</i> | 2 | MO; 90D |
| <i>fenofibrate oral</i> | 2 | MO; 90D |
| <i>fenofibric acid oral capsule delayed release</i> | 2 | MO; 90D |
| <i>flecainide acetate</i> | 2 | MO; 90D |
| <i>fluvastatin sodium</i> | 2 | QL (60 per 30 days); MO; 90D |
| <i>fluvastatin sodium er</i> | 2 | QL (30 per 30 days); MO; 90D |
| <i>fosinopril sodium</i> | 1 | MO; 100D |
| <i>fosinopril sodium-hctz oral tablet 10-12.5 mg</i> | 1 | QL (60 per 30 days); MO; 100D |
| <i>fosinopril sodium-hctz oral tablet 20-12.5 mg</i> | 1 | QL (120 per 30 days); MO; 100D |
| <i>furosemide injection</i> | 1 | |
| <i>furosemide oral tablet</i> | 1 | MO; 100D |
| <i>gemfibrozil oral</i> | 2 | MO; 90D |
| <i>hydralazine hcl oral</i> | 1 | MO; 100D |
| <i>hydrochlorothiazide oral</i> | 1 | MO; 100D |
| <i>icosapent ethyl</i> | 3 | MO |
| <i>indapamide oral</i> | 1 | MO; 100D |
| <i>irbesartan</i> | 1 | QL (30 per 30 days); MO; 100D |
| <i>irbesartan-hydrochlorothiazide oral tablet 150-12.5 mg</i> | 1 | QL (60 per 30 days); MO; 100D |
| <i>irbesartan-hydrochlorothiazide oral tablet 300-12.5 mg</i> | 1 | QL (30 per 30 days); MO; 100D |
| <i>isosorb dinitrate-hydralazine oral tablet 20-37.5 mg</i> | 2 | QL (180 per 30 days); MO; 90D |
| <i>isosorbide dinitrate oral tablet 10 mg, 20 mg, 30 mg, 5 mg</i> | 1 | MO; 100D |
| <i>isosorbide mononitrate</i> | 1 | MO; 100D |
| <i>isosorbide mononitrate er</i> | 1 | MO; 100D |
| <i>isradipine oral capsule 2.5 mg</i> | 2 | MO; 90D |

You can find information on what the symbols and abbreviations in this table mean by going to page 10 of this document. Ou ka jwenn enfòmasyon sou sa senbòl ak abrevyasyon yo nan tablo sa a vle di lè w ale nan paj 19 dokiman sa a.

| DRUG NAME / NON MEDIKAMAN | DRUG TIER / NIVO MEDIKAMAN | REQUIREMENTS / LIMITS KONDISYON / LIMIT |
|--|----------------------------|---|
| <i>isradipine oral capsule 5 mg</i> | 1 | MO; 100D |
| <i>ivabradine hcl</i> | 4 | PA; QL (60 per 30 days); MO |
| <i>labetalol hcl oral</i> | 1 | MO; 100D |
| <i>lisinopril oral</i> | 1 | MO; 100D |
| <i>lisinopril-hydrochlorothiazide oral tablet 10-12.5 mg</i> | 1 | QL (30 per 30 days); MO; 100D |
| <i>lisinopril-hydrochlorothiazide oral tablet 20-12.5 mg</i> | 1 | QL (120 per 30 days); MO; 100D |
| <i>lisinopril-hydrochlorothiazide oral tablet 20-25 mg</i> | 1 | QL (60 per 30 days); MO; 100D |
| <i>losartan potassium oral tablet 100 mg</i> | 1 | QL (30 per 30 days); MO; 100D |
| <i>losartan potassium oral tablet 25 mg, 50 mg</i> | 1 | QL (60 per 30 days); MO; 100D |
| <i>losartan potassium-hctz</i> | 1 | QL (30 per 30 days); MO; 100D |
| <i>lovastatin oral</i> | 1 | QL (60 per 30 days); MO; 100D |
| MATZIM LA | 2 | MO; 90D |
| <i>metolazone</i> | 1 | MO; 100D |
| <i>metoprolol succinate er</i> | 1 | MO; 100D |
| <i>metoprolol tartrate oral tablet 100 mg, 25 mg, 50 mg</i> | 1 | MO; 100D |
| <i>metoprolol tartrate oral tablet 37.5 mg, 75 mg</i> | 2 | MO; 90D |
| <i>metoprolol-hydrochlorothiazide</i> | 1 | MO; 100D |
| <i>metyrosine</i> | 5 | |
| <i>mexiletine hcl oral</i> | 2 | MO; 90D |
| <i>midodrine hcl</i> | 2 | |
| <i>minoxidil oral</i> | 1 | MO; 100D |
| <i>moexipril hcl</i> | 1 | MO; 100D |
| MULTAQ | 3 | QL (60 per 30 days); MO |
| <i>nadolol oral tablet 20 mg, 40 mg, 80 mg</i> | 2 | MO; 90D |
| <i>nebivolol hcl</i> | 2 | MO; 90D |
| <i>niacin (antihyperlipidemic)</i> | 2 | |

You can find information on what the symbols and abbreviations in this table mean by going to page 10 of this document. Ou ka jwenn enfòmasyon sou sa senbòl ak abrevyasyon yo nan tablo sa a vle di lè w ale nan paj 19 dokiman sa a.

| DRUG NAME / NON MEDIKAMAN | DRUG TIER / NIVO MEDIKAMAN | REQUIREMENTS / LIMITS KONDISYON / LIMIT |
|--|-----------------------------------|--|
| <i>niacin er (antihyperlipidemic)</i> | 2 | MO; 90D |
| <i>niacor</i> | 2 | |
| <i>nicardipine hcl oral</i> | 2 | MO; 90D |
| <i>nifedipine er</i> | 1 | MO; 100D |
| <i>nifedipine er osmotic release</i> | 1 | MO; 100D |
| <i>nimodipine oral</i> | 2 | |
| <i>nisoldipine er</i> | 2 | MO; 90D |
| <i>nitroglycerin sublingual</i> | 1 | MO; 100D |
| <i>nitroglycerin transdermal patch 24 hour</i> | 1 | MO; 100D |
| <i>nitroglycerin translingual solution</i> | 2 | MO; 90D |
| <i>olmesartan medoxomil oral tablet 20 mg, 40 mg</i> | 2 | QL (30 per 30 days); MO; 90D |
| <i>olmesartan medoxomil oral tablet 5 mg</i> | 2 | QL (60 per 30 days); MO; 90D |
| <i>olmesartan medoxomil-hctz</i> | 2 | QL (30 per 30 days); MO; 90D |
| <i>olmesartan-amlodipine-hctz</i> | 2 | QL (30 per 30 days); MO; 90D |
| <i>omega-3-acid ethyl esters</i> | 2 | MO; 90D |
| <i>pacerone oral tablet 100 mg, 200 mg, 400 mg</i> | 2 | MO; 90D |
| <i>perindopril erbumine</i> | 1 | MO; 100D |
| <i>pindolol</i> | 1 | MO; 100D |
| <i>pitavastatin calcium</i> | 3 | QL (30 per 30 days); MO |
| <i>pravastatin sodium</i> | 1 | QL (30 per 30 days); MO; 100D |
| <i>prazosin hcl oral</i> | 1 | MO; 100D |
| <i>prevalite</i> | 2 | MO; 90D |
| <i>propafenone hcl</i> | 2 | MO; 90D |
| <i>propafenone hcl er</i> | 2 | MO; 90D |
| <i>propranolol hcl er</i> | 2 | MO; 90D |
| <i>propranolol hcl oral solution</i> | 2 | MO; 90D |
| <i>propranolol hcl oral tablet</i> | 1 | MO; 100D |
| <i>quinapril hcl</i> | 1 | MO; 100D |

You can find information on what the symbols and abbreviations in this table mean by going to page 10 of this document. Ou ka jwenn enfòmasyon sou sa senbòl ak abrevyasyon yo nan tablo sa a vle di lè w ale nan paj 19 dokiman sa a.

| DRUG NAME / NON MEDIKAMAN | DRUG TIER / NIVO MEDIKAMAN | REQUIREMENTS / LIMITS KONDISYON / LIMIT |
|---|----------------------------|---|
| <i>quinapril-hydrochlorothiazide</i> | 1 | QL (60 per 30 days); MO; 100D |
| <i>quinidine gluconate er</i> | 2 | MO; 90D |
| <i>quinidine sulfate oral</i> | 1 | MO; 100D |
| <i>ramipril</i> | 1 | MO; 100D |
| <i>ranolazine er</i> | 2 | PA; QL (60 per 30 days); MO; 90D |
| REPATHA | 3 | PA; QL (3 per 28 days) |
| REPATHA PUSHTRONEX SYSTEM | 3 | PA; QL (3.5 per 28 days) |
| REPATHA SURECLICK | 3 | PA; QL (3 per 28 days) |
| <i>rosuvastatin calcium oral</i> | 2 | QL (30 per 30 days); MO; 90D |
| <i>simvastatin oral tablet</i> | 1 | QL (30 per 30 days); MO; 100D |
| SOAAZ | 1 | MO; 100D |
| SORINE | 2 | MO; 90D |
| <i>sotalol hcl (af)</i> | 2 | MO; 90D |
| <i>sotalol hcl oral</i> | 2 | MO; 90D |
| <i>spironolactone oral tablet</i> | 1 | MO; 100D |
| <i>spironolactone-hctz</i> | 1 | MO; 100D |
| TEGSEDI | 5 | PA; QL (6 per 28 days); LA |
| <i>telmisartan oral tablet 20 mg, 40 mg</i> | 2 | QL (30 per 30 days); MO; 90D |
| <i>telmisartan oral tablet 80 mg</i> | 2 | QL (60 per 30 days); MO; 90D |
| <i>telmisartan-amlodipine</i> | 2 | QL (30 per 30 days); MO; 90D |
| <i>telmisartan-hctz oral tablet 40-12.5 mg, 80-25 mg</i> | 2 | QL (30 per 30 days); MO; 90D |
| <i>telmisartan-hctz oral tablet 80-12.5 mg</i> | 2 | QL (60 per 30 days); MO; 90D |
| <i>terazosin hcl oral</i> | 1 | MO; 100D |
| TIADYLT ER ORAL CAPSULE EXTENDED RELEASE 24 HOUR 120 MG, 180 MG, 240 MG, 300 MG | 3 | MO |
| TIADYLT ER ORAL CAPSULE EXTENDED RELEASE 24 HOUR 360 MG, 420 MG | 2 | MO; 90D |
| <i>timolol maleate oral</i> | 1 | MO; 100D |
| <i>torseamide oral tablet 10 mg, 100 mg, 20 mg</i> | 1 | MO; 100D |

You can find information on what the symbols and abbreviations in this table mean by going to page 10 of this document. Ou ka jwenn enfòmasyon sou sa senbòl ak abrevyasyon yo nan tablo sa a vle di lè w ale nan paj 19 dokiman sa a.

| DRUG NAME / NON MEDIKAMAN | DRUG TIER / NIVO MEDIKAMAN | REQUIREMENTS / LIMITS KONDISYON / LIMIT |
|---|-----------------------------------|--|
| <i>trandolapril</i> | 1 | MO; 100D |
| <i>trandolapril-verapamil hcl er</i> | 2 | QL (30 per 30 days); MO; 90D |
| <i>triamterene-hctz oral capsule 37.5-25 mg</i> | 1 | MO; 100D |
| <i>triamterene-hctz oral tablet</i> | 1 | MO; 100D |
| <i>valsartan oral tablet 160 mg</i> | 2 | QL (60 per 30 days); MO; 90D |
| <i>valsartan oral tablet 320 mg</i> | 2 | QL (30 per 30 days); MO; 90D |
| <i>valsartan oral tablet 40 mg, 80 mg</i> | 2 | QL (90 per 30 days); MO; 90D |
| <i>valsartan-hydrochlorothiazide</i> | 2 | QL (30 per 30 days); MO; 90D |
| VASCEPA | 4 | MO |
| <i>verapamil hcl er</i> | 2 | MO; 90D |
| <i>verapamil hcl oral</i> | 1 | MO; 100D |
| VERQUVO | 4 | PA; MO |

CENTRAL NERVOUS SYSTEM AGENTS / AJAN SISTÈM NÈVE SANTRAL

| | | |
|--|---|----------------------------|
| ABILIFY MAINTENA INTRAMUSCULAR PREFILLED SYRINGE | 5 | QL (1 per 28 days); MO |
| ABILIFY MAINTENA INTRAMUSCULAR SUSPENSION RECONSTITUTED ER | 5 | QL (1 per 28 days); MO |
| <i>acamprosate calcium</i> | 2 | MO; 90D |
| AIMOVIG SUBCUTANEOUS SOLUTION AUTO-INJECTOR 140 MG/ML | 3 | PA; QL (1 per 28 days); MO |
| AIMOVIG SUBCUTANEOUS SOLUTION AUTO-INJECTOR 70 MG/ML | 3 | PA; QL (2 per 28 days); MO |
| <i>almotriptan malate</i> | 2 | QL (9 per 30 days) |
| <i>alprazolam er</i> | 2 | QL (90 per 30 days) |
| ALPRAZOLAM INTENSOL | 3 | QL (300 per 30 days) |
| <i>alprazolam oral tablet</i> | 1 | QL (90 per 30 days) |
| <i>alprazolam oral tablet dispersible</i> | 2 | QL (90 per 30 days) |
| <i>alprazolam xr</i> | 2 | QL (90 per 30 days) |

You can find information on what the symbols and abbreviations in this table mean by going to page 10 of this document. Ou ka jwenn enfòmasyon sou sa senbòl ak abrevyasyon yo nan tablo sa a vle di lè w ale nan paj 19 dokiman sa a.

| DRUG NAME / NON MEDIKAMAN | DRUG TIER / NIVO MEDIKAMAN | REQUIREMENTS / LIMITS KONDISYON / LIMIT |
|---|-----------------------------------|--|
| <i>amantadine hcl oral capsule</i> | 2 | MO; 90D |
| <i>amantadine hcl oral solution</i> | 2 | MO; 90D |
| <i>amantadine hcl oral tablet</i> | 2 | MO; 90D |
| <i>amitriptyline hcl oral tablet 10 mg, 100 mg, 150 mg, 75 mg</i> | 1 | MO; 100D |
| <i>amitriptyline hcl oral tablet 25 mg, 50 mg</i> | 2 | MO; 90D |
| <i>amoxapine</i> | 2 | PA; MO; 90D; HRM |
| <i>amphetamine-dextroamphet er</i> | 2 | PA; QL (30 per 30 days); MO; 90D |
| <i>amphetamine-dextroamphetamine oral tablet 10 mg, 12.5 mg, 15 mg, 20 mg, 5 mg, 7.5 mg</i> | 2 | PA; QL (90 per 30 days); MO; 90D |
| <i>amphetamine-dextroamphetamine oral tablet 30 mg</i> | 2 | PA; QL (60 per 30 days); MO; 90D |
| APLENZIN ORAL TABLET EXTENDED RELEASE 24 HOUR 174 MG | 5 | QL (90 per 30 days); MO |
| APLENZIN ORAL TABLET EXTENDED RELEASE 24 HOUR 348 MG | 5 | QL (45 per 30 days); MO |
| APLENZIN ORAL TABLET EXTENDED RELEASE 24 HOUR 522 MG | 5 | QL (30 per 30 days); MO |
| <i>apomorphine hcl subcutaneous</i> | 5 | PA; QL (60 per 30 days) |
| APTIOM | 5 | MO |
| <i>aripiprazole oral solution</i> | 2 | QL (900 per 30 days); MO; 90D |
| <i>aripiprazole oral tablet 10 mg, 15 mg, 2 mg, 5 mg</i> | 2 | MO; 90D |
| <i>aripiprazole oral tablet 20 mg, 30 mg</i> | 2 | QL (30 per 30 days); MO; 90D |
| <i>aripiprazole oral tablet dispersible 10 mg</i> | 2 | QL (90 per 30 days); MO; 90D |
| <i>aripiprazole oral tablet dispersible 15 mg</i> | 4 | QL (60 per 30 days); MO |
| <i>asenapine maleate sublingual tablet sublingual 10 mg</i> | 2 | QL (60 per 30 days); MO; 90D |
| <i>asenapine maleate sublingual tablet sublingual 2.5 mg</i> | 2 | QL (240 per 30 days); MO; 90D |

You can find information on what the symbols and abbreviations in this table mean by going to page 10 of this document. Ou ka jwenn enfòmasyon sou sa senbòl ak abrevyasyon yo nan tablo sa a vle di lè w ale nan paj 19 dokiman sa a.

| DRUG NAME / NON MEDIKAMAN | DRUG TIER / NIVO MEDIKAMAN | REQUIREMENTS / LIMITS KONDISYON / LIMIT |
|--|----------------------------|---|
| <i>asenapine maleate sublingual tablet sublingual 5 mg</i> | 2 | QL (120 per 30 days); MO; 90D |
| <i>atomoxetine hcl oral capsule 10 mg, 18 mg, 25 mg, 40 mg</i> | 2 | QL (60 per 30 days); MO; 90D |
| <i>atomoxetine hcl oral capsule 100 mg, 60 mg, 80 mg</i> | 2 | QL (30 per 30 days); MO; 90D |
| AUSTEDO | 5 | PA; QL (120 per 30 days) |
| AUVELITY | 5 | PA; QL (60 per 30 days); MO |
| AVONEX PEN INTRAMUSCULAR AUTO-INJECTOR KIT | 5 | PA; QL (4 per 28 days) |
| AVONEX PREFILLED INTRAMUSCULAR PREFILLED SYRINGE KIT | 5 | PA; QL (4 per 28 days) |
| BAC | 2 | PA; QL (180 per 30 days); HRM |
| <i>baclofen oral tablet 10 mg, 15 mg, 5 mg</i> | 1 | QL (90 per 30 days) |
| <i>baclofen oral tablet 20 mg</i> | 1 | QL (120 per 30 days) |
| <i>benztropine mesylate oral</i> | 1 | PA; MO; 100D; HRM |
| BETASERON SUBCUTANEOUS KIT | 5 | PA; QL (15 per 30 days) |
| BRIVIACT ORAL SOLUTION | 5 | QL (600 per 30 days); MO |
| BRIVIACT ORAL TABLET | 5 | QL (60 per 30 days); MO |
| <i>bromocriptine mesylate oral</i> | 2 | MO; 90D |
| <i>buprenorphine hcl sublingual tablet sublingual 2 mg</i> | 2 | QL (240 per 30 days); NEDS |
| <i>buprenorphine hcl sublingual tablet sublingual 8 mg</i> | 2 | QL (60 per 30 days); NEDS |
| <i>buprenorphine hcl-naloxone hcl sublingual film 12-3 mg</i> | 2 | QL (60 per 30 days); NEDS |
| <i>buprenorphine hcl-naloxone hcl sublingual film 2-0.5 mg</i> | 2 | QL (480 per 30 days); NEDS |
| <i>buprenorphine hcl-naloxone hcl sublingual film 4-1 mg</i> | 2 | QL (240 per 30 days); NEDS |

You can find information on what the symbols and abbreviations in this table mean by going to page 10 of this document. Ou ka jwenn enfòmasyon sou sa senbòl ak abrevyasyon yo nan tablo sa a vle di lè w ale nan paj 19 dokiman sa a.

| DRUG NAME / NON MEDIKAMAN | DRUG TIER / NIVO MEDIKAMAN | REQUIREMENTS / LIMITS KONDISYON / LIMIT |
|--|-----------------------------------|--|
| <i>buprenorphine hcl-naloxone hcl sublingual film 8-2 mg</i> | 2 | QL (120 per 30 days); NEDS |
| <i>buprenorphine hcl-naloxone hcl sublingual tablet sublingual 2-0.5 mg</i> | 2 | QL (480 per 30 days); NEDS |
| <i>buprenorphine hcl-naloxone hcl sublingual tablet sublingual 8-2 mg</i> | 2 | QL (120 per 30 days); NEDS |
| <i>bupropion hcl er (smoking det)</i> | 2 | QL (60 per 30 days) |
| <i>bupropion hcl er (sr) oral tablet extended release 12 hour 100 mg</i> | 2 | QL (120 per 30 days); MO; 90D |
| <i>bupropion hcl er (sr) oral tablet extended release 12 hour 150 mg, 200 mg</i> | 2 | QL (60 per 30 days); MO; 90D |
| <i>bupropion hcl er (xl) oral tablet extended release 24 hour 150 mg</i> | 2 | QL (90 per 30 days); MO; 90D |
| <i>bupropion hcl er (xl) oral tablet extended release 24 hour 300 mg, 450 mg</i> | 2 | QL (30 per 30 days); MO; 90D |
| <i>bupropion hcl oral tablet 100 mg</i> | 1 | QL (135 per 30 days); MO; 100D |
| <i>bupropion hcl oral tablet 75 mg</i> | 1 | QL (180 per 30 days); MO; 100D |
| <i>bupirone hcl oral</i> | 1 | |
| <i>butalbital-acetaminophen oral tablet 50-325 mg</i> | 2 | PA; QL (180 per 30 days); HRM |
| <i>butalbital-apap-caffeine oral capsule</i> | 2 | PA; QL (180 per 30 days); HRM |
| <i>butalbital-apap-caffeine oral tablet 50-325-40 mg</i> | 2 | PA; QL (180 per 30 days); HRM |
| <i>CAPLYTA</i> | 5 | QL (30 per 30 days); MO |
| <i>carbamazepine er</i> | 2 | MO; 90D |
| <i>carbamazepine oral suspension</i> | 2 | MO; 90D |
| <i>carbamazepine oral tablet</i> | 2 | MO; 90D |
| <i>carbamazepine oral tablet chewable</i> | 1 | MO; 100D |
| <i>carbidopa oral</i> | 2 | MO; 90D |
| <i>carbidopa-levodopa er oral tablet extended release 25-100 mg, 50-200 mg</i> | 2 | MO; 90D |
| <i>carbidopa-levodopa oral tablet 10-100 mg</i> | 1 | MO; 100D |

You can find information on what the symbols and abbreviations in this table mean by going to page 10 of this document. Ou ka jwenn enfòmasyon sou sa senbòl ak abrevyasyon yo nan tablo sa a vle di lè w ale nan paj 19 dokiman sa a.

| DRUG NAME / NON MEDIKAMAN | DRUG TIER / NIVO MEDIKAMAN | REQUIREMENTS / LIMITS KONDISYON / LIMIT |
|---|----------------------------|---|
| <i>carbidopa-levodopa oral tablet 25-100 mg, 25-250 mg</i> | 2 | MO; 90D |
| <i>carbidopa-levodopa oral tablet dispersible</i> | 2 | MO; 90D |
| <i>carbidopa-levodopa-entacapone oral tablet 12.5-50-200 mg, 18.75-75-200 mg, 25-100-200 mg, 31.25-125-200 mg, 37.5-150-200 mg, 50-200-200 mg</i> | 2 | MO; 90D |
| <i>carisoprodol oral</i> | 2 | |
| <i>chlordiazepoxide hcl</i> | 2 | QL (120 per 30 days) |
| <i>chlordiazepoxide-amitriptyline</i> | 2 | PA; MO; 90D; HRM |
| <i>chlorpromazine hcl oral concentrate</i> | 4 | MO |
| <i>chlorpromazine hcl oral tablet</i> | 2 | MO; 90D |
| <i>chlorzoxazone oral tablet 500 mg</i> | 2 | PA; HRM |
| <i>citalopram hydrobromide oral solution</i> | 2 | QL (600 per 30 days); MO; 90D |
| <i>citalopram hydrobromide oral tablet 10 mg</i> | 1 | QL (120 per 30 days); MO; 100D |
| <i>citalopram hydrobromide oral tablet 20 mg</i> | 1 | QL (60 per 30 days); MO; 100D |
| <i>citalopram hydrobromide oral tablet 40 mg</i> | 1 | QL (30 per 30 days); MO; 100D |
| <i>clobazam oral suspension</i> | 2 | PA; QL (480 per 30 days); MO; 90D |
| <i>clobazam oral tablet 10 mg</i> | 2 | PA; QL (120 per 30 days); MO; 90D |
| <i>clobazam oral tablet 20 mg</i> | 2 | PA; QL (60 per 30 days); MO; 90D |
| <i>clomipramine hcl oral</i> | 2 | PA; MO; 90D; HRM |
| <i>clonazepam oral tablet 0.5 mg</i> | 1 | QL (1200 per 30 days) |
| <i>clonazepam oral tablet 1 mg</i> | 1 | QL (600 per 30 days) |
| <i>clonazepam oral tablet 2 mg</i> | 1 | QL (300 per 30 days) |
| <i>clonazepam oral tablet dispersible 0.125 mg</i> | 2 | QL (4800 per 30 days) |
| <i>clonazepam oral tablet dispersible 0.25 mg</i> | 2 | QL (2400 per 30 days) |
| <i>clonazepam oral tablet dispersible 0.5 mg</i> | 2 | QL (1200 per 30 days) |
| <i>clonazepam oral tablet dispersible 1 mg</i> | 2 | QL (600 per 30 days) |

You can find information on what the symbols and abbreviations in this table mean by going to page 10 of this document. Ou ka jwenn enfòmasyon sou sa senbòl ak abrevyasyon yo nan tablo sa a vle di lè w ale nan paj 19 dokiman sa a.

| DRUG NAME / NON MEDIKAMAN | DRUG TIER / NIVO MEDIKAMAN | REQUIREMENTS / LIMITS KONDISYON / LIMIT |
|--|-----------------------------------|--|
| <i>clonazepam oral tablet dispersible 2 mg</i> | 2 | QL (300 per 30 days) |
| <i>clonidine hcl er oral tablet extended release 12 hour</i> | 2 | QL (120 per 30 days); MO; 90D |
| <i>clorazepate dipotassium</i> | 2 | |
| <i>clozapine oral tablet 100 mg</i> | 2 | QL (270 per 30 days) |
| <i>clozapine oral tablet 200 mg</i> | 2 | QL (120 per 30 days) |
| <i>clozapine oral tablet 25 mg</i> | 2 | QL (1080 per 30 days) |
| <i>clozapine oral tablet 50 mg</i> | 2 | QL (540 per 30 days) |
| <i>clozapine oral tablet dispersible 100 mg</i> | 2 | QL (270 per 30 days) |
| <i>clozapine oral tablet dispersible 12.5 mg</i> | 2 | QL (2160 per 30 days) |
| <i>clozapine oral tablet dispersible 150 mg</i> | 2 | QL (180 per 30 days) |
| <i>clozapine oral tablet dispersible 200 mg</i> | 5 | QL (120 per 30 days) |
| <i>clozapine oral tablet dispersible 25 mg</i> | 2 | QL (1080 per 30 days) |
| <i>cyclobenzaprine hcl oral tablet 10 mg, 5 mg</i> | 2 | PA; HRM |
| <i>dalfampridine er</i> | 3 | PA; QL (60 per 30 days) |
| <i>desipramine hcl oral tablet 10 mg, 25 mg</i> | 1 | PA; MO; 100D; HRM |
| <i>desipramine hcl oral tablet 100 mg, 150 mg, 50 mg, 75 mg</i> | 2 | PA; MO; 90D; HRM |
| <i>desvenlafaxine er</i> | 2 | QL (30 per 30 days); MO; 90D |
| <i>desvenlafaxine succinate er</i> | 2 | MO; 90D |
| <i>dexmethylphenidate hcl er oral capsule extended release 24 hour 10 mg, 25 mg, 35 mg</i> | 1 | QL (30 per 30 days); MO; 100D |
| <i>dexmethylphenidate hcl er oral capsule extended release 24 hour 15 mg, 30 mg, 40 mg, 5 mg</i> | 2 | QL (30 per 30 days); MO; 90D |
| <i>dexmethylphenidate hcl er oral capsule extended release 24 hour 20 mg</i> | 1 | QL (60 per 30 days); MO; 100D |
| <i>dextroamphetamine sulfate er oral capsule extended release 24 hour 10 mg, 5 mg</i> | 2 | QL (60 per 30 days); MO; 90D |

You can find information on what the symbols and abbreviations in this table mean by going to page 10 of this document. Ou ka jwenn enfòmasyon sou sa senbòl ak abrevyasyon yo nan tablo sa a vle di lè w ale nan paj 19 dokiman sa a.

| DRUG NAME / NON MEDIKAMAN | DRUG TIER / NIVO MEDIKAMAN | REQUIREMENTS / LIMITS KONDISYON / LIMIT |
|---|----------------------------|---|
| <i>dextroamphetamine sulfate er oral capsule extended release 24 hour 15 mg</i> | 2 | QL (120 per 30 days); MO; 90D |
| <i>dextroamphetamine sulfate oral tablet 10 mg</i> | 2 | QL (180 per 30 days); MO; 90D |
| <i>dextroamphetamine sulfate oral tablet 5 mg</i> | 2 | QL (90 per 30 days); MO; 90D |
| DIACOMIT ORAL CAPSULE 250 MG | 5 | PA; QL (360 per 30 days); LA |
| DIACOMIT ORAL CAPSULE 500 MG | 5 | PA; QL (180 per 30 days); LA |
| DIACOMIT ORAL PACKET 250 MG | 5 | PA; QL (360 per 30 days); LA |
| DIACOMIT ORAL PACKET 500 MG | 5 | PA; QL (180 per 30 days); LA |
| DIAZEPAM INTENSOL | 2 | QL (240 per 30 days) |
| <i>diazepam oral concentrate</i> | 2 | QL (240 per 30 days) |
| <i>diazepam oral solution 5 mg/5ml</i> | 2 | QL (1200 per 30 days) |
| <i>diazepam oral tablet 10 mg</i> | 1 | QL (120 per 30 days) |
| <i>diazepam oral tablet 2 mg</i> | 1 | QL (600 per 30 days) |
| <i>diazepam oral tablet 5 mg</i> | 1 | QL (240 per 30 days) |
| <i>diazepam rectal</i> | 2 | |
| <i>dihydroergotamine mesylate nasal</i> | 5 | PA; QL (8 per 28 days) |
| DILANTIN ORAL CAPSULE 30 MG | 4 | PA; MO |
| <i>dimethyl fumarate oral capsule delayed release 120 mg</i> | 5 | PA; QL (14 per 7 days) |
| <i>dimethyl fumarate oral capsule delayed release 240 mg</i> | 5 | PA; QL (60 per 30 days) |
| <i>dimethyl fumarate starter pack oral capsule delayed release therapy pack</i> | 5 | PA |
| <i>disulfiram oral</i> | 2 | MO; 90D |
| <i>divalproex sodium er oral tablet extended release 24 hour</i> | 2 | MO; 90D |
| <i>divalproex sodium oral capsule delayed release sprinkle</i> | 2 | MO; 90D |
| <i>divalproex sodium oral tablet delayed release 125 mg</i> | 1 | MO; 100D |

You can find information on what the symbols and abbreviations in this table mean by going to page 10 of this document. Ou ka jwenn enfòmasyon sou sa senbòl ak abrevyasyon yo nan tablo sa a vle di lè w ale nan paj 19 dokiman sa a.

| DRUG NAME / NON MEDIKAMAN | DRUG TIER / NIVO MEDIKAMAN | REQUIREMENTS / LIMITS KONDISYON / LIMIT |
|--|----------------------------|---|
| <i>divalproex sodium oral tablet delayed release 250 mg, 500 mg</i> | 2 | MO; 90D |
| <i>donepezil hcl oral tablet 10 mg, 5 mg</i> | 1 | QL (30 per 30 days); MO; 100D |
| <i>donepezil hcl oral tablet 23 mg</i> | 2 | QL (30 per 30 days); MO; 90D |
| <i>donepezil hcl oral tablet dispersible</i> | 2 | QL (30 per 30 days); MO; 90D |
| <i>doxepin hcl oral capsule</i> | 2 | PA; MO; 90D; HRM |
| <i>doxepin hcl oral concentrate</i> | 2 | PA; MO; 90D; HRM |
| DRIZALMA SPRINKLE ORAL CAPSULE DELAYED RELEASE SPRINKLE 20 MG, 60 MG | 4 | QL (60 per 30 days); MO |
| DRIZALMA SPRINKLE ORAL CAPSULE DELAYED RELEASE SPRINKLE 30 MG, 40 MG | 4 | QL (30 per 30 days); MO |
| <i>duloxetine hcl oral capsule delayed release particles 20 mg</i> | 2 | QL (180 per 30 days); MO; 90D |
| <i>duloxetine hcl oral capsule delayed release particles 30 mg</i> | 2 | QL (120 per 30 days); MO; 90D |
| <i>duloxetine hcl oral capsule delayed release particles 40 mg</i> | 2 | QL (90 per 30 days); MO; 90D |
| <i>duloxetine hcl oral capsule delayed release particles 60 mg</i> | 2 | QL (60 per 30 days); MO; 90D |
| <i>eletriptan hydrobromide</i> | 2 | QL (9 per 30 days) |
| EMSAM | 5 | PA; QL (30 per 30 days); MO |
| <i>entacapone</i> | 2 | MO; 90D |
| EPIDIOLEX | 5 | PA; LA |
| EPITOL | 1 | MO; 100D |
| EPRONTIA | 4 | PA; MO |
| <i>ergoloid mesylates oral</i> | 2 | PA; MO; 90D; HRM |
| <i>ergotamine-caffeine</i> | 2 | |
| <i>escitalopram oxalate oral solution</i> | 2 | QL (600 per 30 days); MO; 90D |
| <i>escitalopram oxalate oral tablet 10 mg</i> | 2 | QL (60 per 30 days); MO; 90D |
| <i>escitalopram oxalate oral tablet 20 mg</i> | 2 | QL (30 per 30 days); MO; 90D |

You can find information on what the symbols and abbreviations in this table mean by going to page 10 of this document. Ou ka jwenn enfòmasyon sou sa senbòl ak abrevyasyon yo nan tablo sa a vle di lè w ale nan paj 19 dokiman sa a.

| DRUG NAME / NON MEDIKAMAN | DRUG TIER / NIVO MEDIKAMAN | REQUIREMENTS / LIMITS KONDISYON / LIMIT |
|--|----------------------------|---|
| <i>escitalopram oxalate oral tablet 5 mg</i> | 2 | QL (120 per 30 days); MO; 90D |
| ESGIC ORAL CAPSULE | 2 | PA; QL (180 per 30 days); HRM |
| <i>estazolam</i> | 2 | QL (30 per 30 days) |
| <i>eszopiclone</i> | 2 | QL (30 per 30 days) |
| <i>ethosuximide oral</i> | 2 | MO; 90D |
| FANAPT ORAL TABLET 1 MG | 5 | PA; QL (720 per 30 days) |
| FANAPT ORAL TABLET 10 MG, 12 MG | 5 | PA; QL (60 per 30 days) |
| FANAPT ORAL TABLET 2 MG | 5 | PA; QL (360 per 30 days) |
| FANAPT ORAL TABLET 4 MG | 5 | PA; QL (180 per 30 days) |
| FANAPT ORAL TABLET 6 MG | 5 | PA; QL (120 per 30 days) |
| FANAPT ORAL TABLET 8 MG | 5 | PA; QL (90 per 30 days) |
| FANAPT TITRATION PACK | 4 | PA |
| <i>felbamate oral suspension</i> | 4 | MO |
| <i>felbamate oral tablet</i> | 2 | MO; 90D |
| FETZIMA | 3 | PA; QL (30 per 30 days); MO |
| FETZIMA TITRATION | 3 | PA |
| <i>fingolimod hcl</i> | 4 | PA; QL (30 per 30 days) |
| FINTEPLA | 5 | PA; LA |
| <i>fluoxetine hcl oral capsule 10 mg</i> | 1 | MO; 100D |
| <i>fluoxetine hcl oral capsule 20 mg</i> | 2 | QL (120 per 30 days); MO; 90D |
| <i>fluoxetine hcl oral capsule 40 mg</i> | 2 | QL (60 per 30 days); MO; 90D |
| <i>fluoxetine hcl oral capsule delayed release</i> | 2 | QL (4 per 28 days); MO; 90D |
| <i>fluoxetine hcl oral solution</i> | 2 | QL (600 per 30 days); MO; 90D |
| <i>fluoxetine hcl oral tablet 10 mg</i> | 2 | MO; 90D |
| <i>fluoxetine hcl oral tablet 20 mg</i> | 2 | QL (120 per 30 days); MO; 90D |
| <i>fluoxetine hcl oral tablet 60 mg</i> | 2 | QL (30 per 30 days); MO; 90D |
| <i>fluphenazine decanoate injection</i> | 2 | |
| <i>fluphenazine hcl injection</i> | 2 | |

You can find information on what the symbols and abbreviations in this table mean by going to page 10 of this document. Ou ka jwenn enfòmasyon sou sa senbòl ak abrevyasyon yo nan tablo sa a vle di lè w ale nan paj 19 dokiman sa a.

| DRUG NAME / NON MEDIKAMAN | DRUG TIER / NIVO MEDIKAMAN | REQUIREMENTS / LIMITS KONDISYON / LIMIT |
|--|----------------------------|---|
| <i>fluphenazine hcl oral concentrate</i> | 2 | MO; 90D |
| <i>fluphenazine hcl oral elixir</i> | 2 | MO; 90D |
| <i>fluphenazine hcl oral tablet 1 mg, 10 mg, 2.5 mg</i> | 1 | MO; 100D |
| <i>fluphenazine hcl oral tablet 5 mg</i> | 2 | MO; 90D |
| <i>flurazepam hcl oral capsule 30 mg</i> | 2 | QL (30 per 30 days) |
| <i>fluvoxamine maleate oral tablet 100 mg</i> | 1 | QL (90 per 30 days); MO; 100D |
| <i>fluvoxamine maleate oral tablet 25 mg, 50 mg</i> | 1 | MO; 100D |
| FYCOMPA ORAL SUSPENSION | 5 | PA; QL (720 per 30 days); MO |
| FYCOMPA ORAL TABLET 10 MG, 12 MG, 4 MG, 6 MG, 8 MG | 5 | PA; QL (30 per 30 days); MO |
| FYCOMPA ORAL TABLET 2 MG | 4 | PA; QL (30 per 30 days); MO |
| <i>gabapentin (once-daily) oral tablet 300 mg</i> | 2 | QL (30 per 30 days); MO; 90D |
| <i>gabapentin (once-daily) oral tablet 600 mg</i> | 2 | QL (90 per 30 days); MO; 90D |
| <i>gabapentin oral capsule 100 mg</i> | 1 | QL (1080 per 30 days); MO; 100D |
| <i>gabapentin oral capsule 300 mg</i> | 2 | QL (360 per 30 days); MO; 90D |
| <i>gabapentin oral capsule 400 mg</i> | 2 | QL (270 per 30 days); MO; 90D |
| <i>gabapentin oral solution</i> | 2 | QL (2160 per 30 days); MO; 90D |
| <i>gabapentin oral tablet 600 mg</i> | 2 | QL (180 per 30 days); MO; 90D |
| <i>gabapentin oral tablet 800 mg</i> | 2 | QL (120 per 30 days); MO; 90D |
| <i>galantamine hydrobromide er</i> | 2 | QL (30 per 30 days); MO; 90D |
| <i>galantamine hydrobromide oral solution</i> | 2 | QL (200 per 30 days); MO; 90D |
| <i>galantamine hydrobromide oral tablet</i> | 2 | QL (60 per 30 days); MO; 90D |
| <i>glatiramer acetate subcutaneous solution prefilled syringe 20 mg/ml</i> | 5 | PA; QL (30 per 30 days) |
| <i>glatiramer acetate subcutaneous solution prefilled syringe 40 mg/ml</i> | 5 | PA; QL (12 per 28 days) |
| GLATOPA SUBCUTANEOUS SOLUTION PREFILLED SYRINGE 20 MG/ML | 5 | PA; QL (30 per 30 days) |

You can find information on what the symbols and abbreviations in this table mean by going to page 10 of this document. Ou ka jwenn enfòmasyon sou sa senbòl ak abrevyasyon yo nan tablo sa a vle di lè w ale nan paj 19 dokiman sa a.

| DRUG NAME / NON MEDIKAMAN | DRUG TIER / NIVO MEDIKAMAN | REQUIREMENTS / LIMITS KONDISYON / LIMIT |
|--|----------------------------|---|
| GLATOPA SUBCUTANEOUS SOLUTION PREFILLED SYRINGE 40 MG/ML | 5 | PA; QL (12 per 28 days) |
| GOCOVRI | 5 | LA |
| GRALISE ORAL TABLET 450 MG | 4 | QL (30 per 30 days); MO |
| GRALISE ORAL TABLET 750 MG, 900 MG | 5 | QL (60 per 30 days); MO |
| <i>guanfacine hcl er</i> | 2 | QL (30 per 30 days); MO; 90D |
| <i>haloperidol decanoate intramuscular</i> | 2 | |
| <i>haloperidol lactate injection</i> | 2 | |
| <i>haloperidol lactate oral</i> | 2 | MO; 90D |
| <i>haloperidol oral tablet 0.5 mg, 1 mg, 2 mg, 5 mg</i> | 1 | MO; 100D |
| <i>haloperidol oral tablet 10 mg, 20 mg</i> | 2 | MO; 90D |
| <i>imipramine hcl oral tablet 10 mg</i> | 1 | PA; MO; 100D; HRM |
| <i>imipramine hcl oral tablet 25 mg, 50 mg</i> | 2 | PA; MO; 90D; HRM |
| <i>imipramine pamoate</i> | 2 | PA; MO; 90D; HRM |
| INGREZZA ORAL CAPSULE 40 MG | 5 | PA; QL (60 per 30 days) |
| INGREZZA ORAL CAPSULE 60 MG, 80 MG | 5 | PA; QL (30 per 30 days) |
| INGREZZA ORAL CAPSULE SPRINKLE 40 MG | 5 | PA; QL (60 per 30 days) |
| INGREZZA ORAL CAPSULE SPRINKLE 60 MG, 80 MG | 5 | PA; QL (30 per 30 days) |
| INGREZZA ORAL CAPSULE THERAPY PACK | 5 | PA; QL (56 per 365 days) |
| INVEGA HAFYERA INTRAMUSCULAR SUSPENSION PREFILLED SYRINGE 1092 MG/3.5ML | 5 | QL (3.5 per 180 days) |
| INVEGA HAFYERA INTRAMUSCULAR SUSPENSION PREFILLED SYRINGE 1560 MG/5ML | 5 | QL (5 per 180 days) |
| INVEGA SUSTENNA INTRAMUSCULAR SUSPENSION PREFILLED SYRINGE 117 MG/0.75ML | 5 | QL (0.75 per 28 days) |
| INVEGA SUSTENNA INTRAMUSCULAR SUSPENSION PREFILLED SYRINGE 156 MG/ML | 5 | QL (1 per 28 days) |
| INVEGA SUSTENNA INTRAMUSCULAR SUSPENSION PREFILLED SYRINGE 234 MG/1.5ML | 5 | QL (1.5 per 28 days) |

You can find information on what the symbols and abbreviations in this table mean by going to page 10 of this document. Ou ka jwenn enfòmasyon sou sa senbòl ak abrevyasyon yo nan tablo sa a vle di lè w ale nan paj 19 dokiman sa a.

| DRUG NAME / NON MEDIKAMAN | DRUG TIER / NIVO MEDIKAMAN | REQUIREMENTS / LIMITS KONDISYON / LIMIT |
|---|----------------------------|---|
| INVEGA SUSTENNA INTRAMUSCULAR SUSPENSION PREFILLED SYRINGE 39 MG/0.25ML | 4 | QL (0.25 per 28 days) |
| INVEGA SUSTENNA INTRAMUSCULAR SUSPENSION PREFILLED SYRINGE 78 MG/0.5ML | 5 | QL (0.5 per 28 days) |
| INVEGA TRINZA INTRAMUSCULAR SUSPENSION PREFILLED SYRINGE 273 MG/0.88ML | 5 | QL (0.88 per 84 days) |
| INVEGA TRINZA INTRAMUSCULAR SUSPENSION PREFILLED SYRINGE 410 MG/1.32ML | 5 | QL (1.32 per 84 days) |
| INVEGA TRINZA INTRAMUSCULAR SUSPENSION PREFILLED SYRINGE 546 MG/1.75ML | 5 | QL (1.75 per 84 days) |
| INVEGA TRINZA INTRAMUSCULAR SUSPENSION PREFILLED SYRINGE 819 MG/2.63ML | 5 | QL (2.63 per 84 days) |
| <i>lacosamide oral solution</i> | 2 | QL (1200 per 30 days); MO; 90D |
| <i>lacosamide oral tablet</i> | 2 | QL (60 per 30 days); MO; 90D |
| LAMICTAL XR ORAL KIT 21 X 25 MG & 7 X 50 MG, 25 & 50 & 100 MG | 4 | PA |
| LAMICTAL XR ORAL KIT 50 & 100 & 200 MG | 5 | PA |
| <i>lamotrigine oral tablet</i> | 1 | MO; 100D |
| <i>lamotrigine oral tablet chewable 25 mg</i> | 1 | MO; 100D |
| <i>lamotrigine oral tablet chewable 5 mg</i> | 2 | MO; 90D |
| <i>lamotrigine oral tablet dispersible</i> | 2 | MO; 90D |
| <i>lamotrigine starter kit-blue</i> | 2 | |
| <i>lamotrigine starter kit-green</i> | 5 | |
| <i>lamotrigine starter kit-orange</i> | 2 | |
| <i>levetiracetam er oral tablet extended release 24 hour 500 mg</i> | 2 | QL (180 per 30 days); MO; 90D |
| <i>levetiracetam er oral tablet extended release 24 hour 750 mg</i> | 2 | QL (120 per 30 days); MO; 90D |
| <i>levetiracetam oral solution</i> | 2 | MO; 90D |
| <i>levetiracetam oral tablet</i> | 1 | MO; 100D |

You can find information on what the symbols and abbreviations in this table mean by going to page 10 of this document. Ou ka jwenn enfòmasyon sou sa senbòl ak abrevyasyon yo nan tablo sa a vle di lè w ale nan paj 19 dokiman sa a.

| DRUG NAME / NON MEDIKAMAN | DRUG TIER / NIVO MEDIKAMAN | REQUIREMENTS / LIMITS KONDISYON / LIMIT |
|--|----------------------------|---|
| LIBERVANT | 4 | QL (10 per 30 days) |
| <i>lithium</i> | 3 | MO |
| <i>lithium carbonate er</i> | 1 | MO; 100D |
| <i>lithium carbonate oral</i> | 1 | MO; 100D |
| LORAZEPAM INTENSOL | 2 | QL (150 per 30 days) |
| <i>lorazepam oral concentrate</i> | 2 | QL (150 per 30 days) |
| <i>lorazepam oral tablet 0.5 mg, 1 mg</i> | 1 | QL (90 per 30 days) |
| <i>lorazepam oral tablet 2 mg</i> | 1 | QL (150 per 30 days) |
| <i>loxapine succinate oral capsule 10 mg, 25 mg, 5 mg</i> | 2 | MO; 90D |
| <i>loxapine succinate oral capsule 50 mg</i> | 1 | MO; 100D |
| <i>lurasidone hcl oral tablet 120 mg, 20 mg, 40 mg, 60 mg</i> | 4 | QL (30 per 30 days); MO |
| <i>lurasidone hcl oral tablet 80 mg</i> | 4 | QL (60 per 30 days); MO |
| LYBALVI | 5 | PA; QL (30 per 30 days); MO |
| MARPLAN | 4 | MO |
| <i>memantine hcl er</i> | 2 | PA; QL (30 per 30 days); MO; 90D |
| <i>memantine hcl oral tablet 10 mg</i> | 2 | PA; QL (60 per 30 days); MO; 90D |
| <i>memantine hcl oral tablet 28 x 5 mg & 21 x 10 mg</i> | 2 | PA; QL (60 per 30 days) |
| <i>memantine hcl oral tablet 5 mg</i> | 2 | PA; QL (90 per 30 days); MO; 90D |
| <i>meprobamate</i> | 2 | PA; HRM |
| <i>methocarbamol oral tablet 500 mg, 750 mg</i> | 2 | |
| <i>methsuximide</i> | 2 | MO; 90D |
| <i>methylphenidate hcl er (cd) oral capsule extended release 10 mg, 20 mg, 40 mg, 50 mg, 60 mg</i> | 2 | PA; QL (30 per 30 days); MO; 90D |
| <i>methylphenidate hcl er (osm) oral tablet extended release 18 mg, 27 mg, 54 mg</i> | 2 | PA; QL (30 per 30 days); MO; 90D |
| <i>methylphenidate hcl er (osm) oral tablet extended release 36 mg</i> | 2 | PA; QL (60 per 30 days); MO; 90D |

You can find information on what the symbols and abbreviations in this table mean by going to page 10 of this document. Ou ka jwenn enfòmasyon sou sa senbòl ak abrevyasyon yo nan tablo sa a vle di lè w ale nan paj 19 dokiman sa a.

| DRUG NAME / NON MEDIKAMAN | DRUG TIER / NIVO MEDIKAMAN | REQUIREMENTS / LIMITS KONDISYON / LIMIT |
|--|----------------------------|---|
| <i>methylphenidate hcl er oral tablet extended release 20 mg</i> | 2 | PA; QL (90 per 30 days); MO; 90D |
| <i>methylphenidate hcl oral solution 10 mg/5ml</i> | 2 | PA; QL (900 per 30 days); MO; 90D |
| <i>methylphenidate hcl oral solution 5 mg/5ml</i> | 2 | PA; QL (1800 per 30 days); MO; 90D |
| <i>methylphenidate hcl oral tablet 10 mg, 20 mg</i> | 2 | PA; QL (90 per 30 days); MO; 90D |
| <i>methylphenidate hcl oral tablet 5 mg</i> | 1 | PA; QL (90 per 30 days); MO; 100D |
| <i>methylphenidate hcl oral tablet chewable 10 mg</i> | 1 | PA; QL (180 per 30 days); MO; 100D |
| <i>methylphenidate hcl oral tablet chewable 2.5 mg, 5 mg</i> | 1 | PA; QL (90 per 30 days); MO; 100D |
| MIGERGOT | 5 | |
| <i>mirtazapine oral tablet 15 mg, 30 mg, 7.5 mg</i> | 1 | MO; 100D |
| <i>mirtazapine oral tablet 45 mg</i> | 1 | QL (30 per 30 days); MO; 100D |
| <i>mirtazapine oral tablet dispersible</i> | 2 | QL (30 per 30 days); MO; 90D |
| <i>modafinil oral tablet 100 mg</i> | 2 | PA; QL (30 per 30 days); MO; 90D |
| <i>modafinil oral tablet 200 mg</i> | 2 | PA; QL (60 per 30 days); MO; 90D |
| <i>molindone hcl</i> | 2 | MO; 90D |
| <i>naloxone hcl injection solution 0.4 mg/ml</i> | 1 | |
| <i>naloxone hcl injection solution cartridge</i> | 2 | |
| <i>naloxone hcl injection solution prefilled syringe</i> | 2 | |
| <i>naloxone hcl nasal</i> | 2 | |
| <i>naltrexone hcl oral</i> | 2 | |
| NAMZARIC ORAL CAPSULE ER 24 HOUR THERAPY PACK | 3 | |
| NAMZARIC ORAL CAPSULE EXTENDED RELEASE 24 HOUR | 3 | MO |
| NAYZILAM | 4 | PA |

You can find information on what the symbols and abbreviations in this table mean by going to page 10 of this document. Ou ka jwenn enfòmasyon sou sa senbòl ak abrevyasyon yo nan tablo sa a vle di lè w ale nan paj 19 dokiman sa a.

| DRUG NAME / NON MEDIKAMAN | DRUG TIER / NIVO MEDIKAMAN | REQUIREMENTS / LIMITS KONDISYON / LIMIT |
|--|----------------------------|---|
| <i>nefazodone hcl</i> | 2 | MO; 90D |
| NEUPRO | 4 | QL (30 per 30 days); MO |
| NICOTROL | 4 | |
| <i>nortriptyline hcl oral capsule</i> | 1 | MO; 100D |
| <i>nortriptyline hcl oral solution</i> | 2 | MO; 90D |
| NUEDEXTA | 5 | PA; QL (60 per 30 days); MO |
| NUPLAZID ORAL CAPSULE | 5 | PA; QL (30 per 30 days); LA |
| NUPLAZID ORAL TABLET 10 MG | 5 | PA; QL (30 per 30 days); LA |
| NURTEC | 5 | PA; QL (16 per 30 days) |
| <i>olanzapine intramuscular</i> | 2 | QL (90 per 30 days) |
| <i>olanzapine oral tablet 10 mg, 15 mg, 2.5 mg, 5 mg, 7.5 mg</i> | 2 | MO; 90D |
| <i>olanzapine oral tablet 20 mg</i> | 2 | QL (30 per 30 days); MO; 90D |
| <i>olanzapine oral tablet dispersible 10 mg, 15 mg, 5 mg</i> | 2 | MO; 90D |
| <i>olanzapine oral tablet dispersible 20 mg</i> | 2 | QL (30 per 30 days); MO; 90D |
| <i>orphenadrine citrate er</i> | 2 | |
| <i>oxazepam</i> | 2 | QL (120 per 30 days) |
| <i>oxcarbazepine oral suspension</i> | 2 | MO; 90D |
| <i>oxcarbazepine oral tablet 150 mg, 600 mg</i> | 2 | MO; 90D |
| <i>oxcarbazepine oral tablet 300 mg</i> | 1 | MO; 100D |
| <i>paliperidone er oral tablet extended release 24 hour 1.5 mg, 3 mg</i> | 2 | QL (30 per 30 days); MO; 90D |
| <i>paliperidone er oral tablet extended release 24 hour 6 mg</i> | 2 | QL (60 per 30 days); MO; 90D |
| <i>paliperidone er oral tablet extended release 24 hour 9 mg</i> | 4 | QL (30 per 30 days); MO |
| <i>paroxetine hcl er oral tablet extended release 24 hour 12.5 mg</i> | 2 | QL (30 per 30 days); MO; 90D |

You can find information on what the symbols and abbreviations in this table mean by going to page 10 of this document. Ou ka jwenn enfòmasyon sou sa senbòl ak abrevyasyon yo nan tablo sa a vle di lè w ale nan paj 19 dokiman sa a.

| DRUG NAME / NON MEDIKAMAN | DRUG TIER / NIVO MEDIKAMAN | REQUIREMENTS / LIMITS KONDISYON / LIMIT |
|--|----------------------------|--|
| <i>paroxetine hcl er oral tablet extended release 24 hour 25 mg, 37.5 mg</i> | 2 | QL (60 per 30 days); MO; 90D |
| <i>paroxetine hcl oral suspension</i> | 2 | QL (900 per 30 days); MO; 90D |
| <i>paroxetine hcl oral tablet 10 mg, 40 mg</i> | 1 | QL (45 per 30 days); MO; 100D |
| <i>paroxetine hcl oral tablet 20 mg</i> | 1 | QL (30 per 30 days); MO; 100D |
| <i>paroxetine hcl oral tablet 30 mg</i> | 2 | QL (60 per 30 days); MO; 90D |
| <i>paroxetine mesylate</i> | 2 | MO; 90D |
| <i>perphenazine oral</i> | 2 | MO; 90D |
| <i>perphenazine-amitriptyline</i> | 2 | PA; MO; 90D; HRM |
| PERSERIS | 5 | QL (1 per 28 days); MO |
| <i>phenelzine sulfate oral</i> | 2 | MO; 90D |
| <i>phenobarbital oral elixir</i> | 1 | PA; QL (3000 per 30 days); MO; 100D; HRM |
| <i>phenobarbital oral tablet 100 mg, 15 mg, 30 mg, 60 mg, 64.8 mg, 97.2 mg</i> | 3 | PA; QL (120 per 30 days); MO; HRM |
| <i>phenobarbital oral tablet 16.2 mg, 32.4 mg</i> | 3 | PA; QL (210 per 30 days); MO; HRM |
| PHENYTOIN INFATABS | 1 | MO; 100D |
| <i>phenytoin oral</i> | 1 | MO; 100D |
| <i>phenytoin sodium extended</i> | 1 | MO; 100D |
| <i>pimozide</i> | 2 | MO; 90D |
| <i>pramipexole dihydrochloride</i> | 2 | MO; 90D |
| <i>pramipexole dihydrochloride er oral tablet extended release 24 hour 0.375 mg, 2.25 mg, 3 mg, 4.5 mg</i> | 2 | MO; 90D |
| <i>pramipexole dihydrochloride er oral tablet extended release 24 hour 3.75 mg</i> | 1 | MO; 100D |
| <i>pregabalin oral capsule 100 mg, 150 mg, 25 mg, 50 mg, 75 mg</i> | 1 | MO; 100D |
| <i>pregabalin oral capsule 200 mg</i> | 1 | QL (90 per 30 days); MO; 100D |

You can find information on what the symbols and abbreviations in this table mean by going to page 10 of this document. Ou ka jwenn enfòmasyon sou sa senbòl ak abrevyasyon yo nan tablo sa a vle di lè w ale nan paj 19 dokiman sa a.

| DRUG NAME / NON MEDIKAMAN | DRUG TIER / NIVO MEDIKAMAN | REQUIREMENTS / LIMITS KONDISYON / LIMIT |
|--|-----------------------------------|--|
| <i>pregabalin oral capsule 225 mg, 300 mg</i> | 1 | QL (60 per 30 days); MO; 100D |
| <i>pregabalin oral solution</i> | 1 | QL (900 per 30 days); MO; 100D |
| <i>primidone oral</i> | 1 | MO; 100D |
| <i>protriptyline hcl</i> | 2 | PA; MO; 90D; HRM |
| <i>pyridostigmine bromide er</i> | 2 | |
| <i>pyridostigmine bromide oral tablet 60 mg</i> | 1 | |
| <i>quetiapine fumarate er oral tablet extended release 24 hour 150 mg, 200 mg</i> | 2 | QL (30 per 30 days); MO; 90D |
| <i>quetiapine fumarate er oral tablet extended release 24 hour 300 mg, 400 mg, 50 mg</i> | 2 | QL (60 per 30 days); MO; 90D |
| <i>quetiapine fumarate oral tablet 100 mg</i> | 1 | QL (240 per 30 days); MO; 100D |
| <i>quetiapine fumarate oral tablet 150 mg</i> | 1 | QL (150 per 30 days); MO; 100D |
| <i>quetiapine fumarate oral tablet 200 mg</i> | 1 | QL (120 per 30 days); MO; 100D |
| <i>quetiapine fumarate oral tablet 25 mg</i> | 1 | QL (960 per 30 days); MO; 100D |
| <i>quetiapine fumarate oral tablet 300 mg</i> | 1 | QL (80 per 30 days); MO; 100D |
| <i>quetiapine fumarate oral tablet 400 mg</i> | 1 | QL (60 per 30 days); MO; 100D |
| <i>quetiapine fumarate oral tablet 50 mg</i> | 1 | QL (480 per 30 days); MO; 100D |
| <i>ramelteon</i> | 2 | QL (30 per 30 days) |
| <i>rasagiline mesylate oral</i> | 2 | MO; 90D |
| REXULTI | 5 | PA; QL (30 per 30 days); MO |
| <i>riluzole</i> | 2 | 90D |
| <i>risperidone microspheres er intramuscular suspension reconstituted er 12.5 mg, 25 mg, 37.5 mg</i> | 2 | QL (2 per 28 days) |
| <i>risperidone microspheres er intramuscular suspension reconstituted er 50 mg</i> | 5 | QL (2 per 28 days) |
| <i>risperidone oral solution</i> | 2 | QL (480 per 30 days); MO; 90D |
| <i>risperidone oral tablet 0.25 mg</i> | 2 | QL (1920 per 30 days); MO; 90D |
| <i>risperidone oral tablet 0.5 mg</i> | 2 | QL (960 per 30 days); MO; 90D |

You can find information on what the symbols and abbreviations in this table mean by going to page 10 of this document. Ou ka jwenn enfòmasyon sou sa senbòl ak abrevyasyon yo nan tablo sa a vle di lè w ale nan paj 19 dokiman sa a.

| DRUG NAME / NON MEDIKAMAN | DRUG TIER / NIVO MEDIKAMAN | REQUIREMENTS / LIMITS KONDISYON / LIMIT |
|--|----------------------------|---|
| <i>risperidone oral tablet 1 mg</i> | 2 | QL (480 per 30 days); MO; 90D |
| <i>risperidone oral tablet 2 mg</i> | 2 | QL (240 per 30 days); MO; 90D |
| <i>risperidone oral tablet 3 mg, 4 mg</i> | 2 | QL (120 per 30 days); MO; 90D |
| <i>risperidone oral tablet dispersible 0.25 mg</i> | 2 | QL (1920 per 30 days); MO; 90D |
| <i>risperidone oral tablet dispersible 0.5 mg</i> | 2 | QL (960 per 30 days); MO; 90D |
| <i>risperidone oral tablet dispersible 1 mg</i> | 2 | QL (480 per 30 days); MO; 90D |
| <i>risperidone oral tablet dispersible 2 mg</i> | 2 | QL (240 per 30 days); MO; 90D |
| <i>risperidone oral tablet dispersible 3 mg</i> | 2 | QL (150 per 30 days); MO; 90D |
| <i>risperidone oral tablet dispersible 4 mg</i> | 2 | QL (120 per 30 days); MO; 90D |
| <i>rivastigmine</i> | 2 | QL (30 per 30 days); MO; 90D |
| <i>rivastigmine tartrate</i> | 2 | QL (60 per 30 days); MO; 90D |
| <i>ropinirole hcl</i> | 2 | MO; 90D |
| ROWEEPRA ORAL TABLET 500 MG | 1 | MO; 100D |
| <i>rufinamide oral suspension</i> | 5 | PA; QL (2400 per 30 days); MO |
| <i>rufinamide oral tablet 200 mg</i> | 4 | PA; QL (480 per 30 days); MO |
| <i>rufinamide oral tablet 400 mg</i> | 5 | PA; QL (240 per 30 days); MO |
| RYTARY | 4 | ST; MO |
| SAVELLA | 4 | PA; QL (60 per 30 days); MO |
| SAVELLA TITRATION PACK | 4 | PA |
| SECUADO | 5 | PA; QL (30 per 30 days); MO |
| <i>selegiline hcl oral</i> | 2 | MO; 90D |
| <i>sertraline hcl oral concentrate</i> | 2 | QL (300 per 30 days); MO; 90D |
| <i>sertraline hcl oral tablet 100 mg</i> | 1 | QL (60 per 30 days); MO; 100D |
| <i>sertraline hcl oral tablet 25 mg</i> | 1 | QL (240 per 30 days); MO; 100D |
| <i>sertraline hcl oral tablet 50 mg</i> | 1 | QL (120 per 30 days); MO; 100D |
| <i>sodium oxybate</i> | 5 | PA; QL (540 per 30 days); LA |
| SPRAVATO (56 MG DOSE) | 4 | PA; QL (16 per 28 days) |
| SPRAVATO (84 MG DOSE) | 5 | PA; QL (24 per 28 days) |

You can find information on what the symbols and abbreviations in this table mean by going to page 10 of this document. Ou ka jwenn enfòmasyon sou sa senbòl ak abrevyasyon yo nan tablo sa a vle di lè w ale nan paj 19 dokiman sa a.

| DRUG NAME / NON MEDIKAMAN | DRUG TIER / NIVO MEDIKAMAN | REQUIREMENTS / LIMITS KONDISYON / LIMIT |
|--|----------------------------|---|
| SPRITAM ORAL TABLET DISINTEGRATING SOLUBLE 1000 MG, 250 MG, 500 MG | 4 | PA; QL (60 per 30 days); MO |
| SPRITAM ORAL TABLET DISINTEGRATING SOLUBLE 750 MG | 4 | PA; QL (120 per 30 days); MO |
| SUBVENITE | 1 | PA; MO; 100D |
| <i>sumatriptan succinate oral</i> | 2 | QL (9 per 30 days) |
| SYMPAZAN ORAL FILM 10 MG, 20 MG | 5 | PA; QL (60 per 30 days); MO |
| SYMPAZAN ORAL FILM 5 MG | 5 | PA; QL (30 per 30 days); MO |
| TEGLUTIK | 5 | |
| <i>temazepam oral capsule 15 mg, 30 mg</i> | 1 | QL (30 per 30 days) |
| <i>temazepam oral capsule 22.5 mg, 7.5 mg</i> | 2 | QL (30 per 30 days) |
| <i>teriflunomide</i> | 5 | PA; QL (30 per 30 days) |
| <i>tetrabenazine oral tablet 12.5 mg</i> | 5 | PA; QL (240 per 30 days) |
| <i>tetrabenazine oral tablet 25 mg</i> | 5 | PA; QL (120 per 30 days) |
| <i>thioridazine hcl oral tablet 10 mg</i> | 2 | MO; 90D |
| <i>thioridazine hcl oral tablet 100 mg, 25 mg, 50 mg</i> | 1 | MO; 100D |
| <i>thiothixene oral capsule 1 mg, 10 mg</i> | 2 | MO; 90D |
| <i>thiothixene oral capsule 2 mg, 5 mg</i> | 1 | MO; 100D |
| <i>tiagabine hcl</i> | 2 | MO; 90D |
| TIGLUTIK | 5 | |
| <i>tizanidine hcl oral</i> | 2 | |
| <i>tolcapone</i> | 5 | PA; QL (180 per 30 days); MO |
| <i>topiramate oral capsule sprinkle</i> | 2 | MO; 90D |
| <i>topiramate oral tablet</i> | 1 | MO; 100D |
| <i>tranylcypromine sulfate</i> | 2 | MO; 90D |
| <i>trazodone hcl oral</i> | 1 | MO; 100D |
| <i>triazolam</i> | 2 | QL (30 per 30 days) |
| <i>trifluoperazine hcl oral tablet 1 mg, 2 mg, 5 mg</i> | 1 | MO; 100D |
| <i>trifluoperazine hcl oral tablet 10 mg</i> | 2 | MO; 90D |

You can find information on what the symbols and abbreviations in this table mean by going to page 10 of this document. Ou ka jwenn enfòmasyon sou sa senbòl ak abrevyasyon yo nan tablo sa a vle di lè w ale nan paj 19 dokiman sa a.

| DRUG NAME / NON MEDIKAMAN | DRUG TIER / NIVO MEDIKAMAN | REQUIREMENTS / LIMITS KONDISYON / LIMIT |
|--|----------------------------|---|
| <i>trihexyphenidyl hcl oral solution</i> | 2 | PA; MO; 90D; HRM |
| <i>trihexyphenidyl hcl oral tablet</i> | 1 | MO; 100D |
| <i>trimipramine maleate oral</i> | 2 | MO; 90D |
| TRINTELLIX | 4 | QL (30 per 30 days); MO |
| UBRELVY ORAL TABLET 100 MG | 5 | PA; QL (16 per 30 days) |
| UBRELVY ORAL TABLET 50 MG | 5 | PA; QL (20 per 30 days) |
| <i>valproic acid oral capsule</i> | 2 | MO; 90D |
| <i>valproic acid oral solution 250 mg/5ml</i> | 2 | MO; 90D |
| VALTOCO 10 MG DOSE | 4 | |
| VALTOCO 15 MG DOSE | 4 | |
| VALTOCO 20 MG DOSE | 4 | |
| VALTOCO 5 MG DOSE | 4 | |
| <i>varenicline tartrate (starter)</i> | 3 | PA |
| <i>varenicline tartrate oral tablet 0.5 mg</i> | 3 | PA; QL (60 per 30 days) |
| <i>varenicline tartrate oral tablet 1 mg, 1 mg (56 pack)</i> | 3 | PA; QL (56 per 28 days) |
| <i>varenicline tartrate(continue)</i> | 3 | PA; QL (56 per 28 days) |
| <i>venlafaxine besylate er</i> | 4 | QL (60 per 30 days); MO |
| <i>venlafaxine hcl</i> | 1 | QL (90 per 30 days); MO; 100D |
| <i>venlafaxine hcl er oral capsule extended release 24 hour 150 mg</i> | 1 | QL (30 per 30 days); MO; 100D |
| <i>venlafaxine hcl er oral capsule extended release 24 hour 37.5 mg</i> | 1 | QL (180 per 30 days); MO; 100D |
| <i>venlafaxine hcl er oral capsule extended release 24 hour 75 mg</i> | 1 | QL (90 per 30 days); MO; 100D |
| <i>venlafaxine hcl er oral tablet extended release 24 hour 150 mg</i> | 2 | MO; 90D |
| <i>venlafaxine hcl er oral tablet extended release 24 hour 225 mg, 37.5 mg</i> | 2 | QL (30 per 30 days); MO; 90D |

You can find information on what the symbols and abbreviations in this table mean by going to page 10 of this document. Ou ka jwenn enfòmasyon sou sa senbòl ak abrevyasyon yo nan tablo sa a vle di lè w ale nan paj 19 dokiman sa a.

| DRUG NAME / NON MEDIKAMAN | DRUG TIER / NIVO MEDIKAMAN | REQUIREMENTS / LIMITS KONDISYON / LIMIT |
|---|----------------------------|---|
| <i>venlafaxine hcl er oral tablet extended release 24 hour 75 mg</i> | 2 | QL (90 per 30 days); MO; 90D |
| VERSACLOZ | 4 | QL (600 per 30 days) |
| <i>vigabatrin oral packet</i> | 5 | PA; QL (150 per 25 days); LA |
| <i>vigabatrin oral tablet</i> | 5 | PA; QL (180 per 30 days); LA |
| VIGADRONE ORAL PACKET | 5 | PA; QL (150 per 25 days); LA |
| VIGADRONE ORAL TABLET | 5 | PA; QL (180 per 30 days) |
| VIGPODER | 5 | PA; QL (150 per 25 days) |
| <i>vilazodone hcl</i> | 2 | QL (30 per 30 days); MO; 90D |
| VRAYLAR ORAL CAPSULE | 5 | PA; QL (30 per 30 days); MO |
| XCOPRI (250 MG DAILY DOSE) ORAL TABLET THERAPY PACK 100 & 150 MG | 5 | PA; QL (56 per 28 days); MO |
| XCOPRI (350 MG DAILY DOSE) | 5 | PA; QL (56 per 28 days); MO |
| XCOPRI ORAL TABLET 100 MG, 25 MG, 50 MG | 5 | PA; QL (30 per 30 days); MO |
| XCOPRI ORAL TABLET 150 MG, 200 MG | 5 | PA; QL (60 per 30 days); MO |
| XCOPRI ORAL TABLET THERAPY PACK 14 X 12.5 MG & 14 X 25 MG | 4 | PA; QL (56 per 365 days) |
| XCOPRI ORAL TABLET THERAPY PACK 14 X 150 MG & 14 X 200 MG, 14 X 50 MG & 14 X 100 MG | 5 | PA; QL (56 per 365 days) |
| <i>zaleplon oral capsule 10 mg</i> | 2 | QL (60 per 30 days) |
| <i>zaleplon oral capsule 5 mg</i> | 2 | QL (30 per 30 days) |
| ZENZEDI ORAL TABLET 10 MG | 2 | QL (180 per 30 days); MO; 90D |
| ZENZEDI ORAL TABLET 5 MG | 2 | QL (90 per 30 days); MO; 90D |
| <i>ziprasidone hcl oral capsule 20 mg</i> | 2 | QL (240 per 30 days); MO; 90D |
| <i>ziprasidone hcl oral capsule 40 mg</i> | 2 | QL (120 per 30 days); MO; 90D |
| <i>ziprasidone hcl oral capsule 60 mg, 80 mg</i> | 2 | QL (60 per 30 days); MO; 90D |
| <i>ziprasidone mesylate</i> | 4 | QL (6 per 3 days) |
| <i>zolpidem tartrate er</i> | 2 | QL (30 per 30 days) |
| <i>zolpidem tartrate oral tablet</i> | 2 | QL (30 per 30 days) |

You can find information on what the symbols and abbreviations in this table mean by going to page 10 of this document. Ou ka jwenn enfòmasyon sou sa senbòl ak abrevyasyon yo nan tablo sa a vle di lè w ale nan paj 19 dokiman sa a.

| DRUG NAME / NON MEDIKAMAN | DRUG TIER / NIVO MEDIKAMAN | REQUIREMENTS / LIMITS KONDISYON / LIMIT |
|--|----------------------------|---|
| ZONISADE | 4 | PA; MO |
| <i>zonisamide oral</i> | 2 | MO; 90D |
| ZTALMY | 5 | QL (1100 per 30 days) |
| ZURZUVAE | 5 | |
| ZYPREXA RELPREVV INTRAMUSCULAR SUSPENSION RECONSTITUTED 210 MG, 300 MG | 4 | QL (2 per 28 days) |
| ZYPREXA RELPREVV INTRAMUSCULAR SUSPENSION RECONSTITUTED 405 MG | 5 | QL (2 per 28 days) |
| DERMATOLOGICAL AGENTS / AJAN DÈMATOLOJIK | | |
| AC CUTANE | 2 | |
| <i>acitretin oral capsule 10 mg, 25 mg</i> | 2 | PA |
| <i>acitretin oral capsule 17.5 mg</i> | 4 | PA |
| <i>acyclovir external ointment</i> | 2 | PA; QL (30 per 30 days) |
| <i>ala-cort external cream</i> | 1 | |
| <i>alclometasone dipropionate</i> | 2 | |
| <i>amcinonide external cream</i> | 2 | |
| <i>ammonium lactate external</i> | 1 | |
| AMNESTEEM | 2 | |
| <i>azelaic acid external</i> | 2 | |
| <i>benzoyl peroxide-erythromycin</i> | 2 | |
| <i>betamethasone dipropionate aug external cream</i> | 2 | |
| <i>betamethasone dipropionate aug external lotion</i> | 2 | |
| <i>betamethasone dipropionate external cream</i> | 2 | |
| <i>betamethasone dipropionate external ointment</i> | 2 | |
| <i>betamethasone valerate external cream</i> | 1 | |
| <i>betamethasone valerate external lotion</i> | 1 | |
| <i>betamethasone valerate external ointment</i> | 1 | |
| <i>bexarotene external</i> | 5 | PA; QL (60 per 30 days) |

You can find information on what the symbols and abbreviations in this table mean by going to page 10 of this document. Ou ka jwenn enfòmasyon sou sa senbòl ak abrevyasyon yo nan tablo sa a vle di lè w ale nan paj 19 dokiman sa a.

| DRUG NAME / NON MEDIKAMAN | DRUG TIER / NIVO MEDIKAMAN | REQUIREMENTS / LIMITS KONDISYON / LIMIT |
|--|----------------------------|---|
| <i>calcipotriene external cream</i> | 2 | QL (120 per 30 days) |
| <i>calcipotriene external ointment</i> | 2 | QL (120 per 30 days) |
| <i>calcipotriene external solution</i> | 2 | QL (60 per 30 days) |
| CALCITRENE | 2 | QL (120 per 30 days) |
| <i>cevimeline hcl</i> | 2 | MO; 90D |
| <i>chlorhexidine gluconate mouth/throat</i> | 1 | |
| CICLODAN EXTERNAL SOLUTION | 2 | |
| <i>ciclopirox external</i> | 2 | |
| <i>ciclopirox olamine external cream</i> | 1 | QL (90 per 30 days) |
| <i>ciclopirox olamine external suspension</i> | 1 | |
| CLARAVIS | 2 | |
| CLINDACIN ETZ EXTERNAL SWAB | 2 | |
| CLINDACIN-P | 2 | |
| <i>clindamycin phosphate external gel</i> | 2 | |
| <i>clindamycin phosphate external lotion</i> | 2 | QL (120 per 30 days) |
| <i>clindamycin phosphate external solution</i> | 2 | QL (120 per 30 days) |
| <i>clindamycin phosphate external swab</i> | 2 | |
| <i>clobetasol propionate e</i> | 2 | QL (120 per 30 days) |
| <i>clobetasol propionate external cream</i> | 2 | QL (120 per 30 days) |
| <i>clobetasol propionate external gel</i> | 2 | QL (60 per 30 days) |
| <i>clobetasol propionate external lotion</i> | 4 | |
| <i>clobetasol propionate external ointment</i> | 2 | QL (120 per 30 days) |
| <i>clobetasol propionate external shampoo</i> | 2 | |
| <i>clobetasol propionate external solution</i> | 2 | QL (50 per 30 days) |
| CLODAN EXTERNAL SHAMPOO | 2 | |
| <i>clotrimazole external cream</i> | 1 | |
| <i>clotrimazole external solution</i> | 1 | |
| <i>clotrimazole mouth/throat troche</i> | 1 | QL (150 per 30 days) |

You can find information on what the symbols and abbreviations in this table mean by going to page 10 of this document. Ou ka jwenn enfòmasyon sou sa senbòl ak abrevyasyon yo nan tablo sa a vle di lè w ale nan paj 19 dokiman sa a.

| DRUG NAME / NON MEDIKAMAN | DRUG TIER / NIVO MEDIKAMAN | REQUIREMENTS / LIMITS KONDISYON / LIMIT |
|--|----------------------------|---|
| <i>clotrimazole-betamethasone</i> | 2 | QL (120 per 30 days) |
| <i>desonide external cream</i> | 2 | |
| <i>desonide external lotion</i> | 2 | |
| <i>desonide external ointment</i> | 2 | |
| <i>desoximetasone external cream</i> | 2 | QL (100 per 30 days) |
| <i>desoximetasone external liquid</i> | 2 | |
| <i>desoximetasone external ointment 0.25 %</i> | 2 | |
| <i>diclofenac sodium external gel 3 %</i> | 2 | PA; QL (100 per 30 days) |
| DUPIXENT SUBCUTANEOUS SOLUTION PEN-INJECTOR 200 MG/1.14ML | 5 | PA; QL (4.56 per 28 days) |
| DUPIXENT SUBCUTANEOUS SOLUTION PEN-INJECTOR 300 MG/2ML | 5 | PA; QL (8 per 28 days) |
| DUPIXENT SUBCUTANEOUS SOLUTION PREFILLED SYRINGE 100 MG/0.67ML | 5 | PA; QL (1.34 per 28 days) |
| DUPIXENT SUBCUTANEOUS SOLUTION PREFILLED SYRINGE 200 MG/1.14ML | 5 | PA; QL (4.56 per 28 days) |
| DUPIXENT SUBCUTANEOUS SOLUTION PREFILLED SYRINGE 300 MG/2ML | 5 | PA; QL (8 per 28 days) |
| <i>econazole nitrate external</i> | 2 | QL (90 per 30 days) |
| <i>erythromycin external gel</i> | 2 | |
| <i>erythromycin external solution</i> | 1 | |
| EUCRISA | 4 | |
| <i>fluocinolone acetonide body</i> | 2 | QL (120 per 30 days) |
| <i>fluocinolone acetonide external</i> | 2 | QL (120 per 30 days) |
| <i>fluocinolone acetonide scalp</i> | 2 | QL (120 per 30 days) |
| <i>fluocinonide emulsified base</i> | 2 | QL (240 per 30 days) |
| <i>fluocinonide external gel</i> | 2 | QL (240 per 30 days) |
| <i>fluocinonide external ointment</i> | 2 | QL (240 per 30 days) |
| <i>fluocinonide external solution</i> | 2 | QL (240 per 30 days) |

You can find information on what the symbols and abbreviations in this table mean by going to page 10 of this document. Ou ka jwenn enfòmasyon sou sa senbòl ak abrevyasyon yo nan tablo sa a vle di lè w ale nan paj 19 dokiman sa a.

| DRUG NAME / NON MEDIKAMAN | DRUG TIER / NIVO MEDIKAMAN | REQUIREMENTS / LIMITS KONDISYON / LIMIT |
|--|----------------------------|---|
| <i>fluorouracil external cream 5 %</i> | 2 | QL (40 per 28 days) |
| <i>fluorouracil external solution</i> | 2 | QL (10 per 28 days) |
| <i>fluticasone propionate external cream</i> | 2 | |
| <i>fluticasone propionate external ointment</i> | 2 | |
| <i>gentamicin sulfate external</i> | 2 | QL (30 per 30 days) |
| <i>halobetasol propionate external cream</i> | 2 | |
| <i>halobetasol propionate external ointment</i> | 2 | |
| <i>hydrocortisone (perianal) external cream 1 %</i> | 2 | |
| <i>hydrocortisone (perianal) external cream 2.5 %</i> | 1 | |
| <i>hydrocortisone butyrate external lotion</i> | 2 | |
| <i>hydrocortisone butyrate external ointment</i> | 2 | |
| <i>hydrocortisone butyrate external solution</i> | 2 | |
| <i>hydrocortisone external cream 1 %, 2.5 %</i> | 1 | |
| <i>hydrocortisone external lotion 2.5 %</i> | 1 | |
| <i>hydrocortisone external ointment 1 %, 2.5 %</i> | 1 | |
| <i>hydrocortisone valerate</i> | 2 | |
| <i>imiquimod external cream 5 %</i> | 2 | QL (24 per 28 days) |
| <i>isotretinoin oral capsule 10 mg, 20 mg, 30 mg, 35 mg, 40 mg</i> | 2 | |
| <i>isotretinoin oral capsule 25 mg</i> | 5 | |
| <i>ivermectin external cream</i> | 2 | |
| JUBLIA | 4 | PA |
| <i>ketokonazole external cream</i> | 2 | QL (120 per 30 days) |
| <i>ketokonazole external shampoo 2 %</i> | 1 | QL (120 per 30 days) |
| KLAYESTA | 2 | |
| KOURZEQ | 2 | |
| <i>malathion external</i> | 4 | |
| <i>methoxsalen rapid</i> | 5 | |
| <i>metronidazole external</i> | 2 | |

You can find information on what the symbols and abbreviations in this table mean by going to page 10 of this document. Ou ka jwenn enfòmasyon sou sa senbòl ak abrevyasyon yo nan tablo sa a vle di lè w ale nan paj 19 dokiman sa a.

| DRUG NAME / NON MEDIKAMAN | DRUG TIER / NIVO MEDIKAMAN | REQUIREMENTS / LIMITS KONDISYON / LIMIT |
|---|----------------------------|---|
| <i>mometasone furoate external cream</i> | 1 | |
| <i>mometasone furoate external ointment</i> | 1 | |
| <i>mupirocin calcium</i> | 2 | QL (30 per 30 days) |
| <i>mupirocin external</i> | 2 | QL (120 per 30 days) |
| MYORISAN | 2 | |
| <i>naftifine hcl external cream</i> | 2 | |
| <i>nitroglycerin rectal</i> | 2 | QL (30 per 30 days) |
| NYAMYC | 2 | |
| <i>nystatin external cream</i> | 1 | |
| <i>nystatin external ointment</i> | 1 | |
| <i>nystatin external powder</i> | 2 | |
| <i>nystatin mouth/throat</i> | 2 | |
| <i>nystatin-triamcinolone</i> | 2 | QL (120 per 30 days) |
| NYSTOP | 2 | |
| ORALONE | 2 | |
| PANRETIN | 5 | |
| PERIOGARD | 1 | |
| <i>permethrin external cream</i> | 2 | |
| <i>pilocarpine hcl oral</i> | 2 | MO; 90D |
| <i>pimecrolimus</i> | 4 | PA; QL (100 per 30 days) |
| <i>podofilox external</i> | 2 | |
| PROCTO-MED HC EXTERNAL | 2 | |
| PROCTOSOL HC EXTERNAL | 2 | |
| PROCTOZONE-HC EXTERNAL | 2 | |
| REGRANEX | 5 | PA |
| SANTYL | 4 | QL (30 per 30 days) |
| <i>selenium sulfide external lotion</i> | 2 | |
| <i>silver sulfadiazine external</i> | 2 | |

You can find information on what the symbols and abbreviations in this table mean by going to page 10 of this document. Ou ka jwenn enfòmasyon sou sa senbòl ak abrevyasyon yo nan tablo sa a vle di lè w ale nan paj 19 dokiman sa a.

| DRUG NAME / NON MEDIKAMAN | DRUG TIER / NIVO MEDIKAMAN | REQUIREMENTS / LIMITS KONDISYON / LIMIT |
|---|----------------------------|---|
| SSD (SILVER SULFADIAZINE) | 2 | |
| <i>sulfacetamide sodium (acne)</i> | 2 | |
| <i>tacrolimus external ointment</i> | 2 | PA; QL (100 per 30 days) |
| <i>tazarotene external cream 0.1 %</i> | 2 | PA |
| <i>tazarotene external gel</i> | 2 | PA |
| TAZORAC EXTERNAL CREAM 0.05 % | 4 | PA |
| <i>tretinoin external</i> | 2 | PA; QL (45 per 30 days) |
| <i>triamcinolone acetonide external aerosol solution</i> | 2 | |
| <i>triamcinolone acetonide external cream</i> | 1 | QL (454 per 30 days) |
| <i>triamcinolone acetonide external lotion 0.025 %</i> | 1 | |
| <i>triamcinolone acetonide external lotion 0.1 %</i> | 2 | |
| <i>triamcinolone acetonide external ointment 0.025 %, 0.1 %, 0.5 %</i> | 1 | |
| <i>triamcinolone acetonide mouth/throat</i> | 2 | |
| TRIDERM EXTERNAL CREAM | 1 | QL (454 per 30 days) |
| VALCHLOR | 5 | PA; LA |
| ZENATANE | 2 | |
| ELECTROLYTES / MINERALS / METALS / VITAMINS / ELEKTWOLIT / MINERAL / METAL / VITAMIN | | |
| <i>carglumic acid oral tablet soluble</i> | 5 | PA; LA |
| CLINIMIX E/DEXTROSE (2.75/5) | 4 | B/D PA |
| CLINIMIX E/DEXTROSE (4.25/10) | 4 | B/D PA |
| CLINIMIX E/DEXTROSE (4.25/5) | 4 | B/D PA |
| CLINIMIX E/DEXTROSE (5/15) | 4 | B/D PA |
| CLINIMIX E/DEXTROSE (5/20) | 4 | B/D PA |
| <i>clinimix e/dextrose (8/10)</i> | 4 | B/D PA |
| <i>clinimix e/dextrose (8/14)</i> | 4 | B/D PA |
| CLINIMIX/DEXTROSE (4.25/10) | 4 | B/D PA |
| CLINIMIX/DEXTROSE (4.25/5) | 4 | B/D PA |

You can find information on what the symbols and abbreviations in this table mean by going to page 10 of this document. Ou ka jwenn enfòmasyon sou sa senbòl ak abrevyasyon yo nan tablo sa a vle di lè w ale nan paj 19 dokiman sa a.

| DRUG NAME / NON MEDIKAMAN | DRUG TIER / NIVO MEDIKAMAN | REQUIREMENTS / LIMITS KONDISYON / LIMIT |
|---|----------------------------|---|
| CLINIMIX/DEXTROSE (5/15) | 4 | B/D PA |
| CLINIMIX/DEXTROSE (5/20) | 4 | B/D PA |
| <i>clanimix/dextrose (6/5)</i> | 4 | B/D PA |
| <i>clanimix/dextrose (8/10)</i> | 4 | B/D PA |
| <i>clanimix/dextrose (8/14)</i> | 4 | B/D PA |
| CLINISOL SF | 2 | B/D PA |
| CLINOLIPID | 2 | B/D PA |
| <i>dextrose intravenous solution 10 %, 5 %</i> | 2 | |
| <i>dextrose-sodium chloride intravenous solution 10-0.2 %</i> | 3 | |
| <i>dextrose-sodium chloride intravenous solution 10-0.45 %, 5-0.2 %, 5-0.225 %, 5-0.3 %, 5-0.45 %, 5-0.9 %</i> | 2 | |
| <i>folic acid oral tablet 1 mg</i> | 6 | ED |
| INTRALIPID INTRAVENOUS EMULSION 20 % | 2 | B/D PA |
| ISOLYTE-P IN D5W | 4 | |
| ISOLYTE-S | 4 | |
| <i>kcl (0.149%) in nacl intravenous solution 20-0.45 meq/l-%</i> | 2 | |
| <i>kcl in dextrose-nacl intravenous solution 10-5-0.45 meq/l-%-%, 20-5-0.2 meq/l-%-%, 20-5-0.225 meq/l-%-%, 20-5-0.45 meq/l-%-%, 20-5-0.9 meq/l-%-%, 30-5-0.45 meq/l-%-%, 40-5-0.45 meq/l-%-%, 40-5-0.9 meq/l-%-%</i> | 2 | |
| <i>kcl-lactated ringers-d5w</i> | 3 | |
| KLOR-CON 10 | 1 | MO; 100D |
| KLOR-CON M10 | 1 | MO; 100D |
| KLOR-CON M15 | 1 | MO; 100D |
| KLOR-CON M20 | 1 | MO; 100D |
| KLOR-CON ORAL PACKET 20 MEQ | 2 | MO; 90D |
| KLOR-CON ORAL TABLET EXTENDED RELEASE | 1 | MO; 100D |

You can find information on what the symbols and abbreviations in this table mean by going to page 10 of this document. Ou ka jwenn enfòmasyon sou sa senbòl ak abrevyasyon yo nan tablo sa a vle di lè w ale nan paj 19 dokiman sa a.

| DRUG NAME / NON MEDIKAMAN | DRUG TIER / NIVO MEDIKAMAN | REQUIREMENTS / LIMITS KONDISYON / LIMIT |
|---|----------------------------|---|
| <i>levocarnitine oral solution</i> | 2 | B/D PA; MO; 90D |
| <i>levocarnitine oral tablet</i> | 3 | B/D PA; MO |
| <i>levocarnitine sf</i> | 2 | B/D PA; MO; 90D |
| <i>magnesium sulfate injection solution 50 %, 50 % (10ml syringe)</i> | 2 | |
| <i>multiple electro type 1 ph 5.5</i> | 2 | |
| <i>multiple electro type 1 ph 7.4</i> | 2 | |
| NUTRILIPID | 2 | B/D PA |
| PLENAMINE | 2 | B/D PA |
| <i>potassium chloride crys er</i> | 1 | MO; 100D |
| <i>potassium chloride er</i> | 1 | MO; 100D |
| <i>potassium chloride in nacl intravenous solution 20-0.45 meq/l-%, 20-0.9 meq/l-%</i> | 2 | |
| <i>potassium chloride intravenous solution 2 meq/ml, 2 meq/ml (20 ml), 20 meq/100ml</i> | 2 | |
| <i>potassium chloride oral packet</i> | 2 | MO; 90D |
| <i>potassium chloride oral solution 10 %, 20 meq/15ml (10%), 40 meq/15ml (20%)</i> | 2 | MO; 90D |
| <i>potassium cl in dextrose 5% intravenous solution 10 meq/l, 20 meq/l</i> | 2 | |
| PREMASOL INTRAVENOUS SOLUTION 10 % | 4 | B/D PA |
| PROSOL | 4 | B/D PA |
| <i>sodium chloride intravenous solution 0.45 %, 0.9 %, 3 %, 5 %</i> | 2 | |
| <i>sodium fluoride oral tablet 2.2 (1 f) mg</i> | 2 | MO; 90D |
| <i>sodium fluoride oral tablet chewable 2.2 (1 f) mg</i> | 2 | MO; 90D |
| TPN ELECTROLYTES INTRAVENOUS CONCENTRATE | 3 | |
| TRAVASOL | 4 | B/D PA |
| TROPHAMINE INTRAVENOUS SOLUTION 10 % | 4 | B/D PA |

You can find information on what the symbols and abbreviations in this table mean by going to page 10 of this document. Ou ka jwenn enfòmasyon sou sa senbòl ak abrevyasyon yo nan tablo sa a vle di lè w ale nan paj 19 dokiman sa a.

| DRUG NAME / NON MEDIKAMAN | DRUG TIER / NIVO MEDIKAMAN | REQUIREMENTS / LIMITS KONDISYON / LIMIT |
|--|----------------------------|---|
| ENDOCRINE AND METABOLIC DISORDER AGENTS / AJAN MALADI ANDOKRIN AK METABOLIS | | |
| <i>acarbose oral</i> | 2 | QL (90 per 30 days); MO; 90D |
| <i>alendronate sodium oral solution</i> | 2 | QL (300 per 28 days); MO; 90D |
| <i>alendronate sodium oral tablet 10 mg</i> | 1 | QL (30 per 30 days); MO; 100D |
| <i>alendronate sodium oral tablet 35 mg, 70 mg</i> | 1 | QL (4 per 28 days); MO; 100D |
| AURYXIA | 5 | PA; MO |
| <i>calcitonin (salmon) nasal</i> | 2 | QL (4 per 30 days); MO; 90D |
| <i>calcitriol oral capsule</i> | 1 | B/D PA; MO; 100D |
| <i>calcitriol oral solution</i> | 2 | B/D PA; MO; 90D |
| <i>calcium acetate (phos binder)</i> | 2 | MO; 90D |
| <i>calcium acetate oral tablet 667 mg</i> | 2 | MO; 90D |
| <i>cinacalcet hcl oral tablet 30 mg</i> | 2 | B/D PA; QL (60 per 30 days); 90D |
| <i>cinacalcet hcl oral tablet 60 mg</i> | 4 | B/D PA; QL (60 per 30 days) |
| <i>cinacalcet hcl oral tablet 90 mg</i> | 5 | B/D PA; QL (120 per 30 days) |
| CYCLOSET | 4 | QL (180 per 30 days); MO |
| <i>deferasirox oral tablet 90 mg</i> | 3 | PA |
| <i>deferasirox oral tablet soluble 125 mg</i> | 4 | PA |
| <i>deferasirox oral tablet soluble 250 mg, 500 mg</i> | 5 | PA |
| <i>diazoxide oral</i> | 2 | MO; 90D |
| <i>doxercalciferol oral</i> | 2 | B/D PA; MO; 90D |
| FARXIGA | 3 | QL (30 per 30 days); MO |
| FIASP FLEXTOUCH | 3 | MO |
| FIASP INJECTION | 3 | MO |
| FIASP PENFILL | 3 | MO |
| FIASP PUMPCART | 3 | MO |
| <i>glimepiride oral tablet 1 mg</i> | 1 | QL (240 per 30 days); MO; 100D |
| <i>glimepiride oral tablet 2 mg</i> | 1 | QL (120 per 30 days); MO; 100D |
| <i>glimepiride oral tablet 4 mg</i> | 1 | QL (60 per 30 days); MO; 100D |

You can find information on what the symbols and abbreviations in this table mean by going to page 10 of this document. Ou ka jwenn enfòmasyon sou sa senbòl ak abrevyasyon yo nan tablo sa a vle di lè w ale nan paj 19 dokiman sa a.

| DRUG NAME / NON MEDIKAMAN | DRUG TIER / NIVO MEDIKAMAN | REQUIREMENTS / LIMITS KONDISYON / LIMIT |
|---|-----------------------------------|--|
| <i>glipizide er oral tablet extended release 24 hour 10 mg</i> | 1 | QL (60 per 30 days); MO; 100D |
| <i>glipizide er oral tablet extended release 24 hour 2.5 mg</i> | 1 | QL (240 per 30 days); MO; 100D |
| <i>glipizide er oral tablet extended release 24 hour 5 mg</i> | 1 | QL (120 per 30 days); MO; 100D |
| <i>glipizide oral tablet 10 mg</i> | 1 | QL (120 per 30 days); MO; 100D |
| <i>glipizide oral tablet 2.5 mg</i> | 1 | MO; 100D |
| <i>glipizide oral tablet 5 mg</i> | 1 | QL (240 per 30 days); MO; 100D |
| <i>glipizide xl oral tablet extended release 24 hour 10 mg</i> | 1 | QL (60 per 30 days); MO; 100D |
| <i>glipizide xl oral tablet extended release 24 hour 2.5 mg</i> | 1 | QL (240 per 30 days); MO; 100D |
| <i>glipizide xl oral tablet extended release 24 hour 5 mg</i> | 1 | QL (120 per 30 days); MO; 100D |
| <i>glipizide-metformin hcl oral tablet 2.5-250 mg</i> | 1 | QL (240 per 30 days); MO; 100D |
| <i>glipizide-metformin hcl oral tablet 2.5-500 mg, 5-500 mg</i> | 1 | QL (120 per 30 days); MO; 100D |
| GLUCAGEN HYPOKIT | 3 | |
| <i>glucagon emergency injection kit</i> | 2 | |
| <i>glyburide micronized oral tablet 1.5 mg</i> | 2 | QL (240 per 30 days); MO; 90D |
| <i>glyburide micronized oral tablet 3 mg</i> | 2 | QL (120 per 30 days); MO; 90D |
| <i>glyburide micronized oral tablet 6 mg</i> | 1 | QL (60 per 30 days); MO; 100D |
| <i>glyburide oral tablet 1.25 mg</i> | 1 | QL (480 per 30 days); MO; 100D |
| <i>glyburide oral tablet 2.5 mg</i> | 1 | QL (240 per 30 days); MO; 100D |
| <i>glyburide oral tablet 5 mg</i> | 1 | QL (120 per 30 days); MO; 100D |
| <i>glyburide-metformin oral tablet 1.25-250 mg</i> | 1 | QL (240 per 30 days); MO; 100D |
| <i>glyburide-metformin oral tablet 2.5-500 mg, 5-500 mg</i> | 2 | QL (120 per 30 days); MO; 90D |
| GLYXAMBI | 3 | QL (30 per 30 days); MO |

You can find information on what the symbols and abbreviations in this table mean by going to page 10 of this document. Ou ka jwenn enfòmasyon sou sa senbòl ak abrevyasyon yo nan tablo sa a vle di lè w ale nan paj 19 dokiman sa a.

| DRUG NAME / NON MEDIKAMAN | DRUG TIER / NIVO MEDIKAMAN | REQUIREMENTS / LIMITS KONDISYON / LIMIT |
|---|----------------------------|---|
| GVOKE PFS SUBCUTANEOUS SOLUTION PREFILLED SYRINGE 1 MG/0.2ML | 4 | |
| <i>ibandronate sodium oral</i> | 2 | QL (1 per 28 days); MO; 90D |
| <i>insulin asp prot & asp flexpen</i> | 3 | MO |
| <i>insulin aspart flexpen</i> | 3 | MO |
| <i>insulin aspart injection</i> | 3 | MO |
| <i>insulin aspart penfill</i> | 3 | MO |
| <i>insulin aspart prot & aspart</i> | 3 | MO |
| INVOKAMET | 4 | QL (60 per 30 days); MO |
| INVOKAMET XR | 4 | QL (60 per 30 days); MO |
| INVOKANA | 4 | QL (30 per 30 days); MO |
| JANUMET | 3 | QL (60 per 30 days); MO |
| JANUMET XR ORAL TABLET EXTENDED RELEASE 24 HOUR 100-1000 MG | 3 | QL (30 per 30 days); MO |
| JANUMET XR ORAL TABLET EXTENDED RELEASE 24 HOUR 50-1000 MG, 50-500 MG | 3 | QL (60 per 30 days); MO |
| JANUVIA | 3 | QL (30 per 30 days); MO |
| JARDIANCE | 3 | QL (30 per 30 days); MO |
| JENTADUETO | 3 | QL (60 per 30 days); MO |
| JENTADUETO XR ORAL TABLET EXTENDED RELEASE 24 HOUR 2.5-1000 MG | 3 | QL (60 per 30 days); MO |
| JENTADUETO XR ORAL TABLET EXTENDED RELEASE 24 HOUR 5-1000 MG | 3 | QL (30 per 30 days); MO |
| KERENDIA | 3 | QL (30 per 30 days); MO |
| KIONEX ORAL SUSPENSION | 2 | |
| LANTUS | 3 | QL (30 per 30 days); MO |
| LANTUS SOLOSTAR SUBCUTANEOUS SOLUTION PEN-INJECTOR | 3 | QL (30 per 30 days); MO |
| LOKELMA ORAL PACKET 10 GM | 3 | QL (34 per 30 days); MO |
| LOKELMA ORAL PACKET 5 GM | 3 | QL (90 per 30 days); MO |

You can find information on what the symbols and abbreviations in this table mean by going to page 10 of this document. Ou ka jwenn enfòmasyon sou sa senbòl ak abrevyasyon yo nan tablo sa a vle di lè w ale nan paj 19 dokiman sa a.

| DRUG NAME / NON MEDIKAMAN | DRUG TIER / NIVO MEDIKAMAN | REQUIREMENTS / LIMITS KONDISYON / LIMIT |
|--|----------------------------|---|
| <i>metformin hcl er (mod) oral tablet extended release 24 hour 1000 mg</i> | 4 | QL (60 per 30 days); MO |
| <i>metformin hcl er (mod) oral tablet extended release 24 hour 500 mg</i> | 4 | QL (120 per 30 days); MO |
| <i>metformin hcl er (osm) oral tablet extended release 24 hour 1000 mg</i> | 4 | QL (60 per 30 days); MO |
| <i>metformin hcl er (osm) oral tablet extended release 24 hour 500 mg</i> | 4 | QL (120 per 30 days); MO |
| <i>metformin hcl er oral tablet extended release 24 hour 500 mg</i> | 1 | QL (120 per 30 days); MO; 100D |
| <i>metformin hcl er oral tablet extended release 24 hour 750 mg</i> | 1 | QL (60 per 30 days); MO; 100D |
| <i>metformin hcl oral tablet 1000 mg</i> | 1 | QL (60 per 30 days); MO; 100D |
| <i>metformin hcl oral tablet 500 mg</i> | 1 | QL (150 per 30 days); MO; 100D |
| <i>metformin hcl oral tablet 850 mg</i> | 1 | QL (90 per 30 days); MO; 100D |
| <i>miglitol</i> | 2 | QL (90 per 30 days); MO; 90D |
| MOUNJARO | 3 | PA; QL (2 per 28 days) |
| <i>nateglinide oral tablet 120 mg</i> | 2 | QL (90 per 30 days); MO; 90D |
| <i>nateglinide oral tablet 60 mg</i> | 2 | QL (180 per 30 days); MO; 90D |
| NOVOLIN 70/30 | 3 | MO |
| NOVOLIN 70/30 RELION | 3 | MO |
| NOVOLIN N | 3 | MO |
| NOVOLIN N FLEXPEN | 3 | MO |
| NOVOLIN N FLEXPEN RELION | 3 | MO |
| NOVOLIN N RELION | 3 | MO |
| NOVOLIN R | 3 | MO |
| NOVOLIN R RELION | 3 | MO |
| NOVOLOG 70/30 FLEXPEN RELION | 3 | MO |
| NOVOLOG FLEXPEN RELION | 3 | MO |

You can find information on what the symbols and abbreviations in this table mean by going to page 10 of this document. Ou ka jwenn enfòmasyon sou sa senbòl ak abrevyasyon yo nan tablo sa a vle di lè w ale nan paj 19 dokiman sa a.

| DRUG NAME / NON MEDIKAMAN | DRUG TIER / NIVO MEDIKAMAN | REQUIREMENTS / LIMITS KONDISYON / LIMIT |
|---|----------------------------|---|
| NOVOLOG FLEXPEN SUBCUTANEOUS SOLUTION PEN-INJECTOR | 3 | MO |
| NOVOLOG INJECTION | 3 | MO |
| NOVOLOG MIX 70/30 | 3 | MO |
| NOVOLOG MIX 70/30 FLEXPEN SUBCUTANEOUS SUSPENSION PEN-INJECTOR | 3 | MO |
| NOVOLOG MIX 70/30 RELION | 3 | MO |
| NOVOLOG PENFILL SUBCUTANEOUS SOLUTION CARTRIDGE | 3 | MO |
| NOVOLOG RELION INJECTION | 3 | MO |
| OZEMPIC (0.25 OR 0.5 MG/DOSE) SUBCUTANEOUS SOLUTION PEN-INJECTOR 2 MG/1.5ML | 3 | PA; QL (1.5 per 28 days) |
| OZEMPIC (0.25 OR 0.5 MG/DOSE) SUBCUTANEOUS SOLUTION PEN-INJECTOR 2 MG/3ML | 3 | PA; QL (3 per 28 days) |
| OZEMPIC (1 MG/DOSE) SUBCUTANEOUS SOLUTION PEN-INJECTOR 4 MG/3ML | 3 | PA; QL (3 per 28 days) |
| OZEMPIC (2 MG/DOSE) | 3 | PA; QL (3 per 28 days) |
| <i>paricalcitol oral</i> | 2 | B/D PA; MO; 90D |
| <i>pioglitazone hcl oral tablet 15 mg</i> | 2 | QL (90 per 30 days); MO; 90D |
| <i>pioglitazone hcl oral tablet 30 mg</i> | 2 | QL (45 per 30 days); MO; 90D |
| <i>pioglitazone hcl oral tablet 45 mg</i> | 2 | QL (30 per 30 days); MO; 90D |
| <i>pioglitazone hcl-glimepiride</i> | 2 | QL (30 per 30 days); MO; 90D |
| <i>pioglitazone hcl-metformin hcl</i> | 2 | QL (90 per 30 days); MO; 90D |
| PROLIA SUBCUTANEOUS SOLUTION PREFILLED SYRINGE | 4 | PA; QL (1 per 180 days) |
| <i>repaglinide oral tablet 0.5 mg</i> | 2 | QL (960 per 30 days); MO; 90D |
| <i>repaglinide oral tablet 1 mg</i> | 2 | QL (480 per 30 days); MO; 90D |
| <i>repaglinide oral tablet 2 mg</i> | 2 | QL (240 per 30 days); MO; 90D |
| <i>risedronate sodium oral tablet 150 mg</i> | 2 | ST; QL (1 per 28 days); MO; 90D |
| <i>risedronate sodium oral tablet 30 mg</i> | 2 | ST; QL (30 per 30 days) |

You can find information on what the symbols and abbreviations in this table mean by going to page 10 of this document. Ou ka jwenn enfòmasyon sou sa senbòl ak abrevyasyon yo nan tablo sa a vle di lè w ale nan paj 19 dokiman sa a.

| DRUG NAME / NON MEDIKAMAN | DRUG TIER / NIVO MEDIKAMAN | REQUIREMENTS / LIMITS KONDISYON / LIMIT |
|--|----------------------------|---|
| <i>risedronate sodium oral tablet 35 mg</i> | 2 | ST; QL (4 per 28 days); MO; 90D |
| <i>risedronate sodium oral tablet 35 mg (12 pack), 35 mg (4 pack)</i> | 2 | ST; QL (4 per 28 days); MO |
| <i>risedronate sodium oral tablet 5 mg</i> | 2 | ST; QL (30 per 30 days); MO; 90D |
| RYBELSUS ORAL TABLET 14 MG, 7 MG | 3 | PA; QL (30 per 30 days) |
| RYBELSUS ORAL TABLET 3 MG | 3 | PA; QL (60 per 365 days) |
| <i>sevelamer carbonate oral packet 0.8 gm</i> | 2 | QL (540 per 30 days); MO; 90D |
| <i>sevelamer carbonate oral packet 2.4 gm</i> | 2 | QL (180 per 30 days); MO; 90D |
| <i>sevelamer carbonate oral tablet</i> | 2 | QL (540 per 30 days); MO; 90D |
| <i>sodium polystyrene sulfonate oral powder</i> | 1 | |
| SOLIQUA | 3 | QL (15 per 25 days); MO |
| SPS | 2 | |
| SYMLINPEN 120 SUBCUTANEOUS SOLUTION PEN-INJECTOR | 5 | PA; QL (11 per 30 days); MO |
| SYMLINPEN 60 SUBCUTANEOUS SOLUTION PEN-INJECTOR | 5 | PA; QL (6 per 30 days); MO |
| SYNJARDY | 3 | QL (60 per 30 days); MO |
| SYNJARDY XR ORAL TABLET EXTENDED RELEASE 24 HOUR 10-1000 MG, 12.5-1000 MG, 5-1000 MG | 3 | QL (60 per 30 days); MO |
| SYNJARDY XR ORAL TABLET EXTENDED RELEASE 24 HOUR 25-1000 MG | 3 | QL (30 per 30 days); MO |
| <i>teriparatide</i> | 5 | PA; QL (3 per 28 days) |
| <i>teriparatide (recombinant)</i> | 5 | PA; QL (3 per 28 days) |
| <i>tolvaptan oral tablet 15 mg</i> | 5 | PA; QL (30 per 30 days) |
| <i>tolvaptan oral tablet 30 mg</i> | 5 | PA; QL (60 per 30 days) |
| TOUJEO MAX SOLOSTAR | 3 | QL (12 per 30 days); MO |
| TOUJEO SOLOSTAR | 3 | QL (13.5 per 30 days); MO |
| TRADJENTA | 3 | QL (30 per 30 days); MO |
| TRESIBA | 3 | QL (30 per 30 days); MO |

You can find information on what the symbols and abbreviations in this table mean by going to page 10 of this document. Ou ka jwenn enfòmasyon sou sa senbòl ak abrevyasyon yo nan tablo sa a vle di lè w ale nan paj 19 dokiman sa a.

| DRUG NAME / NON MEDIKAMAN | DRUG TIER / NIVO MEDIKAMAN | REQUIREMENTS / LIMITS KONDISYON / LIMIT |
|--|-----------------------------------|--|
| TRESIBA FLEXTOUCH SUBCUTANEOUS SOLUTION PEN-INJECTOR 100 UNIT/ML | 3 | QL (30 per 30 days); MO |
| TRESIBA FLEXTOUCH SUBCUTANEOUS SOLUTION PEN-INJECTOR 200 UNIT/ML | 3 | QL (18 per 30 days); MO |
| <i>trientine hcl</i> | 5 | PA |
| TRIJARDY XR ORAL TABLET EXTENDED RELEASE 24 HOUR 10-5-1000 MG, 25-5-1000 MG | 3 | QL (30 per 30 days); MO |
| TRIJARDY XR ORAL TABLET EXTENDED RELEASE 24 HOUR 12.5-2.5-1000 MG, 5-2.5-1000 MG | 3 | QL (60 per 30 days); MO |
| TRULICITY | 3 | PA; QL (2 per 28 days) |
| TYMLOS | 5 | PA; QL (1.56 per 28 days) |
| VELPHORO | 5 | QL (180 per 30 days); MO |
| VELTASSA ORAL PACKET 16.8 GM, 25.2 GM | 5 | QL (30 per 30 days); MO |
| VELTASSA ORAL PACKET 8.4 GM | 5 | QL (90 per 30 days); MO |
| <i>vitamin d (ergocalciferol) oral capsule 1.25 mg (50000 ut), 50000 unit</i> | 6 | ED |
| XGEVA | 5 | PA; QL (5.1 per 28 days) |
| XIGDUO XR ORAL TABLET EXTENDED RELEASE 24 HOUR 10-1000 MG, 10-500 MG, 5-500 MG | 3 | QL (30 per 30 days); MO |
| XIGDUO XR ORAL TABLET EXTENDED RELEASE 24 HOUR 2.5-1000 MG, 5-1000 MG | 3 | QL (60 per 30 days); MO |
| GASTROINTESTINAL AGENTS / AJAN GASTROENTESTINAL | | |
| <i>alosetron hcl oral tablet 0.5 mg</i> | 2 | PA; QL (60 per 30 days); MO; 90D |
| <i>alosetron hcl oral tablet 1 mg</i> | 5 | PA; QL (60 per 30 days); MO |
| <i>amoxicill-clarithro-lansopraz oral therapy pack</i> | 2 | |
| <i>aprepitant oral</i> | 2 | B/D PA; QL (15 per 30 days) |
| <i>aprepitant oral capsule 125 mg</i> | 4 | B/D PA; QL (5 per 30 days) |
| <i>aprepitant oral capsule 40 mg</i> | 2 | B/D PA; QL (1 per 28 days) |
| <i>aprepitant oral capsule 80 & 125 mg</i> | 2 | B/D PA; QL (15 per 30 days) |

You can find information on what the symbols and abbreviations in this table mean by going to page 10 of this document. Ou ka jwenn enfòmasyon sou sa senbòl ak abrevyasyon yo nan tablo sa a vle di lè w ale nan paj 19 dokiman sa a.

| DRUG NAME / NON MEDIKAMAN | DRUG TIER / NIVO MEDIKAMAN | REQUIREMENTS / LIMITS KONDISYON / LIMIT |
|---|----------------------------|---|
| <i>aprepitant oral capsule 80 mg</i> | 2 | B/D PA; QL (10 per 30 days) |
| <i>balsalazide disodium</i> | 2 | |
| <i>budesonide er oral tablet extended release 24 hour</i> | 4 | PA |
| <i>budesonide oral</i> | 2 | |
| <i>budesonide rectal</i> | 2 | |
| <i>chlordiazepoxide-clidinium</i> | 2 | PA; HRM |
| <i>cimetidine hcl oral solution 300 mg/5ml</i> | 2 | MO; 90D |
| <i>cimetidine oral tablet 200 mg</i> | 2 | |
| <i>cimetidine oral tablet 300 mg, 400 mg, 800 mg</i> | 2 | MO; 90D |
| CLENPIQ | 4 | |
| COMPRO | 2 | |
| <i>constulose</i> | 1 | MO; 100D |
| <i>dexlansoprazole</i> | 2 | ST; QL (30 per 30 days); MO; 90D |
| <i>dicyclomine hcl oral capsule</i> | 1 | |
| <i>dicyclomine hcl oral solution</i> | 2 | |
| <i>dicyclomine hcl oral tablet</i> | 1 | |
| <i>diphenoxylate-atropine oral liquid</i> | 2 | |
| <i>diphenoxylate-atropine oral tablet 2.5-0.025 mg</i> | 1 | |
| <i>dronabinol</i> | 2 | B/D PA; QL (120 per 30 days) |
| <i>enulose</i> | 2 | MO; 90D |
| <i>esomeprazole magnesium oral capsule delayed release 20 mg, 40 mg</i> | 2 | QL (30 per 30 days); MO; 90D |
| <i>famotidine oral tablet 20 mg, 40 mg</i> | 1 | MO; 100D |
| <i>fosaprepitant dimeglumine</i> | 2 | |
| GATTEX | 5 | PA; LA |
| GAVILYTE-C | 1 | |
| GAVILYTE-G | 1 | |
| GAVILYTE-N WITH FLAVOR PACK | 2 | |

You can find information on what the symbols and abbreviations in this table mean by going to page 10 of this document. Ou ka jwenn enfòmasyon sou sa senbòl ak abrevyasyon yo nan tablo sa a vle di lè w ale nan paj 19 dokiman sa a.

| DRUG NAME / NON MEDIKAMAN | DRUG TIER / NIVO MEDIKAMAN | REQUIREMENTS / LIMITS KONDISYON / LIMIT |
|--|----------------------------|---|
| <i>generlac</i> | 2 | MO; 90D |
| <i>glycopyrrolate oral tablet 1 mg</i> | 1 | |
| <i>glycopyrrolate oral tablet 2 mg</i> | 2 | |
| <i>granisetron hcl oral</i> | 2 | B/D PA; QL (30 per 30 days) |
| <i>hydrocortisone ace-pramoxine external cream 1-1 %</i> | 1 | |
| <i>hydrocortisone oral</i> | 1 | |
| <i>hyoscyamine sulfate oral tablet</i> | 2 | MO; 90D |
| <i>hyoscyamine sulfate oral tablet dispersible</i> | 2 | MO; 90D |
| <i>hyoscyamine sulfate sublingual</i> | 2 | MO; 90D |
| <i>lactulose encephalopathy</i> | 2 | MO; 90D |
| <i>lactulose oral solution</i> | 1 | MO; 100D |
| <i>lansoprazole oral capsule delayed release 30 mg</i> | 2 | QL (30 per 30 days); MO; 90D |
| LINZESS | 3 | QL (30 per 30 days); MO |
| <i>loperamide hcl oral capsule</i> | 1 | |
| <i>lubiprostone</i> | 2 | QL (60 per 30 days); MO; 90D |
| <i>meclizine hcl oral tablet 12.5 mg, 25 mg</i> | 1 | |
| <i>mesalamine er oral capsule extended release 24 hour</i> | 2 | MO; 90D |
| <i>mesalamine oral capsule delayed release</i> | 2 | MO; 90D |
| <i>mesalamine oral tablet delayed release 1.2 gm</i> | 2 | MO; 90D |
| <i>mesalamine oral tablet delayed release 800 mg</i> | 2 | |
| <i>mesalamine rectal</i> | 2 | |
| <i>methscopolamine bromide oral</i> | 2 | |
| <i>metoclopramide hcl oral solution 10 mg/10ml, 5 mg/5ml</i> | 1 | |
| <i>metoclopramide hcl oral tablet</i> | 1 | |
| <i>misoprostol oral tablet 100 mcg</i> | 1 | MO; 100D |
| <i>misoprostol oral tablet 200 mcg</i> | 2 | MO; 90D |

You can find information on what the symbols and abbreviations in this table mean by going to page 10 of this document. Ou ka jwenn enfòmasyon sou sa senbòl ak abrevyasyon yo nan tablo sa a vle di lè w ale nan paj 19 dokiman sa a.

| DRUG NAME / NON MEDIKAMAN | DRUG TIER / NIVO MEDIKAMAN | REQUIREMENTS / LIMITS KONDISYON / LIMIT |
|---|----------------------------|---|
| MOVANTIK | 4 | QL (30 per 30 days) |
| MYTESI | 5 | |
| <i>nizatidine oral capsule</i> | 1 | MO; 100D |
| <i>omeprazole oral capsule delayed release 10 mg, 40 mg</i> | 2 | MO; 90D |
| <i>ondansetron hcl oral solution</i> | 2 | B/D PA; QL (450 per 30 days) |
| <i>ondansetron hcl oral tablet 24 mg</i> | 2 | B/D PA; QL (30 per 30 days) |
| <i>ondansetron hcl oral tablet 4 mg, 8 mg</i> | 2 | B/D PA; QL (90 per 30 days) |
| <i>ondansetron oral tablet dispersible 16 mg</i> | 2 | B/D PA; QL (30 per 30 days) |
| <i>ondansetron oral tablet dispersible 4 mg, 8 mg</i> | 2 | B/D PA; QL (90 per 30 days) |
| <i>pantoprazole sodium oral tablet delayed release</i> | 2 | MO; 90D |
| <i>peg 3350-kcl-na bicarb-nacl</i> | 2 | |
| <i>peg-3350/electrolytes</i> | 1 | |
| <i>prochlorperazine</i> | 2 | |
| <i>prochlorperazine maleate oral</i> | 1 | MO; 100D |
| <i>promethazine hcl oral solution</i> | 2 | |
| <i>promethazine hcl oral tablet</i> | 1 | |
| PROMETHEGAN | 2 | PA; HRM |
| <i>scopolamine</i> | 2 | QL (10 per 28 days) |
| <i>sucralfate oral suspension</i> | 4 | MO |
| <i>sucralfate oral tablet</i> | 1 | MO; 100D |
| <i>sulfasalazine oral</i> | 1 | MO; 100D |
| SYNDROS | 5 | B/D PA |
| <i>ursodiol oral capsule 300 mg</i> | 2 | MO; 90D |
| <i>ursodiol oral tablet</i> | 2 | MO; 90D |
| VARUBI (180 MG DOSE) | 4 | B/D PA; QL (4 per 28 days) |
| VOWST | 5 | PA; QL (12 per 30 days) |
| XERMELO | 5 | PA; QL (90 per 30 days); LA |

You can find information on what the symbols and abbreviations in this table mean by going to page 10 of this document. Ou ka jwenn enfòmasyon sou sa senbòl ak abrevyasyon yo nan tablo sa a vle di lè w ale nan paj 19 dokiman sa a.

| DRUG NAME / NON MEDIKAMAN | DRUG TIER / NIVO MEDIKAMAN | REQUIREMENTS / LIMITS KONDISYON / LIMIT |
|--|----------------------------|---|
| GENETIC OR ENZYME OR PROTEIN DISORDER: REPLACEMENT, MODIFIERS, TREATMENT / MALADI JÈN, ANZIM, OSWA PWOTEYIN: RANPLASMAN, MODIFIKATÈ, TRETMAN | | |
| <i>betaine</i> | 5 | LA |
| CREON | 3 | MO |
| <i>cromolyn sodium oral</i> | 2 | MO; 90D |
| CYSTAGON | 4 | PA; LA |
| GALAFOLD | 5 | PA; LA |
| JAVYGTOR | 5 | PA |
| <i>miglustat</i> | 5 | PA; LA |
| <i>nitisinone</i> | 5 | PA |
| PROLASTIN-C INTRAVENOUS SOLUTION | 5 | PA; LA |
| <i>sapropterin dihydrochloride oral packet</i> | 5 | PA |
| <i>sapropterin dihydrochloride oral tablet</i> | 5 | PA |
| <i>sodium phenylbutyrate oral powder 3 gm/tsp</i> | 5 | PA |
| <i>sodium phenylbutyrate oral tablet</i> | 5 | PA |
| XURIDEN | 5 | PA; QL (120 per 30 days) |
| YARGESA | 5 | PA |
| ZENPEP ORAL CAPSULE DELAYED RELEASE PARTICLES 10000-32000 UNIT, 15000-47000 UNIT, 20000-63000 UNIT, 25000-79000 UNIT, 3000-10000 UNIT, 40000-126000 UNIT, 5000-24000 UNIT, 60000-189600 UNIT | 3 | MO |
| GENITOURINARY AGENTS / AJAN JENITOURINÈ | | |
| <i>alfuzosin hcl er</i> | 1 | MO; 100D |
| <i>bethanechol chloride oral</i> | 1 | |
| <i>clindamycin phosphate vaginal</i> | 2 | |
| <i>darifenacin hydrobromide er</i> | 2 | QL (30 per 30 days); MO; 90D |
| <i>dutasteride oral</i> | 2 | QL (30 per 30 days); MO; 90D |

You can find information on what the symbols and abbreviations in this table mean by going to page 10 of this document. Ou ka jwenn enfòmasyon sou sa senbòl ak abrevyasyon yo nan tablo sa a vle di lè w ale nan paj 19 dokiman sa a.

| DRUG NAME / NON MEDIKAMAN | DRUG TIER / NIVO MEDIKAMAN | REQUIREMENTS / LIMITS KONDISYON / LIMIT |
|---|----------------------------|---|
| <i>dutasteride-tamsulosin hcl</i> | 2 | QL (30 per 30 days); MO; 90D |
| <i>finasteride oral tablet 5 mg</i> | 1 | MO; 100D |
| GEMTESA | 4 | QL (30 per 30 days); MO |
| LITHOSTAT | 4 | MO |
| <i>metronidazole vaginal</i> | 2 | |
| <i>miconazole 3 vaginal suppository</i> | 2 | |
| MYRBETRIQ ORAL SUSPENSION RECONSTITUTED ER | 3 | QL (300 per 30 days); MO |
| MYRBETRIQ ORAL TABLET EXTENDED RELEASE 24 HOUR | 3 | QL (30 per 30 days); MO |
| <i>oxybutynin chloride er oral tablet extended release 24 hour 10 mg, 15 mg</i> | 2 | QL (60 per 30 days); MO; 90D |
| <i>oxybutynin chloride er oral tablet extended release 24 hour 5 mg</i> | 2 | QL (30 per 30 days); MO; 90D |
| <i>oxybutynin chloride oral solution</i> | 1 | QL (600 per 30 days); MO; 100D |
| <i>oxybutynin chloride oral tablet 2.5 mg</i> | 1 | QL (90 per 30 days); MO; 100D |
| <i>oxybutynin chloride oral tablet 5 mg</i> | 1 | QL (120 per 30 days); MO; 100D |
| <i>penicillamine oral tablet</i> | 5 | |
| <i>potassium citrate er</i> | 2 | |
| <i>sildenafil citrate oral tablet 100 mg, 25 mg, 50 mg</i> | 6 | QL (6 per 30 days); ED |
| <i>silodosin</i> | 2 | MO; 90D |
| <i>solifenacin succinate</i> | 2 | QL (30 per 30 days); MO; 90D |
| <i>tadalafil oral tablet 10 mg, 20 mg</i> | 6 | QL (6 per 30 days); ED |
| <i>tadalafil oral tablet 5 mg</i> | 4 | PA; QL (30 per 30 days); MO |
| <i>tamsulosin hcl</i> | 2 | MO; 90D |
| <i>terconazole vaginal cream 0.4 %</i> | 1 | |
| <i>terconazole vaginal suppository</i> | 2 | |
| <i>tolterodine tartrate er</i> | 2 | QL (30 per 30 days); MO; 90D |
| VANDAZOLE | 2 | |

HORMONAL AGENTS / AJAN ÒMONAL

You can find information on what the symbols and abbreviations in this table mean by going to page 10 of this document. Ou ka jwenn enfòmasyon sou sa senbòl ak abrevyasyon yo nan tablo sa a vle di lè w ale nan paj 19 dokiman sa a.

| DRUG NAME / NON MEDIKAMAN | DRUG TIER / NIVO MEDIKAMAN | REQUIREMENTS / LIMITS KONDISYON / LIMIT |
|---|----------------------------|---|
| ALTAVERA | 1 | MO; 100D |
| APRI | 1 | MO; 100D |
| AUROVELA 1.5/30 | 2 | MO; 90D |
| AUROVELA 1/20 | 1 | MO; 100D |
| AUROVELA FE 1/20 | 1 | MO; 100D |
| AYUNA | 1 | MO; 100D |
| AZURETTE | 2 | MO; 90D |
| BIJUVA | 3 | PA; MO; HRM |
| <i>cabergoline</i> | 2 | |
| CAMILA | 3 | MO |
| CHARLOTTE 24 FE | 2 | MO; 90D |
| CHATEAL EQ | 1 | MO; 100D |
| CLIMARA PRO | 4 | PA; QL (4 per 28 days); MO; HRM |
| CRYSSELLE-28 | 1 | MO; 100D |
| CYRED EQ | 1 | MO; 100D |
| <i>danazol oral</i> | 2 | |
| DEBLITANE | 3 | MO |
| DEPO-SUBQ PROVERA 104 SUBCUTANEOUS SUSPENSION PREFILLED SYRINGE | 3 | |
| DEPO-TESTOSTERONE INTRAMUSCULAR SOLUTION 100 MG/ML | 2 | PA; MO; 90D |
| DEPO-TESTOSTERONE INTRAMUSCULAR SOLUTION 200 MG/ML | 2 | MO; 90D |
| <i>desmopressin ace spray refrig</i> | 2 | MO; 90D |
| <i>desmopressin acetate oral tablet 0.1 mg</i> | 2 | MO; 90D |
| <i>desmopressin acetate oral tablet 0.2 mg</i> | 1 | MO; 100D |
| <i>desmopressin acetate spray</i> | 2 | MO; 90D |
| <i>desogestrel-ethinyl estradiol oral tablet 0.15-0.02/0.01 mg (21/5)</i> | 2 | MO; 90D |

You can find information on what the symbols and abbreviations in this table mean by going to page 10 of this document. Ou ka jwenn enfòmasyon sou sa senbòl ak abrevyasyon yo nan tablo sa a vle di lè w ale nan paj 19 dokiman sa a.

| DRUG NAME / NON MEDIKAMAN | DRUG TIER / NIVO MEDIKAMAN | REQUIREMENTS / LIMITS KONDISYON / LIMIT |
|---|----------------------------|---|
| <i>desogestrel-ethinyl estradiol oral tablet 0.15-30 mg-mcg</i> | 1 | MO; 100D |
| <i>dexamethasone oral elixir</i> | 1 | |
| <i>dexamethasone oral tablet</i> | 1 | |
| <i>drospirenone-ethinyl estradiol oral tablet 3-0.02 mg</i> | 2 | MO; 90D |
| ELINEST | 1 | MO; 100D |
| ELURYNG | 3 | MO |
| EMZAHH | 3 | MO |
| ENILLORING | 4 | MO |
| ENSKYCE ORAL TABLET 0.15-30 MG-MCG | 1 | MO; 100D |
| ERRIN | 3 | MO |
| ESTARYLLA | 2 | MO; 90D |
| <i>estradiol oral</i> | 1 | MO; 100D |
| <i>estradiol vaginal</i> | 2 | MO; 90D |
| <i>ethynodiol diac-eth estradiol oral tablet 1-50 mg-mcg</i> | 1 | MO; 100D |
| <i>etonogestrel-ethinyl estradiol</i> | 4 | MO |
| EUTHYROX | 1 | MO; 100D |
| FEMYNOR | 2 | MO; 90D |
| FINZALA | 2 | MO; 90D |
| <i>fludrocortisone acetate oral</i> | 1 | MO; 100D |
| HAILEY 1.5/30 | 2 | MO; 90D |
| HAILEY FE 1/20 | 1 | MO; 100D |
| HALOETTE | 4 | MO |
| HEATHER | 3 | MO |
| IMVEXXY MAINTENANCE PACK | 3 | QL (18 per 28 days); MO |
| IMVEXXY STARTER PACK | 3 | QL (18 per 28 days); MO |
| INCASSIA | 3 | MO |

You can find information on what the symbols and abbreviations in this table mean by going to page 10 of this document. Ou ka jwenn enfòmasyon sou sa senbòl ak abrevyasyon yo nan tablo sa a vle di lè w ale nan paj 19 dokiman sa a.

| DRUG NAME / NON MEDIKAMAN | DRUG TIER / NIVO MEDIKAMAN | REQUIREMENTS / LIMITS KONDISYON / LIMIT |
|---|----------------------------|---|
| INCRELEX | 5 | PA; LA |
| ISIBLOOM | 1 | MO; 100D |
| JASMIEL | 2 | MO; 90D |
| JENCYCLA | 3 | MO |
| JULEBER | 1 | MO; 100D |
| JUNEL 1.5/30 | 2 | MO; 90D |
| JUNEL 1/20 | 1 | MO; 100D |
| JUNEL FE 1/20 | 1 | MO; 100D |
| KALLIGA | 1 | MO; 100D |
| KARIVA | 2 | MO; 90D |
| KELNOR 1/50 | 1 | MO; 100D |
| KURVELO | 1 | MO; 100D |
| <i>lanreotide acetate</i> | 5 | PA |
| LARIN 1.5/30 | 2 | MO; 90D |
| LARIN 1/20 | 1 | MO; 100D |
| LARIN FE 1/20 | 1 | MO; 100D |
| <i>levonorgestrel-ethinyl estrad oral tablet 0.15-30 mg-mcg</i> | 1 | MO; 100D |
| LEVORA 0.15/30 (28) | 1 | MO; 100D |
| LEVO-T | 1 | MO; 100D |
| <i>levothyroxine sodium oral tablet</i> | 1 | MO; 100D |
| LEVOXYL | 1 | MO; 100D |
| <i>liothyronine sodium oral</i> | 1 | MO; 100D |
| LOESTRIN 1.5/30 (21) | 2 | MO; 90D |
| LOESTRIN 1/20 (21) | 1 | MO; 100D |
| LOESTRIN FE 1/20 | 1 | MO; 100D |
| LORYNA | 2 | MO; 90D |
| LOW-OGESTREL | 1 | MO; 100D |
| LO-ZUMANDIMINE | 2 | MO; 90D |

You can find information on what the symbols and abbreviations in this table mean by going to page 10 of this document. Ou ka jwenn enfòmasyon sou sa senbòl ak abrevyasyon yo nan tablo sa a vle di lè w ale nan paj 19 dokiman sa a.

| DRUG NAME / NON MEDIKAMAN | DRUG TIER / NIVO MEDIKAMAN | REQUIREMENTS / LIMITS KONDISYON / LIMIT |
|--|----------------------------|---|
| LYLEQ | 3 | MO |
| LYZA | 3 | MO |
| <i>marlissa</i> | 1 | MO; 100D |
| <i>medroxyprogesterone acetate intramuscular</i> | 2 | |
| <i>medroxyprogesterone acetate oral tablet 10 mg, 5 mg</i> | 1 | MO; 100D |
| <i>medroxyprogesterone acetate oral tablet 2.5 mg</i> | 2 | MO; 90D |
| <i>megestrol acetate oral suspension 625 mg/5ml</i> | 2 | PA; MO; 90D; HRM |
| <i>methimazole oral</i> | 1 | MO; 100D |
| <i>methylprednisolone oral</i> | 1 | |
| <i>methyltestosterone oral</i> | 5 | MO |
| MIBELAS 24 FE | 2 | MO; 90D |
| MICROGESTIN 1.5/30 | 2 | MO; 90D |
| MICROGESTIN 1/20 | 1 | MO; 100D |
| MICROGESTIN 24 FE | 1 | MO; 100D |
| MICROGESTIN FE 1/20 | 1 | MO; 100D |
| <i>mifepristone oral tablet 300 mg</i> | 2 | PA; LA; 90D |
| MILI | 2 | MO; 90D |
| MONO-LINYAH | 2 | MO; 90D |
| NEXPLANON | 3 | |
| NIKKI | 2 | MO; 90D |
| NORA-BE | 3 | MO |
| NORDITROPIN FLEXPPO SUBCUTANEOUS SOLUTION PEN-INJECTOR | 5 | PA |
| <i>norelgestromin-eth estradiol</i> | 3 | MO |
| <i>norethin ace-eth estrad-fe oral tablet 1-20 mg-mcg</i> | 1 | MO; 100D |
| <i>norethin ace-eth estrad-fe oral tablet chewable</i> | 2 | MO; 90D |
| <i>norethindrone acetate oral</i> | 2 | MO; 90D |

You can find information on what the symbols and abbreviations in this table mean by going to page 10 of this document. Ou ka jwenn enfòmasyon sou sa senbòl ak abrevyasyon yo nan tablo sa a vle di lè w ale nan paj 19 dokiman sa a.

| DRUG NAME / NON MEDIKAMAN | DRUG TIER / NIVO MEDIKAMAN | REQUIREMENTS / LIMITS KONDISYON / LIMIT |
|---|----------------------------|---|
| <i>norethindrone acet-ethinyl est oral tablet 1.5-30 mg-mcg</i> | 2 | MO; 90D |
| <i>norethindrone acet-ethinyl est oral tablet 1-20 mg-mcg</i> | 1 | MO; 100D |
| <i>norethindrone oral</i> | 3 | MO |
| <i>norethin-eth estradiol-fe oral tablet chewable 0.4-35 mg-mcg</i> | 2 | MO; 90D |
| <i>norgestimate-eth estradiol oral tablet 0.25-35 mg-mcg</i> | 2 | MO; 90D |
| <i>norgestim-eth estrad triphasic</i> | 2 | MO; 90D |
| NORLYDA | 3 | MO |
| NORLYROC | 3 | MO |
| <i>octreotide acetate injection solution 100 mcg/ml, 1000 mcg/ml, 200 mcg/ml, 50 mcg/ml</i> | 2 | PA; 90D |
| <i>octreotide acetate injection solution 500 mcg/ml</i> | 5 | PA |
| <i>octreotide acetate subcutaneous solution prefilled syringe 100 mcg/ml, 50 mcg/ml</i> | 2 | PA; 90D |
| <i>octreotide acetate subcutaneous solution prefilled syringe 500 mcg/ml</i> | 5 | PA |
| OMNITROPE SUBCUTANEOUS SOLUTION CARTRIDGE | 5 | PA; LA |
| OMNITROPE SUBCUTANEOUS SOLUTION RECONSTITUTED | 5 | PA; LA |
| OSPHENA | 3 | MO |
| <i>oxandrolone oral tablet 10 mg</i> | 2 | PA; QL (60 per 30 days) |
| <i>oxandrolone oral tablet 2.5 mg</i> | 2 | PA; QL (240 per 30 days) |
| PIMTREA | 2 | MO; 90D |
| PORTIA-28 | 1 | MO; 100D |
| <i>prednicarbate external ointment</i> | 2 | |
| <i>prednisolone oral solution</i> | 2 | |

You can find information on what the symbols and abbreviations in this table mean by going to page 10 of this document. Ou ka jwenn enfòmasyon sou sa senbòl ak abrevyasyon yo nan tablo sa a vle di lè w ale nan paj 19 dokiman sa a.

| DRUG NAME / NON MEDIKAMAN | DRUG TIER / NIVO MEDIKAMAN | REQUIREMENTS / LIMITS KONDISYON / LIMIT |
|---|----------------------------|---|
| <i>prednisolone sodium phosphate oral solution 25 mg/5ml, 6.7 (5 base) mg/5ml</i> | 2 | |
| <i>prednisolone sodium phosphate oral tablet dispersible</i> | 2 | |
| <i>prednisone oral solution</i> | 2 | |
| <i>prednisone oral tablet</i> | 1 | |
| <i>prednisone oral tablet therapy pack</i> | 1 | |
| PREMARIN ORAL | 3 | PA; MO; HRM |
| PREMARIN VAGINAL | 3 | MO |
| <i>progesterone oral</i> | 2 | MO; 90D |
| <i>propylthiouracil oral</i> | 1 | MO; 100D |
| <i>raloxifene hcl</i> | 2 | QL (30 per 30 days); MO; 90D |
| RECLIPSEN | 1 | MO; 100D |
| SHAROBEL | 3 | MO |
| SIGNIFOR | 5 | PA; LA |
| SIMLIYA | 2 | MO; 90D |
| SKYLA | 3 | |
| SOMATULINE DEPOT | 5 | PA |
| SOMAVERT SUBCUTANEOUS SOLUTION RECONSTITUTED 10 MG, 15 MG, 20 MG | 5 | PA; LA |
| SPRINTEC 28 | 2 | MO; 90D |
| SYNAREL | 5 | PA |
| SYNTHROID | 3 | MO |
| TARINA FE 1/20 EQ | 1 | MO; 100D |
| <i>testosterone cypionate intramuscular solution 100 mg/ml</i> | 2 | PA; MO; 90D |
| <i>testosterone cypionate intramuscular solution 200 mg/ml, 200 mg/ml (1 ml)</i> | 2 | MO; 90D |
| <i>testosterone enanthate intramuscular solution</i> | 2 | PA; MO; 90D |

You can find information on what the symbols and abbreviations in this table mean by going to page 10 of this document. Ou ka jwenn enfòmasyon sou sa senbòl ak abrevyasyon yo nan tablo sa a vle di lè w ale nan paj 19 dokiman sa a.

| DRUG NAME / NON MEDIKAMAN | DRUG TIER / NIVO MEDIKAMAN | REQUIREMENTS / LIMITS KONDISYON / LIMIT |
|---|-----------------------------------|--|
| <i>testosterone transdermal gel 1.62 %, 20.25 mg/act (1.62%), 40.5 mg/2.5gm (1.62%)</i> | 2 | PA; QL (150 per 30 days); MO; 90D |
| <i>testosterone transdermal gel 20.25 mg/1.25gm (1.62%)</i> | 2 | PA; QL (112.5 per 30 days); MO; 90D |
| <i>testosterone transdermal gel 25 mg/2.5gm (1%), 50 mg/5gm (1%)</i> | 2 | PA; QL (300 per 30 days); MO; 90D |
| <i>testosterone transdermal solution</i> | 2 | PA; QL (180 per 30 days); MO; 90D |
| TRI FEMYNOR | 2 | MO; 90D |
| TRI-ESTARYLLA | 2 | MO; 90D |
| TRI-LINYAH | 2 | MO; 90D |
| TRI-LO-ESTARYLLA | 2 | MO; 90D |
| TRI-LO-MARZIA | 2 | MO; 90D |
| TRI-LO-MILI | 2 | MO; 90D |
| TRI-LO-SPRINTEC | 2 | MO; 90D |
| TRI-MILI | 2 | MO; 90D |
| TRI-NYMYO | 2 | MO; 90D |
| TRI-SPRINTEC | 2 | MO; 90D |
| TRI-VYLIBRA | 2 | MO; 90D |
| TRI-VYLIBRA LO | 2 | MO; 90D |
| TURQOZ | 1 | MO; 100D |
| UNITHROID | 1 | MO; 100D |
| <i>viorele</i> | 2 | MO; 90D |
| VOLNEA | 2 | MO; 90D |
| VYLIBRA | 2 | MO; 90D |
| WYMZYA FE | 2 | MO; 90D |
| <i>yuvafem</i> | 2 | MO; 90D |
| IMMUNOLOGICAL AGENTS / AJAN IMINOLOJIK | | |
| ABRYSVO | 1 | |

You can find information on what the symbols and abbreviations in this table mean by going to page 10 of this document. Ou ka jwenn enfòmasyon sou sa senbòl ak abrevyasyon yo nan tablo sa a vle di lè w ale nan paj 19 dokiman sa a.

| DRUG NAME / NON MEDIKAMAN | DRUG TIER / NIVO MEDIKAMAN | REQUIREMENTS / LIMITS KONDISYON / LIMIT |
|--|----------------------------|---|
| ACTHIB | 1 | |
| ACTIMMUNE | 5 | PA; LA |
| ADACEL | 1 | |
| ARCALYST | 5 | PA |
| AREXVY | 1 | |
| ASTAGRAF XL ORAL CAPSULE EXTENDED RELEASE 24 HOUR 0.5 MG, 1 MG | 4 | B/D PA |
| ASTAGRAF XL ORAL CAPSULE EXTENDED RELEASE 24 HOUR 5 MG | 5 | B/D PA |
| AZASAN | 4 | B/D PA |
| <i>azathioprine oral</i> | 2 | B/D PA; 90D |
| <i>bcg vaccine injection solution reconstituted</i> | 1 | |
| BENLYSTA SUBCUTANEOUS | 5 | PA |
| BEXSERO | 1 | |
| BIVIGAM INTRAVENOUS SOLUTION 5 GM/50ML | 3 | PA |
| BOOSTRIX INTRAMUSCULAR SUSPENSION 5-2.5-18.5 LF-MCG/0.5 | 1 | |
| BOOSTRIX INTRAMUSCULAR SUSPENSION PREFILLED SYRINGE | 1 | |
| COSENTYX (300 MG DOSE) | 5 | PA; QL (8 per 28 days); LA |
| COSENTYX SENSOREADY (300 MG) | 5 | PA; QL (8 per 28 days); LA |
| COSENTYX SENSOREADY PEN | 5 | PA; QL (8 per 28 days); LA |
| COSENTYX SUBCUTANEOUS SOLUTION PREFILLED SYRINGE 150 MG/ML | 5 | PA; QL (8 per 28 days); LA |
| COSENTYX SUBCUTANEOUS SOLUTION PREFILLED SYRINGE 75 MG/0.5ML | 5 | PA; QL (2 per 28 days) |
| <i>cyclosporine modified oral capsule 100 mg, 50 mg</i> | 2 | B/D PA; 90D |
| <i>cyclosporine modified oral capsule 25 mg</i> | 1 | B/D PA; 100D |
| <i>cyclosporine modified oral solution</i> | 2 | B/D PA; 90D |
| <i>cyclosporine oral capsule 100 mg</i> | 2 | B/D PA; 90D |

You can find information on what the symbols and abbreviations in this table mean by going to page 10 of this document. Ou ka jwenn enfòmasyon sou sa senbòl ak abrevyasyon yo nan tablo sa a vle di lè w ale nan paj 19 dokiman sa a.

| DRUG NAME / NON MEDIKAMAN | DRUG TIER / NIVO MEDIKAMAN | REQUIREMENTS / LIMITS KONDISYON / LIMIT |
|---|----------------------------|---|
| <i>cyclosporine oral capsule 25 mg</i> | 1 | B/D PA; 100D |
| DAPTACEL INTRAMUSCULAR SUSPENSION 23-15-5 | 1 | |
| <i>diphtheria-tetanus toxoids dt</i> | 1 | |
| ENBREL MINI | 5 | PA; QL (8 per 28 days) |
| ENBREL SUBCUTANEOUS SOLUTION 25 MG/0.5ML | 5 | PA; QL (4 per 28 days) |
| ENBREL SUBCUTANEOUS SOLUTION PREFILLED SYRINGE 25 MG/0.5ML | 5 | PA; QL (4.08 per 28 days) |
| ENBREL SUBCUTANEOUS SOLUTION PREFILLED SYRINGE 50 MG/ML | 5 | PA; QL (8 per 28 days) |
| ENBREL SURECLICK SUBCUTANEOUS SOLUTION AUTO-INJECTOR | 5 | PA; QL (8 per 28 days) |
| ENGERIX-B INJECTION SUSPENSION 20 MCG/ML | 1 | B/D PA |
| ENGERIX-B INJECTION SUSPENSION PREFILLED SYRINGE | 1 | B/D PA |
| ENVARUSUS XR | 4 | B/D PA |
| <i>everolimus oral tablet 0.25 mg</i> | 2 | B/D PA; 90D |
| <i>everolimus oral tablet 0.5 mg, 1 mg</i> | 5 | B/D PA |
| <i>everolimus oral tablet 0.75 mg</i> | 4 | B/D PA |
| FLEBOGAMMA DIF INTRAVENOUS SOLUTION 10 GM/200ML | 5 | PA |
| GAMMAGARD INJECTION SOLUTION 1 GM/10ML | 4 | PA |
| GAMMAGARD INJECTION SOLUTION 2.5 GM/25ML | 5 | PA |
| GAMMAGARD S/D LESS IGA | 5 | PA |
| GAMMAKED INJECTION SOLUTION 1 GM/10ML | 5 | PA |
| GAMMAPLEX INTRAVENOUS SOLUTION 10 GM/100ML, 10 GM/200ML, 20 GM/200ML, 5 GM/50ML | 5 | PA |
| GAMUNEX-C INJECTION SOLUTION 1 GM/10ML | 5 | PA |
| GARDASIL 9 | 1 | |
| GENGRAF ORAL CAPSULE 100 MG | 2 | B/D PA; 90D |

You can find information on what the symbols and abbreviations in this table mean by going to page 10 of this document. Ou ka jwenn enfòmasyon sou sa senbòl ak abrevyasyon yo nan tablo sa a vle di lè w ale nan paj 19 dokiman sa a.

| DRUG NAME / NON MEDIKAMAN | DRUG TIER / NIVO MEDIKAMAN | REQUIREMENTS / LIMITS KONDISYON / LIMIT |
|--|----------------------------|---|
| GENGRAF ORAL CAPSULE 25 MG | 1 | B/D PA; 100D |
| GENGRAF ORAL SOLUTION | 2 | B/D PA; 90D |
| HADLIMA PUSHTOUCH SUBCUTANEOUS SOLUTION AUTO-INJECTOR 40 MG/0.4ML | 5 | PA; QL (2.4 per 28 days) |
| HADLIMA PUSHTOUCH SUBCUTANEOUS SOLUTION AUTO-INJECTOR 40 MG/0.8ML | 5 | PA; QL (4.8 per 28 days) |
| HADLIMA SUBCUTANEOUS SOLUTION PREFILLED SYRINGE 40 MG/0.4ML | 5 | PA; QL (2.4 per 28 days) |
| HADLIMA SUBCUTANEOUS SOLUTION PREFILLED SYRINGE 40 MG/0.8ML | 5 | PA; QL (4.8 per 28 days) |
| HAVRIX | 1 | |
| HEPLISAV-B INTRAMUSCULAR SOLUTION PREFILLED SYRINGE | 1 | B/D PA |
| HIBERIX INJECTION | 1 | |
| HUMIRA (2 PEN) SUBCUTANEOUS PEN-INJECTOR KIT 40 MG/0.4ML, 40 MG/0.8ML | 5 | PA; QL (4 per 28 days) |
| HUMIRA (2 PEN) SUBCUTANEOUS PEN-INJECTOR KIT 80 MG/0.8ML | 5 | PA; QL (2 per 28 days) |
| HUMIRA (2 SYRINGE) SUBCUTANEOUS PREFILLED SYRINGE KIT 10 MG/0.1ML, 20 MG/0.2ML | 5 | PA; QL (2 per 28 days) |
| HUMIRA (2 SYRINGE) SUBCUTANEOUS PREFILLED SYRINGE KIT 40 MG/0.4ML, 40 MG/0.8ML | 5 | PA; QL (4 per 28 days) |
| HUMIRA PEN-PEDIATRIC UC START | 5 | PA; QL (8 per 365 days) |
| HUMIRA-CD/UC/HS STARTER SUBCUTANEOUS PEN-INJECTOR KIT 80 MG/0.8ML | 5 | PA; QL (6 per 365 days) |
| HUMIRA-PSORIASIS/UEVIT STARTER | 5 | PA; QL (6 per 365 days) |
| IMOVAX RABIES INTRAMUSCULAR SUSPENSION RECONSTITUTED | 1 | |
| INFANRIX | 1 | |
| IPOL | 1 | |
| IXCHIQ | 1 | |

You can find information on what the symbols and abbreviations in this table mean by going to page 10 of this document. Ou ka jwenn enfòmasyon sou sa senbòl ak abrevyasyon yo nan tablo sa a vle di lè w ale nan paj 19 dokiman sa a.

| DRUG NAME / NON MEDIKAMAN | DRUG TIER / NIVO MEDIKAMAN | REQUIREMENTS / LIMITS KONDISYON / LIMIT |
|---|----------------------------|---|
| IXIARO | 1 | |
| JYLAMVO | 4 | ST |
| JYNNEOS | 1 | B/D PA |
| <i>kedrab injection solution 1500 unit/10ml</i> | 3 | |
| KINRIX INTRAMUSCULAR SUSPENSION PREFILLED SYRINGE | 1 | |
| <i>leflunomide oral</i> | 2 | QL (30 per 30 days); MO; 90D |
| MENACTRA INTRAMUSCULAR SOLUTION | 1 | |
| MENQUADFI INTRAMUSCULAR SOLUTION | 1 | |
| MENVEO | 1 | |
| <i>methotrexate sodium (pf) injection solution 50 mg/2ml</i> | 1 | |
| <i>methotrexate sodium injection solution 50 mg/2ml</i> | 1 | |
| <i>methotrexate sodium oral</i> | 1 | |
| M-M-R II INJECTION | 1 | |
| MRESVIA | 1 | |
| <i>mycophenolate mofetil oral capsule</i> | 2 | B/D PA; 90D |
| <i>mycophenolate mofetil oral suspension reconstituted</i> | 4 | B/D PA |
| <i>mycophenolate mofetil oral tablet</i> | 2 | B/D PA; 90D |
| <i>mycophenolate sodium</i> | 2 | B/D PA; 90D |
| <i>mycophenolic acid oral tablet delayed release 180 mg, 360 mg</i> | 2 | B/D PA; 90D |
| MYHIBBIN | 5 | B/D PA |
| OCTAGAM INTRAVENOUS SOLUTION 1 GM/20ML, 10 GM/100ML, 10 GM/200ML, 2 GM/20ML, 20 GM/200ML, 5 GM/50ML | 5 | PA |
| OTEZLA ORAL TABLET | 5 | PA; QL (60 per 30 days) |
| OTEZLA ORAL TABLET THERAPY PACK | 5 | PA |

You can find information on what the symbols and abbreviations in this table mean by going to page 10 of this document. Ou ka jwenn enfòmasyon sou sa senbòl ak abrevyasyon yo nan tablo sa a vle di lè w ale nan paj 19 dokiman sa a.

| DRUG NAME / NON MEDIKAMAN | DRUG TIER / NIVO MEDIKAMAN | REQUIREMENTS / LIMITS KONDISYON / LIMIT |
|---|----------------------------|---|
| PEDIARIX INTRAMUSCULAR SUSPENSION PREFILLED SYRINGE | 1 | |
| PEDVAX HIB INTRAMUSCULAR SUSPENSION | 1 | |
| PEGASYS SUBCUTANEOUS SOLUTION 180 MCG/ML | 5 | |
| PEGASYS SUBCUTANEOUS SOLUTION PREFILLED SYRINGE | 5 | |
| PENBRAYA | 1 | |
| PENTACEL | 1 | |
| PREHEVBRIO | 1 | B/D PA |
| PRIORIX | 1 | |
| PRIVIGEN INTRAVENOUS SOLUTION 10 GM/100ML, 20 GM/200ML, 5 GM/50ML | 5 | PA |
| PROGRAF ORAL PACKET | 4 | B/D PA |
| PROQUAD SUBCUTANEOUS SUSPENSION RECONSTITUTED | 1 | |
| QUADRACEL | 1 | |
| RABAVERT | 1 | |
| RECOMBIVAX HB | 1 | B/D PA |
| REZUROCK | 5 | PA; LA |
| RINVOQ | 5 | PA; QL (30 per 30 days) |
| RINVOQ LQ | 5 | PA; QL (360 per 30 days) |
| ROTARIX | 1 | |
| ROTATEQ ORAL SOLUTION | 1 | |
| SHINGRIX INTRAMUSCULAR SUSPENSION RECONSTITUTED 50 MCG/0.5ML | 1 | |
| <i>sirolimus oral solution</i> | 4 | B/D PA |
| <i>sirolimus oral tablet</i> | 2 | B/D PA; 90D |
| SKYRIZI INTRAVENOUS | 5 | PA; QL (10 per 28 days) |
| SKYRIZI PEN | 5 | PA; QL (6 per 365 days) |

You can find information on what the symbols and abbreviations in this table mean by going to page 10 of this document. Ou ka jwenn enfòmasyon sou sa senbòl ak abrevyasyon yo nan tablo sa a vle di lè w ale nan paj 19 dokiman sa a.

| DRUG NAME / NON MEDIKAMAN | DRUG TIER / NIVO MEDIKAMAN | REQUIREMENTS / LIMITS KONDISYON / LIMIT |
|---|-----------------------------------|--|
| SKYRIZI SUBCUTANEOUS SOLUTION CARTRIDGE 180 MG/1.2ML | 5 | PA; QL (1.2 per 56 days) |
| SKYRIZI SUBCUTANEOUS SOLUTION CARTRIDGE 360 MG/2.4ML | 5 | PA; QL (2.4 per 56 days) |
| SKYRIZI SUBCUTANEOUS SOLUTION PREFILLED SYRINGE | 5 | PA; QL (6 per 365 days) |
| STELARA INTRAVENOUS | 5 | PA; LA |
| STELARA SUBCUTANEOUS SOLUTION 45 MG/0.5ML | 5 | PA; QL (1 per 28 days); LA |
| STELARA SUBCUTANEOUS SOLUTION PREFILLED SYRINGE | 5 | PA; QL (1 per 28 days) |
| <i>tacrolimus oral</i> | 2 | B/D PA; 90D |
| TDVAX | 1 | |
| TENIVAC | 1 | |
| TICOVAC | 1 | |
| TRUMENBA | 1 | |
| TWINRIX INTRAMUSCULAR SUSPENSION PREFILLED SYRINGE | 1 | |
| TYPHIM VI | 1 | |
| VAQTA | 1 | |
| VARIVAX | 1 | |
| VARIZIG INTRAMUSCULAR SOLUTION | 3 | |
| VAXCHORA | 1 | |
| XATMEP | 4 | ST |
| YF-VAX | 1 | |
| INFECTIOUS DISEASE AGENTS / AJAN MALADI ENFEKTYE | | |
| <i>abacavir sulfate oral solution</i> | 2 | QL (960 per 30 days); 90D |
| <i>abacavir sulfate oral tablet</i> | 2 | QL (60 per 30 days); 90D |
| <i>abacavir sulfate-lamivudine</i> | 2 | QL (30 per 30 days); 90D |
| ABELCET | 4 | B/D PA |

You can find information on what the symbols and abbreviations in this table mean by going to page 10 of this document. Ou ka jwenn enfòmasyon sou sa senbòl ak abrevyasyon yo nan tablo sa a vle di lè w ale nan paj 19 dokiman sa a.

| DRUG NAME / NON MEDIKAMAN | DRUG TIER / NIVO MEDIKAMAN | REQUIREMENTS / LIMITS KONDISYON / LIMIT |
|--|----------------------------|---|
| <i>acyclovir oral capsule</i> | 1 | MO |
| <i>acyclovir oral suspension</i> | 2 | MO |
| <i>acyclovir oral tablet</i> | 1 | MO |
| <i>acyclovir sodium intravenous solution</i> | 2 | B/D PA |
| <i>adefovir dipivoxil</i> | 2 | PA; 90D |
| <i>albendazole oral</i> | 4 | |
| <i>amikacin sulfate injection solution 500 mg/2ml</i> | 2 | |
| <i>amoxicillin oral capsule</i> | 1 | |
| <i>amoxicillin oral suspension reconstituted</i> | 1 | |
| <i>amoxicillin oral tablet</i> | 1 | |
| <i>amoxicillin oral tablet chewable 125 mg, 250 mg</i> | 1 | |
| <i>amoxicillin-pot clavulanate er</i> | 2 | |
| <i>amoxicillin-pot clavulanate oral</i> | 2 | |
| <i>amphotericin b intravenous</i> | 2 | B/D PA |
| <i>ampicillin oral capsule 500 mg</i> | 1 | |
| <i>ampicillin sodium injection solution reconstituted 1 gm, 125 mg</i> | 2 | |
| <i>ampicillin sodium intravenous solution reconstituted 1 gm, 10 gm</i> | 2 | |
| <i>ampicillin-sulbactam sodium injection solution reconstituted 1.5 (1-0.5) gm, 3 (2-1) gm</i> | 2 | |
| <i>ampicillin-sulbactam sodium intravenous</i> | 2 | |
| APTIVUS ORAL CAPSULE | 5 | QL (120 per 30 days) |
| ARIKAYCE | 5 | LA |
| <i>atazanavir sulfate oral capsule 150 mg, 200 mg</i> | 2 | QL (60 per 30 days); 90D |
| <i>atazanavir sulfate oral capsule 300 mg</i> | 2 | QL (30 per 30 days); 90D |
| <i>atovaquone oral</i> | 2 | PA |
| <i>atovaquone-proguanil hcl</i> | 2 | |
| <i>azithromycin intravenous</i> | 2 | |

You can find information on what the symbols and abbreviations in this table mean by going to page 10 of this document. Ou ka jwenn enfòmasyon sou sa senbòl ak abrevyasyon yo nan tablo sa a vle di lè w ale nan paj 19 dokiman sa a.

| DRUG NAME / NON MEDIKAMAN | DRUG TIER / NIVO MEDIKAMAN | REQUIREMENTS / LIMITS KONDISYON / LIMIT |
|--|----------------------------|---|
| <i>azithromycin oral packet</i> | 2 | |
| <i>azithromycin oral suspension reconstituted</i> | 2 | |
| <i>azithromycin oral tablet 250 mg, 250 mg (6 pack), 500 mg, 500 mg (3 pack)</i> | 1 | |
| <i>azithromycin oral tablet 600 mg</i> | 2 | |
| <i>aztreonam injection solution reconstituted 1 gm</i> | 2 | |
| BARACLUDGE ORAL SOLUTION | 5 | PA |
| <i>benznidazole</i> | 3 | |
| BICILLIN C-R | 4 | |
| BICILLIN L-A INTRAMUSCULAR SUSPENSION PREFILLED SYRINGE | 4 | |
| BIKTARVY ORAL TABLET 30-120-15 MG | 5 | QL (30 per 30 days); MO |
| BIKTARVY ORAL TABLET 50-200-25 MG | 5 | QL (30 per 30 days) |
| CABENUVA INTRAMUSCULAR SUSPENSION EXTENDED RELEASE 400 & 600 MG/2ML | 5 | QL (4 per 28 days) |
| CABENUVA INTRAMUSCULAR SUSPENSION EXTENDED RELEASE 600 & 900 MG/3ML | 5 | QL (6 per 28 days) |
| <i>caspofungin acetate</i> | 4 | B/D PA |
| <i>cefaclor er</i> | 3 | |
| <i>cefaclor oral capsule</i> | 2 | |
| <i>cefadroxil</i> | 2 | |
| <i>cefazolin sodium injection solution reconstituted 1 gm, 10 gm, 2 gm, 3 gm, 500 mg</i> | 2 | |
| <i>cefazolin sodium intravenous solution reconstituted 1 gm</i> | 2 | |
| <i>cefdinir</i> | 2 | |
| <i>cefepime hcl injection solution reconstituted 1 gm</i> | 2 | |
| <i>cefepime hcl intravenous solution reconstituted 2 gm</i> | 2 | |
| <i>cefixime</i> | 2 | |

You can find information on what the symbols and abbreviations in this table mean by going to page 10 of this document. Ou ka jwenn enfòmasyon sou sa senbòl ak abrevyasyon yo nan tablo sa a vle di lè w ale nan paj 19 dokiman sa a.

| DRUG NAME / NON MEDIKAMAN | DRUG TIER / NIVO MEDIKAMAN | REQUIREMENTS / LIMITS KONDISYON / LIMIT |
|---|----------------------------|---|
| <i>cefoxitin sodium intravenous solution reconstituted 1 gm, 10 gm</i> | 2 | |
| <i>cefoxitin sodium intravenous solution reconstituted 2 gm</i> | 4 | |
| <i>cefpodoxime proxetil</i> | 2 | |
| <i>cefprozil</i> | 2 | |
| <i>ceftazidime injection solution reconstituted 1 gm, 6 gm</i> | 2 | |
| <i>ceftazidime intravenous</i> | 2 | |
| <i>ceftriaxone sodium in dextrose</i> | 2 | |
| <i>ceftriaxone sodium injection solution reconstituted 1 gm, 2 gm, 250 mg, 500 mg</i> | 2 | |
| <i>ceftriaxone sodium intravenous</i> | 2 | |
| <i>cefuroxime axetil oral tablet</i> | 2 | |
| <i>cefuroxime sodium injection solution reconstituted 750 mg</i> | 2 | |
| <i>cefuroxime sodium intravenous solution reconstituted 1.5 gm</i> | 2 | |
| <i>cephalexin oral capsule 250 mg, 500 mg</i> | 1 | |
| <i>cephalexin oral suspension reconstituted</i> | 2 | |
| <i>cephalexin oral tablet</i> | 2 | |
| <i>chloroquine phosphate oral</i> | 1 | MO; 100D |
| CIMDUO | 5 | QL (30 per 30 days) |
| <i>ciprofloxacin hcl oral tablet 250 mg, 500 mg</i> | 1 | |
| <i>ciprofloxacin hcl oral tablet 750 mg</i> | 2 | |
| <i>ciprofloxacin in d5w intravenous solution 200 mg/100ml</i> | 2 | |
| <i>clarithromycin er</i> | 2 | |
| <i>clarithromycin oral</i> | 2 | |
| <i>clindamycin hcl oral</i> | 1 | |

You can find information on what the symbols and abbreviations in this table mean by going to page 10 of this document. Ou ka jwenn enfòmasyon sou sa senbòl ak abrevyasyon yo nan tablo sa a vle di lè w ale nan paj 19 dokiman sa a.

| DRUG NAME / NON MEDIKAMAN | DRUG TIER / NIVO MEDIKAMAN | REQUIREMENTS / LIMITS KONDISYON / LIMIT |
|--|----------------------------|---|
| <i>clindamycin palmitate hcl</i> | 2 | |
| <i>clindamycin phosphate in d5w</i> | 2 | |
| <i>clindamycin phosphate injection solution 600 mg/4ml</i> | 2 | |
| COARTEM | 4 | |
| <i>colistimethate sodium (cba)</i> | 2 | |
| COMPLERA | 5 | QL (30 per 30 days) |
| <i>dapsone oral</i> | 2 | MO; 90D |
| <i>daptomycin</i> | 5 | |
| <i>darunavir oral tablet 600 mg</i> | 4 | QL (60 per 30 days) |
| <i>darunavir oral tablet 800 mg</i> | 5 | QL (60 per 30 days) |
| DELSTRIGO | 5 | QL (30 per 30 days) |
| DESCOVY | 5 | QL (30 per 30 days) |
| <i>dicloxacillin sodium</i> | 2 | |
| DIFICID | 5 | PA |
| DOVATO | 5 | QL (30 per 30 days) |
| DOXY 100 | 2 | |
| <i>doxycycline hyclate intravenous</i> | 2 | |
| <i>doxycycline hyclate oral capsule</i> | 2 | |
| <i>doxycycline hyclate oral tablet 100 mg</i> | 2 | |
| <i>doxycycline hyclate oral tablet 20 mg</i> | 1 | |
| <i>doxycycline hyclate oral tablet delayed release 200 mg, 50 mg</i> | 2 | |
| <i>doxycycline monohydrate oral capsule 100 mg</i> | 2 | |
| <i>doxycycline monohydrate oral capsule 50 mg</i> | 1 | |
| <i>doxycycline monohydrate oral suspension reconstituted</i> | 2 | |
| <i>doxycycline monohydrate oral tablet</i> | 2 | |
| E.E.S. 400 ORAL TABLET | 2 | |

You can find information on what the symbols and abbreviations in this table mean by going to page 10 of this document. Ou ka jwenn enfòmasyon sou sa senbòl ak abrevyasyon yo nan tablo sa a vle di lè w ale nan paj 19 dokiman sa a.

| DRUG NAME / NON MEDIKAMAN | DRUG TIER / NIVO MEDIKAMAN | REQUIREMENTS / LIMITS KONDISYON / LIMIT |
|--|----------------------------|---|
| EDURANT | 5 | QL (30 per 30 days) |
| <i>efavirenz oral capsule 200 mg</i> | 2 | QL (120 per 30 days); 90D |
| <i>efavirenz oral capsule 50 mg</i> | 2 | QL (360 per 30 days); 90D |
| <i>efavirenz oral tablet</i> | 4 | QL (30 per 30 days) |
| <i>efavirenz-emtricitab-tenofo df</i> | 4 | QL (30 per 30 days) |
| <i>efavirenz-lamivudine-tenofovir</i> | 4 | QL (30 per 30 days) |
| <i>emtricitabine</i> | 2 | QL (30 per 30 days); 90D |
| <i>emtricitabine-tenofovir df oral tablet 100-150 mg</i> | 4 | QL (30 per 30 days) |
| <i>emtricitabine-tenofovir df oral tablet 133-200 mg, 167-250 mg</i> | 5 | QL (30 per 30 days) |
| <i>emtricitabine-tenofovir df oral tablet 200-300 mg</i> | 2 | QL (30 per 30 days); 90D |
| EMTRIVA ORAL SOLUTION | 4 | QL (850 per 30 days) |
| EMVERM | 5 | |
| <i>entecavir</i> | 2 | PA; 90D |
| EPCLUSA ORAL PACKET 150-37.5 MG | 5 | PA; QL (30 per 30 days) |
| EPCLUSA ORAL PACKET 200-50 MG | 5 | PA; QL (60 per 30 days) |
| EPCLUSA ORAL TABLET 200-50 MG | 5 | PA; QL (60 per 30 days) |
| EPCLUSA ORAL TABLET 400-100 MG | 5 | PA; QL (30 per 30 days) |
| ERAXIS INTRAVENOUS SOLUTION RECONSTITUTED 100 MG | 5 | PA |
| ERAXIS INTRAVENOUS SOLUTION RECONSTITUTED 50 MG | 4 | PA |
| <i>ertapenem sodium</i> | 2 | |
| ERY-TAB ORAL TABLET DELAYED RELEASE 250 MG, 500 MG | 2 | |
| ERY-TAB ORAL TABLET DELAYED RELEASE 333 MG | 3 | |
| ERYTHROCIN STEARATE ORAL TABLET 250 MG | 3 | |
| <i>erythromycin base oral capsule delayed release particles</i> | 2 | |

You can find information on what the symbols and abbreviations in this table mean by going to page 10 of this document. Ou ka jwenn enfòmasyon sou sa senbòl ak abrevyasyon yo nan tablo sa a vle di lè w ale nan paj 19 dokiman sa a.

| DRUG NAME / NON MEDIKAMAN | DRUG TIER / NIVO MEDIKAMAN | REQUIREMENTS / LIMITS KONDISYON / LIMIT |
|---|-----------------------------------|--|
| <i>erythromycin base oral tablet 250 mg</i> | 2 | |
| <i>erythromycin base oral tablet delayed release 250 mg, 500 mg</i> | 2 | |
| <i>erythromycin base oral tablet delayed release 333 mg</i> | 3 | |
| <i>erythromycin ethylsuccinate oral suspension reconstituted 200 mg/5ml</i> | 1 | |
| <i>erythromycin ethylsuccinate oral suspension reconstituted 400 mg/5ml</i> | 4 | |
| <i>erythromycin ethylsuccinate oral tablet</i> | 2 | |
| <i>erythromycin lactobionate</i> | 4 | |
| <i>erythromycin oral tablet delayed release 250 mg, 500 mg</i> | 2 | |
| <i>erythromycin oral tablet delayed release 333 mg</i> | 3 | |
| <i>ethambutol hcl oral tablet 100 mg</i> | 2 | |
| <i>ethambutol hcl oral tablet 400 mg</i> | 1 | |
| <i>etravirine oral tablet 100 mg</i> | 4 | QL (120 per 30 days) |
| <i>etravirine oral tablet 200 mg</i> | 4 | QL (60 per 30 days) |
| EVOTAZ | 5 | QL (30 per 30 days) |
| <i>famciclovir oral tablet 125 mg, 250 mg</i> | 2 | QL (60 per 30 days) |
| <i>famciclovir oral tablet 500 mg</i> | 2 | QL (21 per 7 days) |
| <i>fluconazole in sodium chloride intravenous solution 200-0.9 mg/100ml-%, 400-0.9 mg/200ml-%</i> | 2 | |
| <i>fluconazole oral</i> | 2 | |
| <i>flucytosine oral</i> | 5 | |
| <i>fosamprenavir calcium</i> | 4 | QL (120 per 30 days) |
| FUZEON SUBCUTANEOUS SOLUTION RECONSTITUTED | 5 | QL (60 per 30 days) |

You can find information on what the symbols and abbreviations in this table mean by going to page 10 of this document. Ou ka jwenn enfòmasyon sou sa senbòl ak abrevyasyon yo nan tablo sa a vle di lè w ale nan paj 19 dokiman sa a.

| DRUG NAME / NON MEDIKAMAN | DRUG TIER / NIVO MEDIKAMAN | REQUIREMENTS / LIMITS KONDISYON / LIMIT |
|---|----------------------------|---|
| <i>gentamicin in saline intravenous solution 0.8-0.9 mg/ml-%, 1-0.9 mg/ml-%, 1.2-0.9 mg/ml-%, 1.6-0.9 mg/ml-%</i> | 2 | |
| <i>gentamicin sulfate injection solution 40 mg/ml</i> | 2 | |
| GENVOYA | 5 | QL (30 per 30 days) |
| <i>griseofulvin microsize oral suspension</i> | 2 | |
| <i>hydroxychloroquine sulfate oral tablet 200 mg</i> | 1 | MO; 100D |
| <i>imipenem-cilastatin intravenous solution reconstituted 250 mg</i> | 2 | |
| INTELENCE ORAL TABLET 25 MG | 4 | QL (480 per 30 days) |
| ISENTRESS HD | 5 | QL (60 per 30 days) |
| ISENTRESS ORAL PACKET | 3 | QL (180 per 30 days) |
| ISENTRESS ORAL TABLET | 5 | QL (120 per 30 days) |
| ISENTRESS ORAL TABLET CHEWABLE 100 MG | 4 | QL (180 per 30 days) |
| ISENTRESS ORAL TABLET CHEWABLE 25 MG | 3 | QL (720 per 30 days) |
| <i>isoniazid oral</i> | 1 | MO; 100D |
| <i>itraconazole oral capsule</i> | 2 | PA |
| <i>ivermectin oral</i> | 2 | PA |
| JULUCA | 5 | QL (30 per 30 days) |
| <i>ketoconazole oral</i> | 1 | |
| LAGEVRIO | 5 | QL (40 per 90 days) |
| <i>lamivudine oral solution</i> | 2 | QL (960 per 30 days); 90D |
| <i>lamivudine oral tablet 100 mg</i> | 2 | 90D |
| <i>lamivudine oral tablet 150 mg</i> | 2 | QL (60 per 30 days); 90D |
| <i>lamivudine oral tablet 300 mg</i> | 2 | QL (30 per 30 days); 90D |
| <i>lamivudine-zidovudine</i> | 2 | QL (60 per 30 days); 90D |
| <i>levofloxacin in d5w intravenous solution 500 mg/100ml, 750 mg/150ml</i> | 2 | |
| <i>levofloxacin intravenous</i> | 2 | |

You can find information on what the symbols and abbreviations in this table mean by going to page 10 of this document. Ou ka jwenn enfòmasyon sou sa senbòl ak abrevyasyon yo nan tablo sa a vle di lè w ale nan paj 19 dokiman sa a.

| DRUG NAME / NON MEDIKAMAN | DRUG TIER / NIVO MEDIKAMAN | REQUIREMENTS / LIMITS KONDISYON / LIMIT |
|--|----------------------------|---|
| <i>levofloxacin oral solution</i> | 2 | |
| <i>levofloxacin oral tablet</i> | 1 | |
| LEXIVA ORAL SUSPENSION | 4 | QL (1800 per 30 days) |
| <i>linezolid in sodium chloride</i> | 2 | |
| <i>linezolid intravenous solution 600 mg/300ml</i> | 2 | |
| <i>linezolid oral suspension reconstituted</i> | 5 | PA; QL (1800 per 30 days) |
| <i>linezolid oral tablet</i> | 4 | PA; QL (56 per 28 days) |
| LIVTENCITY | 5 | PA |
| <i>lopinavir-ritonavir oral solution</i> | 2 | QL (480 per 30 days); 90D |
| <i>lopinavir-ritonavir oral tablet 100-25 mg</i> | 4 | QL (300 per 30 days) |
| <i>lopinavir-ritonavir oral tablet 200-50 mg</i> | 4 | QL (120 per 30 days) |
| <i>maraviroc</i> | 4 | QL (120 per 30 days) |
| MAVYRET ORAL PACKET | 5 | PA; QL (180 per 30 days) |
| MAVYRET ORAL TABLET | 5 | PA; QL (90 per 30 days) |
| <i>mefloquine hcl</i> | 2 | MO; 90D |
| <i>meropenem intravenous solution reconstituted 1 gm, 500 mg</i> | 2 | |
| <i>methenamine hippurate</i> | 2 | |
| <i>metronidazole intravenous solution 500 mg/100ml</i> | 2 | |
| <i>metronidazole oral capsule</i> | 2 | |
| <i>metronidazole oral tablet</i> | 1 | |
| <i>micafungin sodium</i> | 5 | |
| <i>minocycline hcl oral capsule 100 mg, 75 mg</i> | 2 | |
| <i>minocycline hcl oral capsule 50 mg</i> | 1 | |
| <i>minocycline hcl oral tablet</i> | 2 | |
| MONDOXYNE NL ORAL CAPSULE 100 MG | 2 | |
| <i>moxifloxacin hcl in nacl</i> | 2 | |
| <i>moxifloxacin hcl oral</i> | 4 | |

You can find information on what the symbols and abbreviations in this table mean by going to page 10 of this document. Ou ka jwenn enfòmasyon sou sa senbòl ak abrevyasyon yo nan tablo sa a vle di lè w ale nan paj 19 dokiman sa a.

| DRUG NAME / NON MEDIKAMAN | DRUG TIER / NIVO MEDIKAMAN | REQUIREMENTS / LIMITS KONDISYON / LIMIT |
|---|----------------------------|---|
| <i>nafcillin sodium injection solution reconstituted 1 gm, 2 gm</i> | 4 | |
| <i>nafcillin sodium intravenous solution reconstituted 10 gm</i> | 5 | |
| <i>neomycin sulfate oral</i> | 2 | |
| <i>nevirapine er oral tablet extended release 24 hour 400 mg</i> | 2 | QL (30 per 30 days); 90D |
| <i>nevirapine oral suspension</i> | 2 | QL (1200 per 30 days); 90D |
| <i>nevirapine oral tablet</i> | 2 | QL (60 per 30 days); 90D |
| <i>nitazoxanide oral</i> | 4 | QL (6 per 30 days) |
| <i>nitrofurantoin macrocrystal oral</i> | 2 | |
| <i>nitrofurantoin monohyd macro</i> | 2 | |
| NORVIR ORAL PACKET | 4 | QL (360 per 30 days) |
| <i>nystatin oral tablet</i> | 1 | |
| ODEFSEY | 5 | QL (30 per 30 days) |
| <i>ofloxacin oral tablet 300 mg, 400 mg</i> | 2 | |
| <i>oseltamivir phosphate oral capsule 30 mg</i> | 2 | QL (168 per 365 days) |
| <i>oseltamivir phosphate oral capsule 45 mg, 75 mg</i> | 2 | QL (84 per 365 days) |
| <i>oseltamivir phosphate oral suspension reconstituted</i> | 2 | QL (1080 per 365 days) |
| PAXLOVID (150/100) | 2 | QL (20 per 90 days) |
| PAXLOVID (300/100) | 2 | QL (30 per 90 days) |
| <i>penicillin g potassium</i> | 2 | |
| <i>penicillin g sodium</i> | 2 | |
| <i>penicillin v potassium oral solution reconstituted</i> | 2 | |
| <i>penicillin v potassium oral tablet</i> | 1 | |
| <i>pentamidine isethionate inhalation</i> | 2 | B/D PA |
| <i>pentamidine isethionate injection</i> | 2 | |

You can find information on what the symbols and abbreviations in this table mean by going to page 10 of this document. Ou ka jwenn enfòmasyon sou sa senbòl ak abrevyasyon yo nan tablo sa a vle di lè w ale nan paj 19 dokiman sa a.

| DRUG NAME / NON MEDIKAMAN | DRUG TIER / NIVO MEDIKAMAN | REQUIREMENTS / LIMITS KONDISYON / LIMIT |
|--|----------------------------|---|
| PFIZERPEN INJECTION SOLUTION RECONSTITUTED 20000000 UNIT | 2 | |
| PIFELTRO | 5 | QL (30 per 30 days) |
| <i>piperacillin sod-tazobactam intravenous solution reconstituted 2.25 (2-0.25) gm, 3-0.375 gm, 3.375 (3-0.375) gm, 4-0.5 gm, 4.5 (4-0.5) gm</i> | 2 | |
| <i>posaconazole oral</i> | 5 | PA; MO |
| <i>praziquantel oral</i> | 4 | |
| PREVYMIS ORAL | 5 | PA; QL (30 per 30 days) |
| PREZCOBIX | 5 | QL (30 per 30 days) |
| PREZISTA ORAL SUSPENSION | 5 | QL (400 per 30 days) |
| PREZISTA ORAL TABLET 150 MG | 4 | QL (180 per 30 days) |
| PREZISTA ORAL TABLET 75 MG | 4 | QL (300 per 30 days) |
| PRIFTIN | 4 | |
| <i>primaquine phosphate oral tablet 26.3 (15 base) mg</i> | 4 | |
| <i>pyrazinamide oral</i> | 2 | |
| <i>pyrimethamine oral</i> | 5 | PA |
| <i>quinine sulfate oral</i> | 2 | PA |
| RELENZA DISKHALER INHALATION AEROSOL POWDER BREATH ACTIVATED 5 MG/ACT | 4 | QL (60 per 180 days) |
| RETROVIR INTRAVENOUS | 4 | |
| REYATAZ ORAL PACKET | 4 | QL (240 per 30 days) |
| <i>ribavirin oral capsule</i> | 2 | |
| <i>ribavirin oral tablet 200 mg</i> | 2 | |
| <i>rifabutin</i> | 2 | |
| <i>rifampin intravenous</i> | 4 | |
| <i>rifampin oral</i> | 2 | |
| <i>rimantadine hcl</i> | 2 | |

You can find information on what the symbols and abbreviations in this table mean by going to page 10 of this document. Ou ka jwenn enfòmasyon sou sa senbòl ak abrevyasyon yo nan tablo sa a vle di lè w ale nan paj 19 dokiman sa a.

| DRUG NAME / NON MEDIKAMAN | DRUG TIER / NIVO MEDIKAMAN | REQUIREMENTS / LIMITS KONDISYON / LIMIT |
|--|----------------------------|---|
| <i>ritonavir</i> | 2 | QL (360 per 30 days); 90D |
| RUKOBIA | 5 | QL (60 per 30 days); MO |
| SELZENTRY ORAL SOLUTION | 3 | QL (1840 per 30 days) |
| SELZENTRY ORAL TABLET 25 MG | 4 | QL (240 per 30 days) |
| SELZENTRY ORAL TABLET 75 MG | 4 | QL (60 per 30 days) |
| SIRTURO | 5 | PA; LA |
| <i>sofosbuvir-velpatasvir</i> | 5 | PA; QL (30 per 30 days) |
| <i>streptomycin sulfate intramuscular</i> | 5 | |
| STRIBILD | 5 | QL (30 per 30 days) |
| <i>sulfadiazine oral</i> | 4 | |
| <i>sulfamethoxazole-trimethoprim oral suspension 200-40 mg/5ml</i> | 1 | |
| <i>sulfamethoxazole-trimethoprim oral tablet</i> | 1 | |
| SUNLENCA ORAL | 5 | LA |
| SUNLENCA SUBCUTANEOUS | 5 | QL (3 per 168 days); MO |
| SYMTUZA | 5 | QL (30 per 30 days) |
| TAZICEF INJECTION SOLUTION RECONSTITUTED 1 GM | 2 | |
| TAZICEF INTRAVENOUS SOLUTION RECONSTITUTED | 2 | |
| TEFLARO | 5 | |
| <i>tenofovir disoproxil fumarate</i> | 2 | QL (30 per 30 days); 90D |
| <i>terbinafine hcl oral</i> | 1 | |
| <i>tetracycline hcl oral capsule</i> | 2 | |
| <i>tigecycline</i> | 5 | |
| <i>tinidazole oral</i> | 2 | |
| TIVICAY ORAL TABLET 10 MG | 4 | QL (120 per 30 days) |
| TIVICAY ORAL TABLET 25 MG, 50 MG | 5 | QL (60 per 30 days) |
| TIVICAY PD | 5 | QL (360 per 30 days) |

You can find information on what the symbols and abbreviations in this table mean by going to page 10 of this document. Ou ka jwenn enfòmasyon sou sa senbòl ak abrevyasyon yo nan tablo sa a vle di lè w ale nan paj 19 dokiman sa a.

| DRUG NAME / NON MEDIKAMAN | DRUG TIER / NIVO MEDIKAMAN | REQUIREMENTS / LIMITS KONDISYON / LIMIT |
|--|----------------------------|---|
| <i>tobramycin sulfate injection solution 10 mg/ml, 80 mg/2ml</i> | 2 | |
| TRECTOR | 4 | |
| <i>trifluridine ophthalmic</i> | 2 | |
| <i>trimethoprim oral</i> | 1 | |
| TRIUMEQ | 5 | QL (30 per 30 days) |
| TRIUMEQ PD | 5 | QL (180 per 30 days) |
| TRIZIVIR | 5 | QL (60 per 30 days) |
| TYBOST | 3 | QL (30 per 30 days) |
| <i>valacyclovir hcl oral tablet 1 gm</i> | 2 | QL (90 per 30 days) |
| <i>valacyclovir hcl oral tablet 500 mg</i> | 2 | QL (60 per 30 days) |
| <i>valganciclovir hcl oral solution reconstituted</i> | 4 | |
| <i>valganciclovir hcl oral tablet</i> | 3 | |
| <i>vancomycin hcl intravenous solution 1000 mg/200ml, 1250 mg/250ml, 1500 mg/300ml, 1750 mg/350ml, 2000 mg/400ml, 500 mg/100ml, 750 mg/150ml</i> | 3 | |
| <i>vancomycin hcl intravenous solution reconstituted 1 gm, 10 gm, 100 gm, 500 mg, 750 mg</i> | 2 | |
| <i>vancomycin hcl oral capsule 125 mg</i> | 2 | PA; QL (240 per 30 days) |
| <i>vancomycin hcl oral capsule 250 mg</i> | 4 | PA; QL (240 per 30 days) |
| <i>vancomycin hcl oral solution reconstituted 25 mg/ml, 250 mg/5ml</i> | 2 | PA; QL (1200 per 30 days) |
| VIRACEPT ORAL TABLET 250 MG | 5 | QL (300 per 30 days) |
| VIRACEPT ORAL TABLET 625 MG | 5 | QL (120 per 30 days) |
| VIREAD ORAL POWDER | 3 | QL (240 per 30 days) |
| VIREAD ORAL TABLET 150 MG, 250 MG | 5 | QL (30 per 30 days) |
| VIREAD ORAL TABLET 200 MG | 4 | QL (30 per 30 days) |
| <i>voriconazole intravenous</i> | 4 | PA |
| <i>voriconazole oral suspension reconstituted</i> | 5 | PA; QL (300 per 30 days) |

You can find information on what the symbols and abbreviations in this table mean by going to page 10 of this document. Ou ka jwenn enfòmasyon sou sa senbòl ak abrevyasyon yo nan tablo sa a vle di lè w ale nan paj 19 dokiman sa a.

| DRUG NAME / NON MEDIKAMAN | DRUG TIER / NIVO MEDIKAMAN | REQUIREMENTS / LIMITS KONDISYON / LIMIT |
|---|----------------------------|---|
| <i>voriconazole oral tablet 200 mg</i> | 4 | PA; QL (60 per 30 days) |
| <i>voriconazole oral tablet 50 mg</i> | 2 | PA; QL (120 per 30 days) |
| XIFAXAN ORAL TABLET 200 MG | 4 | PA; QL (9 per 3 days) |
| XIFAXAN ORAL TABLET 550 MG | 5 | PA; QL (84 per 28 days); MO |
| <i>zidovudine oral capsule</i> | 2 | QL (180 per 30 days); 90D |
| <i>zidovudine oral syrup</i> | 2 | QL (1920 per 30 days); 90D |
| <i>zidovudine oral tablet</i> | 2 | QL (60 per 30 days); 90D |
| ZIRGAN | 3 | |
| MISCELLANEOUS THERAPEUTIC AGENTS / AJAN TERAPI DIVÈS | | |
| ALCOHOL SWABS | 2 | MO |
| <i>benzonatate oral capsule 100 mg, 200 mg</i> | 6 | QL (30 per 10 days); ED |
| GAUZE STERILE PADS 2 | 2 | MO |
| <i>hydrocodone bit-homatrop mbr</i> | 6 | ED |
| IGALMI | 4 | QL (30 per 30 days) |
| INSULIN PEN NEEDLE | 2 | QL (200 per 30 days); MO |
| INSULIN SYRINGE | 2 | QL (200 per 30 days); MO |
| KOSELUGO | 5 | PA |
| <i>promethazine vc/codeine</i> | 6 | ED |
| <i>promethazine-codeine oral solution</i> | 6 | ED |
| <i>sodium chloride irrigation solution 0.9 %</i> | 1 | |
| OPHTHALMIC AGENTS / AJAN OFTALMIK | | |
| <i>acetazolamide er</i> | 2 | MO; 90D |
| <i>ak-poly-bac</i> | 1 | |
| <i>atropine sulfate ophthalmic ointment</i> | 3 | MO |
| <i>atropine sulfate ophthalmic solution 1 %</i> | 2 | MO; 90D |
| <i>azelastine hcl ophthalmic</i> | 2 | |
| <i>bacitracin ophthalmic</i> | 2 | |

You can find information on what the symbols and abbreviations in this table mean by going to page 10 of this document. Ou ka jwenn enfòmasyon sou sa senbòl ak abrevyasyon yo nan tablo sa a vle di lè w ale nan paj 19 dokiman sa a.

| DRUG NAME / NON MEDIKAMAN | DRUG TIER / NIVO MEDIKAMAN | REQUIREMENTS / LIMITS KONDISYON / LIMIT |
|---|----------------------------|---|
| <i>bacitracin-polymyxin b ophthalmic ointment 500-10000 unit/gm</i> | 1 | |
| <i>bacitra-neomycin-polymyxin-hc</i> | 2 | |
| BESIVANCE | 4 | |
| <i>betaxolol hcl ophthalmic</i> | 2 | MO; 90D |
| <i>bimatoprost ophthalmic</i> | 2 | MO; 90D |
| <i>brimonidine tartrate ophthalmic</i> | 2 | MO; 90D |
| <i>brimonidine tartrate-timolol</i> | 2 | MO; 90D |
| <i>brinzolamide</i> | 2 | MO; 90D |
| <i>bromfenac sodium ophthalmic solution 0.07 %, 0.075 %</i> | 2 | |
| <i>carteolol hcl</i> | 1 | MO; 100D |
| <i>ciprofloxacin hcl ophthalmic</i> | 1 | |
| <i>cromolyn sodium ophthalmic</i> | 1 | |
| <i>cyclopentolate hcl ophthalmic solution 1 %</i> | 2 | MO; 90D |
| CYSTARAN | 5 | LA |
| <i>dexamethasone sodium phosphate ophthalmic</i> | 2 | |
| <i>diclofenac sodium ophthalmic</i> | 1 | |
| <i>difluprednate</i> | 2 | |
| <i>dorzolamide hcl ophthalmic</i> | 1 | MO; 100D |
| <i>dorzolamide hcl-timolol mal</i> | 1 | MO; 100D |
| <i>dorzolamide hcl-timolol mal pf ophthalmic solution 2-0.5 %</i> | 1 | MO; 100D |
| <i>erythromycin ophthalmic</i> | 1 | QL (3.5 per 30 days) |
| <i>fluorometholone ophthalmic</i> | 2 | |
| <i>flurbiprofen sodium</i> | 2 | |
| FML FORTE | 4 | |
| <i>gatifloxacin ophthalmic</i> | 2 | |
| <i>gentamicin sulfate ophthalmic solution</i> | 1 | |

You can find information on what the symbols and abbreviations in this table mean by going to page 10 of this document. Ou ka jwenn enfòmasyon sou sa senbòl ak abrevyasyon yo nan tablo sa a vle di lè w ale nan paj 19 dokiman sa a.

| DRUG NAME / NON MEDIKAMAN | DRUG TIER / NIVO MEDIKAMAN | REQUIREMENTS / LIMITS KONDISYON / LIMIT |
|--|----------------------------|---|
| ILEVRO | 3 | |
| <i>ketorolac tromethamine ophthalmic</i> | 2 | |
| <i>latanoprost ophthalmic</i> | 1 | MO; 100D |
| <i>levobunolol hcl ophthalmic solution 0.5 %</i> | 1 | MO; 100D |
| <i>levofloxacin ophthalmic</i> | 2 | |
| LOTEMAX OPHTHALMIC OINTMENT | 3 | |
| LOTEMAX SM | 3 | |
| <i>loteprednol etabonate</i> | 2 | |
| LUMIGAN OPHTHALMIC SOLUTION 0.01 % | 3 | MO |
| <i>methazolamide oral</i> | 2 | MO; 90D |
| <i>moxifloxacin hcl (2x day)</i> | 2 | |
| <i>moxifloxacin hcl ophthalmic solution</i> | 2 | |
| NATACYN | 4 | |
| <i>neomycin-bacitracin zn-polymyx</i> | 2 | |
| <i>neomycin-polymyxin-dexameth</i> | 1 | |
| <i>neomycin-polymyxin-gramicidin ophthalmic solution 1.75-10000-.025</i> | 2 | |
| <i>neomycin-polymyxin-hc ophthalmic suspension 3.5-10000-1</i> | 2 | |
| NEO-POLYCIN | 2 | |
| NEO-POLYCIN HC | 2 | |
| <i>ofloxacin ophthalmic</i> | 1 | |
| <i>olopatadine hcl ophthalmic solution 0.2 %</i> | 2 | |
| OXERVATE | 5 | PA |
| <i>pilocarpine hcl ophthalmic solution 1 %, 2 %, 4 %</i> | 2 | MO; 90D |
| POLYCIN | 1 | |
| <i>polymyxin b-trimethoprim</i> | 1 | |
| <i>prednisolone acetate ophthalmic</i> | 2 | |
| <i>prednisolone sodium phosphate ophthalmic</i> | 3 | |

You can find information on what the symbols and abbreviations in this table mean by going to page 10 of this document. Ou ka jwenn enfòmasyon sou sa senbòl ak abrevyasyon yo nan tablo sa a vle di lè w ale nan paj 19 dokiman sa a.

| DRUG NAME / NON MEDIKAMAN | DRUG TIER / NIVO MEDIKAMAN | REQUIREMENTS / LIMITS KONDISYON / LIMIT |
|--|----------------------------|---|
| <i>proparacaine hcl ophthalmic</i> | 1 | |
| RESTASIS | 3 | QL (60 per 30 days); MO |
| RESTASIS MULTIDOSE OPHTHALMIC EMULSION 0.05 % | 3 | QL (5.5 per 28 days); MO |
| RHOPRESSA | 3 | MO |
| ROCKLATAN | 3 | MO |
| SIMBRINZA | 4 | MO |
| <i>sulfacetamide sodium ophthalmic solution</i> | 1 | |
| <i>sulfacetamide-prednisolone ophthalmic solution</i> | 2 | |
| <i>timolol maleate (once-daily)</i> | 1 | MO; 100D |
| <i>timolol maleate ophthalmic gel forming solution</i> | 2 | MO; 90D |
| <i>timolol maleate ophthalmic solution</i> | 1 | MO; 100D |
| TOBRADEX OPHTHALMIC OINTMENT | 4 | |
| TOBRADEX ST | 4 | |
| <i>tobramycin ophthalmic</i> | 1 | |
| <i>tobramycin-dexamethasone</i> | 2 | |
| TOBEX OPHTHALMIC OINTMENT | 4 | |
| <i>travoprost (bak free)</i> | 2 | MO; 90D |
| VYZULTA | 4 | MO |
| XDEMZY | 5 | LA |
| XIIDRA | 3 | QL (60 per 30 days); MO |
| ZYLET | 4 | |
| OTIC AGENTS / AJAN OTIK | | |
| <i>acetic acid otic</i> | 1 | |
| <i>ciprofloxacin hcl otic</i> | 2 | |
| <i>ciprofloxacin-dexamethasone</i> | 2 | |
| FLAC | 2 | |
| <i>fluocinolone acetonide otic</i> | 2 | |
| <i>hydrocortisone-acetic acid</i> | 2 | |

You can find information on what the symbols and abbreviations in this table mean by going to page 10 of this document. Ou ka jwenn enfòmasyon sou sa senbòl ak abrevyasyon yo nan tablo sa a vle di lè w ale nan paj 19 dokiman sa a.

| DRUG NAME / NON MEDIKAMAN | DRUG TIER / NIVO MEDIKAMAN | REQUIREMENTS / LIMITS KONDISYON / LIMIT |
|---|----------------------------|---|
| <i>neomycin-polymyxin-hc otic</i> | 2 | |
| <i>ofloxacin otic</i> | 2 | |
| RESPIRATORY TRACT/PULMONARY AGENTS / AJAN RESPIRATWA/PILMONÈ | | |
| <i>acetylcysteine inhalation</i> | 2 | B/D PA |
| ADEMPAS | 5 | PA; QL (90 per 30 days); LA |
| ADVAIR HFA | 3 | QL (12 per 30 days); MO |
| <i>albuterol sulfate hfa</i> | 2 | MO; 90D |
| <i>albuterol sulfate inhalation nebulization solution (2.5 mg/3ml) 0.083%, 0.63 mg/3ml, 1.25 mg/3ml</i> | 2 | B/D PA; QL (360 per 30 days); MO; 90D |
| <i>albuterol sulfate inhalation nebulization solution (5 mg/ml) 0.5%</i> | 2 | B/D PA; MO; 90D |
| <i>albuterol sulfate inhalation nebulization solution 2.5 mg/0.5ml</i> | 2 | B/D PA; QL (60 per 30 days); MO; 90D |
| <i>albuterol sulfate oral syrup</i> | 1 | MO; 100D |
| <i>albuterol sulfate oral tablet</i> | 2 | MO; 90D |
| <i>ambrisentan</i> | 5 | PA; QL (30 per 30 days); LA |
| ANORO ELLIPTA INHALATION AEROSOL POWDER BREATH ACTIVATED 62.5-25 MCG/ACT | 3 | QL (60 per 30 days); MO |
| <i>arformoterol tartrate</i> | 4 | B/D PA; QL (120 per 30 days); MO |
| ARNUIY ELLIPTA | 3 | QL (30 per 30 days); MO |
| ATROVENT HFA | 3 | QL (26 per 30 days); MO |
| <i>azelastine hcl nasal</i> | 2 | QL (30 per 25 days) |
| <i>azelastine-fluticasone</i> | 2 | QL (23 per 28 days) |
| <i>bosentan</i> | 5 | PA; QL (60 per 30 days); LA |
| BREO ELLIPTA INHALATION AEROSOL POWDER BREATH ACTIVATED 100-25 MCG/ACT, 200-25 MCG/ACT, 50-25 MCG/INH | 3 | QL (60 per 30 days); MO |
| <i>breynd</i> | 3 | QL (30.9 per 30 days); MO |

You can find information on what the symbols and abbreviations in this table mean by going to page 10 of this document. Ou ka jwenn enfòmasyon sou sa senbòl ak abrevyasyon yo nan tablo sa a vle di lè w ale nan paj 19 dokiman sa a.

| DRUG NAME / NON MEDIKAMAN | DRUG TIER / NIVO MEDIKAMAN | REQUIREMENTS / LIMITS KONDISYON / LIMIT |
|---|----------------------------|---|
| BREZTRI AEROSPHERE | 3 | QL (10.7 per 30 days); MO |
| BRONCHITOL | 5 | PA; LA |
| <i>budesonide inhalation suspension 0.25 mg/2ml, 0.5 mg/2ml</i> | 2 | B/D PA; QL (120 per 30 days); MO; 90D |
| <i>budesonide inhalation suspension 1 mg/2ml</i> | 2 | B/D PA; QL (60 per 30 days); MO; 90D |
| <i>budesonide-formoterol fumarate</i> | 3 | QL (30.6 per 30 days); MO |
| <i>carbinoxamine maleate oral solution</i> | 2 | PA; HRM |
| CAYSTON | 5 | PA; LA |
| <i>cetirizine hcl oral solution</i> | 1 | |
| <i>clemastine fumarate oral tablet 2.68 mg</i> | 2 | PA; HRM |
| COMBIVENT RESPIMAT | 4 | QL (8 per 30 days); MO |
| <i>cromolyn sodium inhalation</i> | 2 | B/D PA; MO; 90D |
| <i>cyproheptadine hcl oral syrup</i> | 1 | PA; HRM |
| <i>cyproheptadine hcl oral tablet</i> | 1 | |
| DULERA | 4 | QL (13 per 30 days); MO |
| <i>epinephrine injection solution 0.3 mg/0.3ml</i> | 2 | QL (2 per 28 days) |
| <i>epinephrine injection solution auto-injector 0.15 mg/0.3ml, 0.3 mg/0.3ml</i> | 2 | QL (2 per 28 days) |
| FASENRA PEN | 5 | PA; QL (1 per 28 days) |
| FASENRA SUBCUTANEOUS SOLUTION PREFILLED SYRINGE 10 MG/0.5ML | 5 | PA; QL (0.5 per 28 days) |
| FASENRA SUBCUTANEOUS SOLUTION PREFILLED SYRINGE 30 MG/ML | 5 | PA; QL (1 per 28 days); LA |
| <i>flunisolide nasal solution 25 mcg/act (0.025%)</i> | 1 | QL (75 per 30 days) |
| <i>fluticasone propionate diskus inhalation aerosol powder breath activated 100 mcg/act, 50 mcg/act</i> | 3 | QL (60 per 30 days); MO |
| <i>fluticasone propionate diskus inhalation aerosol powder breath activated 250 mcg/act</i> | 3 | QL (240 per 30 days); MO |

You can find information on what the symbols and abbreviations in this table mean by going to page 10 of this document. Ou ka jwenn enfòmasyon sou sa senbòl ak abrevyasyon yo nan tablo sa a vle di lè w ale nan paj 19 dokiman sa a.

| DRUG NAME / NON MEDIKAMAN | DRUG TIER / NIVO MEDIKAMAN | REQUIREMENTS / LIMITS KONDISYON / LIMIT |
|---|-----------------------------------|--|
| <i>fluticasone propionate hfa inhalation aerosol 110 mcg/act</i> | 3 | QL (12 per 30 days); MO |
| <i>fluticasone propionate hfa inhalation aerosol 220 mcg/act</i> | 3 | QL (24 per 30 days); MO |
| <i>fluticasone propionate hfa inhalation aerosol 44 mcg/act</i> | 3 | QL (11 per 30 days); MO |
| <i>fluticasone propionate nasal</i> | 1 | QL (16 per 30 days) |
| <i>fluticasone-salmeterol inhalation aerosol powder breath activated 100-50 mcg/act, 250-50 mcg/act, 500-50 mcg/act</i> | 2 | QL (60 per 30 days); MO; 90D |
| <i>fluticasone-salmeterol inhalation aerosol powder breath activated 113-14 mcg/act, 232-14 mcg/act, 55-14 mcg/act</i> | 2 | QL (1 per 30 days); MO; 90D |
| <i>hydroxyzine hcl oral syrup</i> | 1 | QL (2880 per 28 days) |
| <i>hydroxyzine hcl oral tablet 10 mg, 25 mg</i> | 1 | QL (120 per 30 days) |
| <i>hydroxyzine hcl oral tablet 50 mg</i> | 1 | QL (240 per 30 days) |
| <i>hydroxyzine pamoate oral</i> | 2 | QL (120 per 30 days) |
| <i>ipratropium bromide inhalation</i> | 1 | B/D PA; MO; 100D |
| <i>ipratropium bromide nasal</i> | 1 | QL (30 per 30 days); MO; 100D |
| <i>ipratropium-albuterol</i> | 2 | B/D PA; QL (540 per 30 days); MO; 90D |
| KALYDECO ORAL PACKET | 5 | PA; QL (56 per 28 days) |
| KALYDECO ORAL TABLET | 5 | PA; QL (60 per 30 days) |
| <i>levalbuterol hcl inhalation nebulization solution 0.31 mg/3ml, 1.25 mg/0.5ml, 1.25 mg/3ml</i> | 2 | B/D PA; QL (270 per 30 days); MO; 90D |
| <i>levalbuterol hcl inhalation nebulization solution 0.63 mg/3ml</i> | 2 | B/D PA; QL (540 per 30 days); MO; 90D |
| <i>levalbuterol tartrate</i> | 2 | QL (45 per 30 days); MO; 90D |
| <i>levocetirizine dihydrochloride oral tablet</i> | 1 | QL (30 per 30 days) |
| <i>mometasone furoate nasal</i> | 2 | |

You can find information on what the symbols and abbreviations in this table mean by going to page 10 of this document. Ou ka jwenn enfòmasyon sou sa senbòl ak abrevyasyon yo nan tablo sa a vle di lè w ale nan paj 19 dokiman sa a.

| DRUG NAME / NON MEDIKAMAN | DRUG TIER / NIVO MEDIKAMAN | REQUIREMENTS / LIMITS KONDISYON / LIMIT |
|---|----------------------------|---|
| <i>montelukast sodium oral</i> | 2 | MO; 90D |
| NUCALA SUBCUTANEOUS SOLUTION AUTO-INJECTOR | 5 | PA; QL (3 per 28 days); LA |
| NUCALA SUBCUTANEOUS SOLUTION PREFILLED SYRINGE 100 MG/ML | 5 | PA; QL (3 per 28 days); LA |
| NUCALA SUBCUTANEOUS SOLUTION PREFILLED SYRINGE 40 MG/0.4ML | 5 | PA; QL (0.4 per 28 days); LA |
| NUCALA SUBCUTANEOUS SOLUTION RECONSTITUTED | 5 | PA; QL (3 per 28 days); LA |
| OFEV | 5 | PA; QL (60 per 30 days) |
| <i>olopatadine hcl nasal</i> | 2 | QL (31 per 30 days) |
| OPSUMIT | 5 | PA; QL (30 per 30 days); LA |
| ORKAMBI ORAL PACKET | 5 | PA; QL (60 per 30 days) |
| ORKAMBI ORAL TABLET | 5 | PA; QL (120 per 30 days) |
| <i>pirfenidone oral tablet 267 mg</i> | 5 | PA; QL (270 per 30 days) |
| <i>pirfenidone oral tablet 534 mg, 801 mg</i> | 5 | PA; QL (90 per 30 days) |
| <i>promethazine-phenylephrine</i> | 2 | |
| PROVENTIL HFA | 4 | MO |
| PULMOZYME INHALATION SOLUTION 2.5 MG/2.5ML | 5 | B/D PA |
| <i>roflumilast</i> | 2 | PA; QL (30 per 30 days); MO; 90D |
| SEREVENT DISKUS INHALATION AEROSOL POWDER BREATH ACTIVATED 50 MCG/ACT | 3 | QL (60 per 30 days); MO |
| <i>sildenafil citrate oral tablet 20 mg</i> | 2 | PA; QL (360 per 30 days); 90D |
| SPIRIVA HANDIHALER | 3 | QL (30 per 30 days); MO |
| SPIRIVA RESPIMAT | 3 | QL (4 per 30 days); MO |
| STIOLTO RESPIMAT | 3 | QL (4 per 30 days); MO |
| SYMDEKO ORAL TABLET THERAPY PACK 100-150 & 150 MG | 5 | PA; QL (56 per 28 days); LA |
| SYMDEKO ORAL TABLET THERAPY PACK 50-75 & 75 MG | 5 | PA; QL (56 per 28 days) |

You can find information on what the symbols and abbreviations in this table mean by going to page 10 of this document. Ou ka jwenn enfòmasyon sou sa senbòl ak abrevyasyon yo nan tablo sa a vle di lè w ale nan paj 19 dokiman sa a.

| DRUG NAME / NON MEDIKAMAN | DRUG TIER / NIVO MEDIKAMAN | REQUIREMENTS / LIMITS KONDISYON / LIMIT |
|---|----------------------------|---|
| <i>theophylline er oral tablet extended release 12 hour 300 mg</i> | 1 | MO; 100D |
| <i>theophylline er oral tablet extended release 24 hour</i> | 1 | MO; 100D |
| <i>theophylline oral</i> | 2 | MO; 90D |
| <i>tobramycin inhalation nebulization solution 300 mg/5ml</i> | 5 | B/D PA; QL (280 per 28 days) |
| TRELEGY ELLIPTA INHALATION AEROSOL POWDER BREATH ACTIVATED 100-62.5-25 MCG/ACT, 200-62.5-25 MCG/ACT | 3 | QL (60 per 30 days); MO |
| TRIKAFTA ORAL TABLET THERAPY PACK | 5 | PA; QL (84 per 28 days); LA |
| TRIKAFTA ORAL THERAPY PACK | 5 | PA; QL (56 per 28 days) |
| UPTRAVI ORAL | 5 | PA; QL (60 per 30 days); LA |
| UPTRAVI TITRATION | 5 | PA; LA |
| <i>wixela inhub inhalation aerosol powder breath activated 100-50 mcg/act, 250-50 mcg/act, 500-50 mcg/act</i> | 2 | QL (60 per 30 days); MO; 90D |
| XOLAIR SUBCUTANEOUS SOLUTION AUTO-INJECTOR 150 MG/ML, 300 MG/2ML | 5 | PA; QL (8 per 28 days); LA |
| XOLAIR SUBCUTANEOUS SOLUTION AUTO-INJECTOR 75 MG/0.5ML | 5 | PA; QL (4 per 28 days); LA |
| XOLAIR SUBCUTANEOUS SOLUTION PREFILLED SYRINGE 150 MG/ML, 300 MG/2ML | 5 | PA; QL (8 per 28 days); LA |
| XOLAIR SUBCUTANEOUS SOLUTION PREFILLED SYRINGE 75 MG/0.5ML | 5 | PA; QL (4 per 28 days); LA |
| XOLAIR SUBCUTANEOUS SOLUTION RECONSTITUTED | 5 | PA; QL (8 per 28 days); LA |
| <i>zafirlukast</i> | 2 | MO; 90D |

You can find information on what the symbols and abbreviations in this table mean by going to page 10 of this document. Ou ka jwenn enfòmasyon sou sa senbòl ak abrevyasyon yo nan tablo sa a vle di lè w ale nan paj 19 dokiman sa a.

Index of Drugs/Endèks Medikaman

A

| | | | | | |
|--|--------|---|--------|--|----------|
| <i>abacavir sulfate</i> | 96 | <i>amcinonide</i> | 64 | <i>atenolol-chlorthalidone</i> | 36 |
| <i>abacavir sulfate-lamivudine</i> ... | 96 | <i>amikacin sulfate</i> | 97 | <i>atomoxetine hcl</i> | 45 |
| ABELCET | 96 | <i>amiloride hcl</i> | 36 | <i>atorvastatin calcium</i> | 36 |
| ABILIFY MAINTENA..... | 43 | <i>amiloride-hydrochlorothiazide</i> | 36 | <i>atovaquone</i> | 97 |
| <i>abiraterone acetate</i> | 24 | <i>amiodarone hcl</i> | 36 | <i>atovaquone-proguanil hcl</i> | 97 |
| ABRYSVO..... | 90 | <i>amitriptyline hcl</i> | 44 | <i>atropine sulfate</i> | 109 |
| <i>acamprosate calcium</i> | 43 | <i>amlodipine besy-benazepril hcl</i> | 36 | ATROVENT HFA..... | 113 |
| <i>acarbose</i> | 72 | <i>amlodipine besylate</i> | 36 | AUGTYRO..... | 24 |
| ACCUTANE | 64 | <i>amlodipine besylate-valsartan</i> | 36 | AUROVELA 1.5/30 | 84 |
| <i>acebutolol hcl</i> | 36 | <i>amlodipine-atorvastatin</i> | 36 | AUROVELA 1/20 | 84 |
| <i>acetaminophen-codeine</i> | 21 | <i>amlodipine-olmesartan</i> | 36 | AUROVELA FE 1/20 | 84 |
| <i>acetazolamide</i> | 36 | <i>amlodipine-valsartan-hctz</i> | 36 | AURYXIA..... | 72 |
| <i>acetazolamide er</i> | 109 | <i>ammonium lactate</i> | 64 | AUSTEDO | 45 |
| <i>acetic acid</i> | 112 | AMNESTEEM | 64 | AUVELITY | 45 |
| <i>acetylcysteine</i> | 113 | <i>amoxapine</i> | 44 | AVONEX PEN..... | 45 |
| <i>acitretin</i> | 64 | <i>amoxicill-clarithro-lansopraz</i> | 78 | AVONEX PREFILLED | 45 |
| ACTHIB..... | 91 | <i>amoxicillin</i> | 97 | AYUNA..... | 84 |
| ACTIMMUNE | 91 | <i>amoxicillin-pot clavulanate</i> | 97 | AYVAKIT | 24 |
| <i>acyclovir</i> | 64, 97 | <i>amoxicillin-pot clavulanate er</i> | 97 | AZASAN..... | 91 |
| <i>acyclovir sodium</i> | 97 | <i>amphetamine-dextroamphet er</i> | 44 | <i>azathioprine</i> | 91 |
| ADACEL..... | 91 | <i>amphetamine-</i> <i>dextroamphetamine</i> | 44 | <i>azelaic acid</i> | 64 |
| <i>adefovir dipivoxil</i> | 97 | <i>amphotericin b</i> | 97 | <i>azelastine hcl</i> | 109, 113 |
| ADEMPAS..... | 113 | <i>ampicillin</i> | 97 | <i>azelastine-fluticasone</i> | 113 |
| ADVAIR HFA | 113 | <i>ampicillin sodium</i> | 97 | <i>azithromycin</i> | 97, 98 |
| AIMOVIG | 43 | <i>ampicillin-sulbactam sodium</i> | 97 | <i>aztreonam</i> | 98 |
| AKEEGA | 24 | <i>anagrelide hcl</i> | 33 | AZURETTE | 84 |
| <i>ak-poly-bac</i> | 109 | <i>anastrozole</i> | 24 | B | |
| <i>ala-cort</i> | 64 | ANORO ELLIPTA..... | 113 | BAC..... | 45 |
| <i>albendazole</i> | 97 | APLENZIN | 44 | <i>bacitracin</i> | 109 |
| <i>albuterol sulfate</i> | 113 | <i>apomorphine hcl</i> | 44 | <i>bacitracin-polymyxin b</i> | 110 |
| <i>albuterol sulfate hfa</i> | 113 | <i>aprepitant</i> | 78, 79 | <i>bacitra-neomycin-polymyxin-hc</i> | 110 |
| <i>alclometasone dipropionate</i> ... | 64 | APRI..... | 84 | <i>baclofen</i> | 45 |
| ALCOHOL SWABS | 109 | APTIOM..... | 44 | <i>balsalazide disodium</i> | 79 |
| ALECENSA..... | 24 | APTIVUS | 97 | BALVERSA..... | 24 |
| <i>alendronate sodium</i> | 72 | ARCALYST | 91 | BARACLUDGE..... | 98 |
| <i>alfuzosin hcl er</i> | 82 | AREXVY | 91 | BAVENCIO | 24 |
| <i>aliskiren fumarate</i> | 36 | <i>arformoterol tartrate</i> | 113 | <i>bcg vaccine</i> | 91 |
| <i>allopurinol</i> | 21 | ARIKAYCE | 97 | <i>benazepril hcl</i> | 36 |
| <i>almotriptan malate</i> | 43 | <i>aripiprazole</i> | 44 | <i>benazepril-hydrochlorothiazide</i> | 36 |
| <i>alosetron hcl</i> | 78 | ARNUITY ELLIPTA..... | 113 | BENLYSTA | 91 |
| <i>alprazolam</i> | 43 | <i>asenapine maleate</i> | 44, 45 | <i>benznidazole</i> | 98 |
| <i>alprazolam er</i> | 43 | <i>aspirin-dipyridamole er</i> | 33 | <i>benzonatate</i> | 109 |
| ALPRAZOLAM INTENSOL | 43 | ASTAGRAF XL..... | 91 | <i>benzoyl peroxide-erythromycin</i> | 64 |
| <i>alprazolam xr</i> | 43 | <i>atazanavir sulfate</i> | 97 | <i>benztropine mesylate</i> | 45 |
| ALTAVERA | 84 | <i>atenolol</i> | 36 | BESIVANCE..... | 110 |
| ALUNBRIG | 24 | | | BESREMI..... | 24 |
| <i>amantadine hcl</i> | 44 | | | | |
| <i>ambrisentan</i> | 113 | | | | |

| | | | | | |
|---------------------------------------|---------|---|--------|--|--------------|
| <i>betaine</i> | 82 | <i>butalbital-apap-caffeine</i> | 46 | <i>celecoxib</i> | 21 |
| <i>betamethasone dipropionate</i> .. | 64 | <i>butorphanol tartrate</i> | 21 | <i>cephalexin</i> | 99 |
| <i>betamethasone dipropionate aug</i> | | C | | <i>cetirizine hcl</i> | 114 |
| | 64 | CABENUVA..... | 98 | <i>cevimeline hcl</i> | 65 |
| <i>betamethasone valerate</i> | 64 | <i>cabergoline</i> | 84 | CHARLOTTE 24 FE..... | 84 |
| BETASERON | 45 | CABOMETYX..... | 25 | CHATEAL EQ..... | 84 |
| <i>betaxolol hcl</i> | 36, 110 | <i>calcipotriene</i> | 65 | <i>chlordiazepoxide hcl</i> | 47 |
| <i>bethanechol chloride</i> | 82 | <i>calcitonin (salmon)</i> | 72 | <i>chlordiazepoxide-amitriptyline</i> | |
| <i>bexarotene</i> | 24, 64 | CALCITRENE | 65 | | 47 |
| BEXSERO..... | 91 | <i>calcitriol</i> | 72 | <i>chlordiazepoxide-clidinium</i> | 79 |
| <i>bicalutamide</i> | 25 | <i>calcium acetate</i> | 72 | <i>chlorhexidine gluconate</i> | 65 |
| BICILLIN C-R | 98 | <i>calcium acetate (phos binder)</i> | 72 | <i>chloroquine phosphate</i> | 99 |
| BICILLIN L-A | 98 | CALQUENCE..... | 25 | <i>chlorpromazine hcl</i> | 47 |
| BIJUVA..... | 84 | CAMILA | 84 | <i>chlorthalidone</i> | 37 |
| BIKTARVY | 98 | <i>candesartan cilexetil</i> | 37 | <i>chlorzoxazone</i> | 47 |
| <i>bimatoprost</i> | 110 | <i>candesartan cilexetil-hctz</i> | 37 | <i>cholestyramine</i> | 37 |
| <i>bisoprolol fumarate</i> | 36 | CAPLYTA..... | 46 | <i>cholestyramine light</i> | 37 |
| <i>bisoprolol-hydrochlorothiazide</i> | | CAPRELSA..... | 25 | CICLODAN | 65 |
| | 36 | <i>captopril</i> | 37 | <i>ciclopirox</i> | 65 |
| BIVIGAM | 91 | <i>captopril-hydrochlorothiazide</i> | 37 | <i>ciclopirox olamine</i> | 65 |
| BOOSTRIX..... | 91 | <i>carbamazepine</i> | 46 | <i>cilostazol</i> | 33 |
| <i>bosentan</i> | 113 | <i>carbamazepine er</i> | 46 | CIMDUO | 99 |
| BOSULIF | 25 | <i>carbidopa</i> | 46 | <i>cimetidine</i> | 79 |
| BRAFTOVI..... | 25 | <i>carbidopa-levodopa</i> | 46, 47 | <i>cimetidine hcl</i> | 79 |
| BREO ELLIPTA | 113 | <i>carbidopa-levodopa er</i> | 46 | <i>cinacalcet hcl</i> | 72 |
| <i>brey-na</i> | 113 | <i>carbidopa-levodopa-entacapone</i> | | <i>ciprofloxacin hcl</i> | 99, 110, 112 |
| BREZTRI AEROSPHERE .. | 114 | | 47 | <i>ciprofloxacin in d5w</i> | 99 |
| BRILINTA | 33 | <i>carbinoxamine maleate</i> | 114 | <i>ciprofloxacin-dexamethasone</i> | |
| <i>brimonidine tartrate</i> | 110 | <i>carglumic acid</i> | 69 | | 112 |
| <i>brimonidine tartrate-timolol</i> | 110 | <i>carisoprodol</i> | 47 | <i>citalopram hydrobromide</i> | 47 |
| <i>brinzolamide</i> | 110 | <i>carteolol hcl</i> | 110 | CLARAVIS | 65 |
| BRIVIACT | 45 | CARTIA XT..... | 37 | <i>clarithromycin</i> | 99 |
| <i>bromfenac sodium</i> | 110 | <i>carvedilol</i> | 37 | <i>clarithromycin er</i> | 99 |
| <i>bromocriptine mesylate</i> | 45 | <i>carvedilol phosphate er</i> | 37 | <i>clemastine fumarate</i> | 114 |
| BRONCHITOL | 114 | <i>casprofungin acetate</i> | 98 | CLENPIQ | 79 |
| BRUKINSA | 25 | CAYSTON | 114 | CLIMARA PRO..... | 84 |
| <i>budesonide</i> | 79, 114 | <i>cefaclor</i> | 98 | CLINDACIN ETZ..... | 65 |
| <i>budesonide er</i> | 79 | <i>cefaclor er</i> | 98 | CLINDACIN-P..... | 65 |
| <i>budesonide-formoterol fumarate</i> | | <i>cefadroxil</i> | 98 | <i>clindamycin hcl</i> | 99 |
| | 114 | <i>cefazolin sodium</i> | 98 | <i>clindamycin palmitate hcl</i> | 100 |
| <i>bumetanide</i> | 36, 37 | <i>cefdinir</i> | 98 | <i>clindamycin phosphate</i> | 65, 82, |
| <i>buprenorphine</i> | 21 | <i>cefepime hcl</i> | 98 | 100 | |
| <i>buprenorphine hcl</i> | 45 | <i>cefixime</i> | 98 | <i>clindamycin phosphate in d5w</i> | |
| <i>buprenorphine hcl-naloxone hcl</i> | | <i>cefoxitin sodium</i> | 99 | | 100 |
| | 45, 46 | <i>cefpodoxime proxetil</i> | 99 | CLINIMIX E/DEXTROSE | |
| <i>bupropion hcl</i> | 46 | <i>cefprozil</i> | 99 | (2.75/5) | 69 |
| <i>bupropion hcl er (smoking det)</i> | | <i>ceftazidime</i> | 99 | CLINIMIX E/DEXTROSE | |
| | 46 | <i>ceftriaxone sodium</i> | 99 | (4.25/10) | 69 |
| <i>bupropion hcl er (sr)</i> | 46 | <i>ceftriaxone sodium in dextrose</i> | | CLINIMIX E/DEXTROSE | |
| <i>bupropion hcl er (xl)</i> | 46 | | 99 | (4.25/5) | 69 |
| <i>buspironone hcl</i> | 46 | <i>cefuroxime axetil</i> | 99 | CLINIMIX E/DEXTROSE | |
| <i>butalbital-acetaminophen</i> | 46 | <i>cefuroxime sodium</i> | 99 | (5/15) | 69 |

| | | |
|---|---|---|
| CLINIMIX E/DEXTROSE | COSENTYX SENSOREADY | <i>dexmethylphenidate hcl er</i>48 |
| (5/20).....69 | (300 MG).....91 | <i>dextroamphetamine sulfate</i>49 |
| <i>clinimix e/dextrose (8/10)</i>69 | COSENTYX SENSOREADY | <i>dextroamphetamine sulfate er</i> 48, |
| <i>clinimix e/dextrose (8/14)</i>69 | PEN91 | 49 |
| CLINIMIX/DEXTROSE | COTELLIC.....25 | <i>dextrose</i>70 |
| (4.25/10).....69 | CREON82 | <i>dextrose-sodium chloride</i>70 |
| CLINIMIX/DEXTROSE | <i>cromolyn sodium</i>82, 110, 114 | DIACOMIT49 |
| (4.25/5).....69 | CRYSSELLE-2884 | <i>diazepam</i>49 |
| CLINIMIX/DEXTROSE (5/15) | <i>cyclobenzaprine hcl</i>48 | DIAZEPAM INTENSOL49 |
|70 | <i>cyclopentolate hcl</i>110 | <i>diazoxide</i>72 |
| CLINIMIX/DEXTROSE (5/20) | <i>cyclophosphamide</i>25 | <i>diclofenac potassium</i>21 |
|70 | CYCLOSET72 | <i>diclofenac sodium</i>21, 66, 110 |
| <i>clinimix/dextrose (6/5)</i>70 | <i>cyclosporine</i>91, 92 | <i>diclofenac sodium er</i>21 |
| <i>clinimix/dextrose (8/10)</i>70 | <i>cyclosporine modified</i>91 | <i>diclofenac-misoprostol</i>21 |
| <i>clinimix/dextrose (8/14)</i>70 | <i>cyproheptadine hcl</i>114 | <i>dicloxacillin sodium</i>100 |
| CLINISOL SF70 | CYRAMZA.....25 | <i>dicyclomine hcl</i>79 |
| CLINOLIPID70 | CYRED EQ.....84 | DIFICID100 |
| <i>clobazam</i>47 | CYSTAGON82 | <i>diflunisal</i>21 |
| <i>clobetasol propionate</i>65 | CYSTARAN110 | <i>difluprednate</i>110 |
| <i>clobetasol propionate e</i>65 | D | <i>digox</i>37 |
| CLODAN65 | <i>dabigatran etexilate mesylate</i> .33 | <i>digoxin</i>37 |
| <i>clomipramine hcl</i>47 | <i>dalfampridine er</i>48 | <i>dihydroergotamine mesylate</i> .49 |
| <i>clonazepam</i>47, 48 | <i>danazol</i>84 | DILANTIN49 |
| <i>clonidine</i>37 | <i>dapsone</i>100 | <i>diltiazem hcl</i>38 |
| <i>clonidine hcl</i>37 | DAPTACEL92 | <i>diltiazem hcl er</i>38 |
| <i>clonidine hcl er</i>48 | <i>daptomycin</i>100 | <i>diltiazem hcl er beads</i>38 |
| <i>clopidogrel bisulfate</i>33 | <i>darifenacin hydrobromide er</i> ..82 | <i>diltiazem hcl er coated beads</i> .38 |
| <i>clorazepate dipotassium</i>48 | <i>darunavir</i>100 | <i>dilt-xr</i>38 |
| <i>clotrimazole</i>65 | DARZALEX25 | <i>dimethyl fumarate</i>49 |
| <i>clotrimazole-betamethasone</i> ..66 | DARZALEX FASPRO25 | <i>dimethyl fumarate starter pack</i> |
| <i>clozapine</i>48 | DAURISMO.....25 |49 |
| COARTEM100 | DEBLITANE.....84 | <i>diphenoxylate-atropine</i>79 |
| <i>colchicine</i>21 | <i>deferasirox</i>72 | <i>diphtheria-tetanus toxoids dt</i> ..92 |
| <i>colchicine-probenecid</i>21 | DELSTRIGO.....100 | <i>dipyridamole</i>33 |
| <i>colesevelam hcl</i>37 | DEPO-SUBQ PROVERA 104 | <i>disopyramide phosphate</i>38 |
| <i>colestipol hcl</i>37 |84 | <i>disulfiram</i>49 |
| <i>colistimethate sodium (cba)</i> .100 | DEPO-TESTOSTERONE.....84 | <i>divalproex sodium</i>49, 50 |
| COMBIVENT RESPIMAT .114 | DESCOVY100 | <i>divalproex sodium er</i>49 |
| COMETRIQ (100 MG DAILY | <i>desipramine hcl</i>48 | <i>dofetilide</i>38 |
| DOSE).....25 | <i>desmopressin ace spray refrig</i> 84 | <i>donepezil hcl</i>50 |
| COMETRIQ (140 MG DAILY | <i>desmopressin acetate</i>84 | <i>dorzolamide hcl</i>110 |
| DOSE).....25 | <i>desmopressin acetate spray</i>84 | <i>dorzolamide hcl-timolol mal</i> .110 |
| COMETRIQ (60 MG DAILY | <i>desogestrel-ethinyl estradiol</i> .84, | <i>dorzolamide hcl-timolol mal pf</i> |
| DOSE).....25 | 85 |110 |
| COMPLERA100 | <i>desonide</i>66 | DOVATO100 |
| COMPRO.....79 | <i>desoximetasone</i>66 | <i>doxazosin mesylate</i>38 |
| <i>constulose</i>79 | <i>desvenlafaxine er</i>48 | <i>doxepin hcl</i>50 |
| COPIKTRA.....25 | <i>desvenlafaxine succinate er</i>48 | <i>doxercalciferol</i>72 |
| CORLANOR.....37 | <i>dexamethasone</i>85 | DOXY 100.....100 |
| COSENTYX.....91 | <i>dexamethasone sodium</i> | <i>doxycycline hyclate</i>100 |
| COSENTYX (300 MG DOSE) | <i>phosphate</i>110 | <i>doxycycline monohydrate</i>100 |
|91 | <i>dexlansoprazole</i>79 | DRIZALMA SPRINKLE50 |

| | | | | | |
|--|--------|---|--------------|---|---------|
| <i>dronabinol</i> | 79 | <i>epinephrine</i> | 114 | <i>felodipine er</i> | 39 |
| <i>drospirenone-ethinyl estradiol</i> | 85 | EPITOL..... | 50 | FEMYNOR..... | 85 |
| DROXIA..... | 33 | <i>eplerenone</i> | 38 | <i>fenofibrate</i> | 39 |
| <i>droxidopa</i> | 38 | EPRONTIA..... | 50 | <i>fenofibrate micronized</i> | 39 |
| DULERA..... | 114 | ERAXIS..... | 101 | <i>fenofibric acid</i> | 39 |
| <i>duloxetine hcl</i> | 50 | <i>ergoloid mesylates</i> | 50 | <i>fenopropfen calcium</i> | 21 |
| DUPIXENT..... | 66 | <i>ergotamine-caffeine</i> | 50 | <i>fentanyl</i> | 21 |
| <i>duramorph</i> | 21 | ERIVEDGE..... | 26 | <i>fentanyl citrate</i> | 22 |
| <i>dutasteride</i> | 82 | ERLEADA..... | 26 | FETZIMA..... | 51 |
| <i>dutasteride-tamsulosin hcl</i> | 83 | <i>erlotinib hcl</i> | 26 | FETZIMA TITRATION..... | 51 |
| E | | ERRIN..... | 85 | FIASP..... | 72 |
| E.E.S. 400..... | 100 | <i>ertapenem sodium</i> | 101 | FIASP FLEXTOUCH..... | 72 |
| <i>ec-naproxen</i> | 21 | ERY-TAB..... | 101 | FIASP PENFILL..... | 72 |
| <i>econazole nitrate</i> | 66 | ERYTHROCIN STEARATE | | FIASP PUMPCART..... | 72 |
| EDURANT..... | 101 | | 101 | <i>finasteride</i> | 83 |
| <i>efavirenz</i> | 101 | <i>erythromycin</i> | 66, 102, 110 | <i>finolimid hcl</i> | 51 |
| <i>efavirenz-emtricitab-tenofo df</i> | | <i>erythromycin base</i> | 101, 102 | FINTEPLA..... | 51 |
| | 101 | <i>erythromycin ethylsuccinate</i> | 102 | FINZALA..... | 85 |
| <i>efavirenz-lamivudine-tenofovir</i> | | <i>erythromycin lactobionate</i> | 102 | FIRMAGON..... | 26 |
| | 101 | <i>escitalopram oxalate</i> | 50, 51 | FIRMAGON (240 MG DOSE) | |
| <i>eletriptan hydrobromide</i> | 50 | ESGIC..... | 51 | | 26 |
| ELIGARD..... | 25 | <i>esomeprazole magnesium</i> | 79 | FLAC..... | 112 |
| ELINEST..... | 85 | ESTARYLLA..... | 85 | FLEBOGAMMA DIF..... | 92 |
| ELIQUIS..... | 33 | <i>estazolam</i> | 51 | <i>flecainide acetate</i> | 39 |
| ELIQUIS DVT/PE STARTER | | <i>estradiol</i> | 85 | <i>fluconazole</i> | 102 |
| PACK..... | 33 | <i>eszopiclone</i> | 51 | <i>fluconazole in sodium chloride</i> | |
| ELURYNG..... | 85 | <i>ethambutol hcl</i> | 102 | | 102 |
| EMCYT..... | 25 | <i>ethosuximide</i> | 51 | <i>flucytosine</i> | 102 |
| EMSAM..... | 50 | <i>ethynodiol diac-eth estradiol</i> | 85 | <i>fludrocortisone acetate</i> | 85 |
| <i>emtricitabine</i> | 101 | <i>etodolac</i> | 21 | <i>flunisolide</i> | 114 |
| <i>emtricitabine-tenofovir df</i> | 101 | <i>etodolac er</i> | 21 | <i>fluocinolone acetonide</i> | 66, 112 |
| EMTRIVA..... | 101 | <i>etonogestrel-ethinyl estradiol</i> | 85 | <i>fluocinolone acetonide body</i> | 66 |
| EMVERM..... | 101 | <i>etravirine</i> | 102 | <i>fluocinolone acetonide scalp</i> | 66 |
| EMZAHH..... | 85 | EUCRISA..... | 66 | <i>fluocinonide</i> | 66 |
| <i>enalapril maleate</i> | 38 | EUTHYROX..... | 85 | <i>fluocinonide emulsified base</i> | 66 |
| <i>enalapril-hydrochlorothiazide</i> | 38 | <i>everolimus</i> | 26, 92 | <i>fluorometholone</i> | 110 |
| ENBREL..... | 92 | EVOTAZ..... | 102 | <i>fluorouracil</i> | 67 |
| ENBREL MINI..... | 92 | <i>exemestane</i> | 26 | <i>fluoxetine hcl</i> | 51 |
| ENBREL SURECLICK..... | 92 | EXKIVITY..... | 26 | <i>fluphenazine decanoate</i> | 51 |
| ENDOCET..... | 21 | <i>ezetimibe</i> | 38 | <i>fluphenazine hcl</i> | 51, 52 |
| ENGERIX-B..... | 92 | <i>ezetimibe-simvastatin</i> | 38 | <i>flurazepam hcl</i> | 52 |
| ENHERTU..... | 25 | F | | <i>flurbiprofen</i> | 22 |
| ENILLORING..... | 85 | <i>famciclovir</i> | 102 | <i>flurbiprofen sodium</i> | 110 |
| <i>enoxaparin sodium</i> | 33, 34 | <i>famotidine</i> | 79 | <i>fluticasone propionate</i> | 67, 115 |
| ENSKYCE..... | 85 | FANAPT..... | 51 | <i>fluticasone propionate diskus</i> | |
| <i>entacapone</i> | 50 | FANAPT TITRATION PACK | | | 114 |
| <i>entecavir</i> | 101 | | 51 | <i>fluticasone propionate hfa</i> | 115 |
| ENTRESTO..... | 38 | FARXIGA..... | 72 | <i>fluticasone-salmeterol</i> | 115 |
| <i>enulose</i> | 79 | FASENRA..... | 114 | <i>fluvastatin sodium</i> | 39 |
| ENVARUSUS XR..... | 92 | FASENRA PEN..... | 114 | <i>fluvastatin sodium er</i> | 39 |
| EPCLUSA..... | 101 | <i>febuxostat</i> | 21 | <i>fluvoxamine maleate</i> | 52 |
| EPIDIOLEX..... | 50 | <i>felbamate</i> | 51 | FML FORTE..... | 110 |

| | | | | | |
|--|--------|--|--------|--|--------|
| <i>folic acid</i> | 70 | <i>glucagon emergency</i> | 73 | <i>hydroxychloroquine sulfate</i> .. | 103 |
| <i>fondaparinux sodium</i> | 34 | <i>glyburide</i> | 73 | <i>hydroxyurea</i> | 26 |
| <i>fosamprenavir calcium</i> | 102 | <i>glyburide micronized</i> | 73 | <i>hydroxyzine hcl</i> | 115 |
| <i>fosaprepitant dimeglumine</i> | 79 | <i>glyburide-metformin</i> | 73 | <i>hydroxyzine pamoate</i> | 115 |
| <i>fosinopril sodium</i> | 39 | <i>glycopyrrolate</i> | 80 | <i>hyoscyamine sulfate</i> | 80 |
| <i>fosinopril sodium-hctz</i> | 39 | GLYDO | 22 | I | |
| FOTIVDA | 26 | GLYXAMBI | 73 | <i>ibandronate sodium</i> | 74 |
| FRAGMIN | 34 | GOCOVRI..... | 53 | IBRANCE..... | 26 |
| FRUZAQLA..... | 26 | GRALISE | 53 | IBU | 22 |
| <i>furosemide</i> | 39 | <i>granisetron hcl</i> | 80 | <i>ibuprofen</i> | 22 |
| FUZEON | 102 | <i>griseofulvin microsize</i> | 103 | <i>icatibant acetate</i> | 34 |
| FYCOMPA | 52 | <i>guanfacine hcl er</i> | 53 | ICLUSIG | 26 |
| G | | GVOKE PFS | 74 | <i>icosapent ethyl</i> | 39 |
| <i>gabapentin</i> | 52 | H | | IDHIFA..... | 26 |
| <i>gabapentin (once-daily)</i> | 52 | HADLIMA | 93 | IGALMI..... | 109 |
| GALAFOLD | 82 | HADLIMA PUSHTOUCH ... | 93 | ILEVRO | 111 |
| <i>galantamine hydrobromide</i> | 52 | HAILEY 1.5/30..... | 85 | <i>imatinib mesylate</i> | 26 |
| <i>galantamine hydrobromide er</i> | 52 | HAILEY FE 1/20 | 85 | IMBRUVICA | 27 |
| GAMMAGARD..... | 92 | <i>halobetasol propionate</i> | 67 | <i>imipenem-cilastatin</i> | 103 |
| GAMMAGARD S/D LESS IGA | | HALOETTE | 85 | <i>imipramine hcl</i> | 53 |
| | 92 | <i>haloperidol</i> | 53 | <i>imipramine pamoate</i> | 53 |
| GAMMAKED..... | 92 | <i>haloperidol decanoate</i> | 53 | <i>imiquimod</i> | 67 |
| GAMMAPLEX | 92 | <i>haloperidol lactate</i> | 53 | IMOVAX RABIES | 93 |
| GAMUNEX-C | 92 | HAVRIX | 93 | IMVEXXY MAINTENANCE | |
| GARDASIL 9..... | 92 | HEATHER | 85 | PACK | 85 |
| <i>gatifloxacin</i> | 110 | <i>heparin sodium (porcine)</i> | 34 | IMVEXXY STARTER PACK | |
| GATTEX..... | 79 | <i>heparin sodium (porcine) pf</i> .. | 34 | | 85 |
| GAUZE STERILE PADS 2 . | 109 | HEPLISAV-B..... | 93 | INCASSIA..... | 85 |
| GAVILYTE-C..... | 79 | HERCEPTIN HYLECTA | 26 | INCRELEX | 86 |
| GAVILYTE-G | 79 | HIBERIX..... | 93 | <i>indapamide</i> | 39 |
| GAVILYTE-N WITH FLAVOR | | HUMIRA (2 PEN)..... | 93 | <i>indomethacin</i> | 22 |
| PACK..... | 79 | HUMIRA (2 SYRINGE)..... | 93 | INFANRIX | 93 |
| GAVRETO..... | 26 | HUMIRA PEN-PEDIATRIC | | INGREZZA | 53 |
| GAZYVA..... | 26 | UC START..... | 93 | INLYTA | 27 |
| <i>gefitinib</i> | 26 | HUMIRA-CD/UC/HS | | INQOVI..... | 27 |
| <i>gemfibrozil</i> | 39 | STARTER | 93 | INREBIC | 27 |
| GEMTESA | 83 | HUMIRA-PSORIASIS/UEVIT | | <i>insulin asp prot & asp flexpen</i> | 74 |
| <i>generlac</i> | 80 | STARTER | 93 | <i>insulin aspart</i> | 74 |
| GENGRAF | 92, 93 | <i>hydralazine hcl</i> | 39 | <i>insulin aspart flexpen</i> | 74 |
| <i>gentamicin in saline</i> | 103 | <i>hydrochlorothiazide</i> | 39 | <i>insulin aspart penfill</i> | 74 |
| <i>gentamicin sulfate</i> ..67, 103, 110 | | <i>hydrocodone bit-homatrop mbr</i> | | <i>insulin aspart prot & aspart</i> .. | 74 |
| GENVOYA | 103 | | 109 | INSULIN PEN NEEDLE | 109 |
| GILOTRIF..... | 26 | <i>hydrocodone-acetaminophen</i> . | 22 | INSULIN SYRINGE..... | 109 |
| <i>glatiramer acetate</i> | 52 | <i>hydrocodone-ibuprofen</i> | 22 | INTELENCE | 103 |
| GLATOPA | 52, 53 | <i>hydrocortisone</i> | 67, 80 | INTRALIPID..... | 70 |
| GLEOSTINE | 26 | <i>hydrocortisone (perianal)</i> | 67 | INVEGA HAFYERA..... | 53 |
| <i>glimepiride</i> | 72 | <i>hydrocortisone ace-pramoxine</i> | | INVEGA SUSTENNA..... | 53, 54 |
| <i>glipizide</i> | 73 | | 80 | INVEGA TRINZA | 54 |
| <i>glipizide er</i> | 73 | <i>hydrocortisone butyrate</i> | 67 | INVOKAMET | 74 |
| <i>glipizide xl</i> | 73 | <i>hydrocortisone valerate</i> | 67 | INVOKAMET XR | 74 |
| <i>glipizide-metformin hcl</i> | 73 | <i>hydrocortisone-acetic acid</i> ... | 112 | INVOKANA..... | 74 |
| GLUCAGEN HYPOKIT | 73 | <i>hydromorphone hcl</i> | 22 | IPOL | 93 |

| | | | | | |
|--|---------|--|---------|---|---------------|
| <i>ipratropium bromide</i> | 115 | <i>kedrab</i> | 94 | LENVIMA (10 MG DAILY | |
| <i>ipratropium-albuterol</i> | 115 | KELNOR 1/50..... | 86 | DOSE) | 27 |
| <i>irbesartan</i> | 39 | KERENDIA..... | 74 | LENVIMA (12 MG DAILY | |
| <i>irbesartan-hydrochlorothiazide</i> | | <i>ketoconazole</i> | 67, 103 | DOSE) | 27 |
| | 39 | <i>ketoprofen</i> | 22 | LENVIMA (14 MG DAILY | |
| ISENTRESS | 103 | <i>ketorolac tromethamine</i> .. | 22, 111 | DOSE) | 27 |
| ISENTRESS HD | 103 | KINRIX | 94 | LENVIMA (18 MG DAILY | |
| ISIBLOOM..... | 86 | KIONEX..... | 74 | DOSE) | 27 |
| ISOLYTE-P IN D5W..... | 70 | KISQALI (200 MG DOSE) ... | 27 | LENVIMA (20 MG DAILY | |
| ISOLYTE-S..... | 70 | KISQALI (400 MG DOSE) ... | 27 | DOSE) | 28 |
| <i>isoniazid</i> | 103 | KISQALI (600 MG DOSE) ... | 27 | LENVIMA (24 MG DAILY | |
| <i>isosorb dinitrate-hydralazine</i> . | 39 | KISQALI FEMARA (200 MG | | DOSE) | 28 |
| <i>isosorbide dinitrate</i> | 39 | DOSE) | 27 | LENVIMA (4 MG DAILY | |
| <i>isosorbide mononitrate</i> | 39 | KISQALI FEMARA (400 MG | | DOSE) | 28 |
| <i>isosorbide mononitrate er</i> | 39 | DOSE) | 27 | LENVIMA (8 MG DAILY | |
| <i>isotretinoin</i> | 67 | KISQALI FEMARA (600 MG | | DOSE) | 28 |
| <i>isradipine</i> | 39, 40 | DOSE) | 27 | <i>letrozole</i> | 28 |
| <i>itraconazole</i> | 103 | KLAYESTA | 67 | <i>leucovorin calcium</i> | 28 |
| <i>ivabradine hcl</i> | 40 | KLOR-CON | 70 | LEUKERAN..... | 28 |
| <i>ivermectin</i> | 67, 103 | KLOR-CON 10 | 70 | LEUKINE..... | 34 |
| IWILFIN..... | 27 | KLOR-CON M10..... | 70 | <i>leuprolide acetate</i> | 28 |
| IXCHIQ..... | 93 | KLOR-CON M15..... | 70 | <i>leuprolide acetate (3 month)</i> .. | 28 |
| IXIARO..... | 94 | KLOR-CON M20..... | 70 | <i>levabuterol hcl</i> | 115 |
| J | | KOSELUGO | 109 | <i>levabuterol tartrate</i> | 115 |
| JAKAFI | 27 | KOURZEQ..... | 67 | <i>levetiracetam</i> | 54 |
| <i>jantoven</i> | 34 | KRAZATI | 27 | <i>levetiracetam er</i> | 54 |
| JANUMET | 74 | KURVELO..... | 86 | <i>levobunolol hcl</i> | 111 |
| JANUMET XR..... | 74 | L | | <i>levocarnitine</i> | 71 |
| JANUVIA..... | 74 | <i>labetalol hcl</i> | 40 | <i>levocarnitine sf</i> | 71 |
| JARDIANCE..... | 74 | <i>lacosamide</i> | 54 | <i>levocetirizine dihydrochloride</i> | |
| JASMIEL | 86 | <i>lactulose</i> | 80 | | 115 |
| JAVYGTOR..... | 82 | <i>lactulose encephalopathy</i> | 80 | <i>levofloxacin</i> | 103, 104, 111 |
| JAYPIRCA..... | 27 | LAGEVRIO..... | 103 | <i>levofloxacin in d5w</i> | 103 |
| JENCYCLA | 86 | LAMICTAL XR..... | 54 | <i>levonorgestrel-ethinyl estrad</i> .. | 86 |
| JENTADUETO | 74 | <i>lamivudine</i> | 103 | LEVORA 0.15/30 (28)..... | 86 |
| JENTADUETO XR..... | 74 | <i>lamivudine-zidovudine</i> | 103 | LEVO-T..... | 86 |
| JUBLIA | 67 | <i>lamotrigine</i> | 54 | <i>levothyroxine sodium</i> | 86 |
| JULEBER..... | 86 | <i>lamotrigine starter kit-blue</i> ... | 54 | LEVOXYL | 86 |
| JULUCA..... | 103 | <i>lamotrigine starter kit-green</i> .. | 54 | LEXIVA | 104 |
| JUNEL 1.5/30..... | 86 | <i>lamotrigine starter kit-orange</i> 54 | | <i>l-glutamine</i> | 34 |
| JUNEL 1/20..... | 86 | <i>lanreotide acetate</i> | 86 | LIBERVANT | 55 |
| JUNEL FE 1/20..... | 86 | <i>lansoprazole</i> | 80 | <i>lidocaine</i> | 22 |
| JYLAMVO..... | 94 | LANTUS | 74 | <i>lidocaine hcl</i> | 22 |
| JYNNEOS | 94 | LANTUS SOLOSTAR..... | 74 | <i>lidocaine hcl urethral/mucosal</i> | |
| K | | <i>lapatinib ditosylate</i> | 27 | | 22 |
| KADCYLA | 27 | LARIN 1.5/30..... | 86 | <i>lidocaine viscous hcl</i> | 22 |
| KALLIGA | 86 | LARIN 1/20..... | 86 | <i>lidocaine-prilocaine</i> | 22 |
| KALYDECO | 115 | LARIN FE 1/20 | 86 | <i>linezolid</i> | 104 |
| KARIVA | 86 | <i>latanoprost</i> | 111 | <i>linezolid in sodium chloride</i> . | 104 |
| <i>kcl (0.149%) in nacl</i> | 70 | <i>leflunomide</i> | 94 | LINZESS | 80 |
| <i>kcl in dextrose-nacl</i> | 70 | <i>lenalidomide</i> | 27 | <i>liothyronine sodium</i> | 86 |
| <i>kcl-lactated ringers-d5w</i> | 70 | | | <i>lisinopril</i> | 40 |

| | | | | | |
|---------------------------------------|-----|--|-------------|---|----------|
| <i>lisinopril-hydrochlorothiazide</i> | 40 | <i>maraviroc</i> | 104 | <i>metyrosine</i> | 40 |
| <i>lithium</i> | 55 | <i>marlissa</i> | 87 | <i>mexiletine hcl</i> | 40 |
| <i>lithium carbonate</i> | 55 | MARPLAN | 55 | MIBELAS 24 FE..... | 87 |
| <i>lithium carbonate er</i> | 55 | MATULANE..... | 28 | <i>micafungin sodium</i> | 104 |
| LITHOSTAT | 83 | MATZIM LA | 40 | <i>miconazole 3</i> | 83 |
| LIVTENCITY | 104 | MAVYRET | 104 | MICROGESTIN 1.5/30..... | 87 |
| LOESTRIN 1.5/30 (21)..... | 86 | <i>meclizine hcl</i> | 80 | MICROGESTIN 1/20..... | 87 |
| LOESTRIN 1/20 (21)..... | 86 | <i>medroxyprogesterone acetate</i> | 87 | MICROGESTIN 24 FE | 87 |
| LOESTRIN FE 1/20..... | 86 | <i>mefloquine hcl</i> | 104 | MICROGESTIN FE 1/20 | 87 |
| LOKELMA | 74 | <i>megestrol acetate</i> | 28, 87 | <i>midodrine hcl</i> | 40 |
| LONSURF..... | 28 | MEKINIST | 29 | <i>mifepristone</i> | 87 |
| <i>loperamide hcl</i> | 80 | MEKTOVI..... | 29 | MIGERGOT | 56 |
| <i>lopinavir-ritonavir</i> | 104 | <i>meloxicam</i> | 22 | <i>miglitol</i> | 75 |
| <i>lorazepam</i> | 55 | <i>memantine hcl</i> | 55 | <i>miglustat</i> | 82 |
| LORAZEPAM INTENSOL...55 | | <i>memantine hcl er</i> | 55 | MILI | 87 |
| LORBRENA | 28 | MENACTRA..... | 94 | <i>minocycline hcl</i> | 104 |
| LORYNA | 86 | MENQUADFI..... | 94 | <i>minoxidil</i> | 40 |
| <i>losartan potassium</i> | 40 | MENVEO | 94 | <i>mirtazapine</i> | 56 |
| <i>losartan potassium-hctz</i> | 40 | <i>meperidine hcl</i> | 22, 23 | <i>misoprostol</i> | 80 |
| LOTEMAX | 111 | <i>meprobamate</i> | 55 | M-M-R II | 94 |
| LOTEMAX SM..... | 111 | <i>mercaptopurine</i> | 29 | <i>modafinil</i> | 56 |
| <i>loteprednol etabonate</i> | 111 | <i>meropenem</i> | 104 | <i>moexipril hcl</i> | 40 |
| <i>lovastatin</i> | 40 | <i>mesalamine</i> | 80 | <i>molindone hcl</i> | 56 |
| LOW-OGESTREL | 86 | <i>mesalamine er</i> | 80 | <i>mometasone furoate</i> | 68, 115 |
| <i>loxapine succinate</i> | 55 | MESNEX..... | 29 | MONDOXYNE NL..... | 104 |
| LO-ZUMANDIMINE | 86 | <i>metformin hcl</i> | 75 | MONO-LINYAH | 87 |
| <i>lubiprostone</i> | 80 | <i>metformin hcl er</i> | 75 | <i>montelukast sodium</i> | 116 |
| LUMAKRAS | 28 | <i>metformin hcl er (mod)</i> | 75 | <i>morphine sulfate</i> | 23 |
| LUMIGAN | 111 | <i>metformin hcl er (osm)</i> | 75 | <i>morphine sulfate (concentrate)</i> | |
| LUPRON DEPOT (1-MONTH) | | <i>methadone hcl</i> | 23 | | 23 |
| | 28 | <i>methazolamide</i> | 111 | <i>morphine sulfate (pf)</i> | 23 |
| LUPRON DEPOT (3-MONTH) | | <i>methenamine hippurate</i> | 104 | <i>morphine sulfate er</i> | 23 |
| | 28 | <i>methimazole</i> | 87 | MOUNJARO | 75 |
| LUPRON DEPOT (4-MONTH) | | <i>methocarbamol</i> | 55 | MOVANTIK | 81 |
| | 28 | <i>methotrexate sodium</i> | 94 | <i>moxifloxacin hcl</i> | 104, 111 |
| LUPRON DEPOT (6-MONTH) | | <i>methotrexate sodium (pf)</i> | 94 | <i>moxifloxacin hcl (2x day)</i> | 111 |
| | 28 | <i>methoxsalen rapid</i> | 67 | <i>moxifloxacin hcl in nacl</i> | 104 |
| <i>lurasidone hcl</i> | 55 | <i>methscopolamine bromide</i> | 80 | MRESVIA | 94 |
| LYBALVI | 55 | <i>methsuximide</i> | 55 | MULTAQ..... | 40 |
| LYLEQ..... | 87 | <i>methylphenidate hcl</i> | 56 | <i>multiple electro type 1 ph 5.5</i> .71 | |
| LYNPARZA..... | 28 | <i>methylphenidate hcl er</i> | 56 | <i>multiple electro type 1 ph 7.4</i> .71 | |
| LYSODREN..... | 28 | <i>methylphenidate hcl er (cd)</i> | 55 | <i>mupirocin</i> | 68 |
| LYTGOBI (12 MG DAILY | | <i>methylphenidate hcl er (osm)</i> .55 | | <i>mupirocin calcium</i> | 68 |
| DOSE)..... | 28 | <i>methylprednisolone</i> | 87 | <i>mycophenolate mofetil</i> | 94 |
| LYTGOBI (16 MG DAILY | | <i>methyltestosterone</i> | 87 | <i>mycophenolate sodium</i> | 94 |
| DOSE)..... | 28 | <i>metoclopramide hcl</i> | 80 | <i>mycophenolic acid</i> | 94 |
| LYTGOBI (20 MG DAILY | | <i>metolazone</i> | 40 | MYHIBBIN..... | 94 |
| DOSE)..... | 28 | <i>metoprolol succinate er</i> | 40 | MYORISAN..... | 68 |
| LYZA | 87 | <i>metoprolol tartrate</i> | 40 | MYRBETRIQ..... | 83 |
| M | | <i>metoprolol-hydrochlorothiazide</i> | | MYTESI | 81 |
| <i>magnesium sulfate</i> | 71 | | 40 | N | |
| <i>malathion</i> | 67 | <i>metronidazole</i> | 67, 83, 104 | <i>nabumetone</i> | 23 |

| | | | | | |
|---|----------|---|---------------|--|----------|
| <i>nadolol</i> | 40 | <i>norelgestromin-eth estradiol</i> .. | 87 | OJEMDA..... | 29 |
| <i>nafcillin sodium</i> | 105 | <i>norethin ace-eth estrad-fe</i> | 87 | OJJAARA..... | 29 |
| <i>naftifine hcl</i> | 68 | <i>norethindrone</i> | 88 | <i>olanzapine</i> | 57 |
| <i>naloxone hcl</i> | 56 | <i>norethindrone acetate</i> | 87 | <i>olmesartan medoxomil</i> | 41 |
| <i>naltrexone hcl</i> | 56 | <i>norethindrone acet-ethinyl est</i> | 88 | <i>olmesartan medoxomil-hctz</i> | 41 |
| NAMZARIC..... | 56 | <i>norethin-eth estradiol-fe</i> | 88 | <i>olmesartan-amlodipine-hctz</i> .. | 41 |
| <i>naproxen</i> | 23 | <i>norgestimate-eth estradiol</i> | 88 | <i>olopatadine hcl</i> | 111, 116 |
| <i>naproxen dr</i> | 23 | <i>norgestim-eth estrad triphasic</i> | 88 | <i>omega-3-acid ethyl esters</i> | 41 |
| <i>naproxen sodium</i> | 23 | NORLYDA | 88 | <i>omeprazole</i> | 81 |
| NATACYN | 111 | NORLYROC | 88 | OMNITROPE..... | 88 |
| <i>nateglinide</i> | 75 | <i>nortriptyline hcl</i> | 57 | <i>ondansetron</i> | 81 |
| NAYZILAM..... | 56 | NORVIR..... | 105 | <i>ondansetron hcl</i> | 81 |
| <i>neбиволоl hcl</i> | 40 | NOVOLIN 70/30..... | 75 | ONUREG | 29 |
| <i>nefazodone hcl</i> | 57 | NOVOLIN 70/30 RELION ... | 75 | OPSUMIT..... | 116 |
| <i>neomycin sulfate</i> | 105 | NOVOLIN N..... | 75 | ORALONE | 68 |
| <i>neomycin-bacitracin zn-polymyx</i> | | NOVOLIN N FLEXPEN | 75 | ORGOVYX | 29 |
| | 111 | NOVOLIN N FLEXPEN | | ORKAMBI..... | 116 |
| <i>neomycin-polymyxin-dexameth</i> | | RELION | 75 | <i>orphenadrine citrate er</i> | 57 |
| | 111 | NOVOLIN N RELION | 75 | ORSERDU | 29 |
| <i>neomycin-polymyxin-gramicidin</i> | | NOVOLIN R | 75 | <i>oseltamivir phosphate</i> | 105 |
| | 111 | NOVOLIN R RELION | 75 | OSPHERA..... | 88 |
| <i>neomycin-polymyxin-hc</i> | 111, 113 | NOVOLOG | 76 | OTEZLA..... | 94 |
| NEO-POLYCIN..... | 111 | NOVOLOG 70/30 FLEXPEN | | <i>oxaliplatin</i> | 29 |
| NEO-POLYCIN HC | 111 | RELION | 75 | <i>oxandrolone</i> | 88 |
| NERLYNX..... | 29 | NOVOLOG FLEXPEN..... | 76 | <i>oxaprozin</i> | 23 |
| NEULASTA..... | 35 | NOVOLOG FLEXPEN | | <i>oxazepam</i> | 57 |
| NEUPOGEN | 35 | RELION | 75 | <i>oxcarbazepine</i> | 57 |
| NEUPRO..... | 57 | NOVOLOG MIX 70/30 | 76 | OXERVATE..... | 111 |
| <i>nevirapine</i> | 105 | NOVOLOG MIX 70/30 | | <i>oxybutynin chloride</i> | 83 |
| <i>nevirapine er</i> | 105 | FLEXPEN | 76 | <i>oxybutynin chloride er</i> | 83 |
| NEXPLANON | 87 | NOVOLOG MIX 70/30 | | <i>oxycodone hcl</i> | 23 |
| <i>niacin (antihyperlipidemic)</i> ... | 40 | RELION | 76 | <i>oxycodone-acetaminophen</i> | 23 |
| <i>niacin er (antihyperlipidemic)</i> | 41 | NOVOLOG PENFILL | 76 | <i>oxymorphone hcl</i> | 23 |
| <i>niacor</i> | 41 | NOVOLOG RELION..... | 76 | OZEMPIC (0.25 OR 0.5 | |
| <i>nicardipine hcl</i> | 41 | NUBEQA | 29 | MG/DOSE)..... | 76 |
| NICOTROL..... | 57 | NUCALA | 116 | OZEMPIC (1 MG/DOSE)..... | 76 |
| <i>nifedipine er</i> | 41 | NUDEXTA | 57 | OZEMPIC (2 MG/DOSE)..... | 76 |
| <i>nifedipine er osmotic release</i> .. | 41 | NUPLAZID | 57 | P | |
| NIKKI..... | 87 | NURTEC | 57 | <i>pacerone</i> | 41 |
| <i>nilutamide</i> | 29 | NUTRILIPID..... | 71 | <i>paliperidone er</i> | 57 |
| <i>nimodipine</i> | 41 | NYAMYC | 68 | PANRETIN | 68 |
| NINLARO | 29 | <i>nystatin</i> | 68, 105 | <i>pantoprazole sodium</i> | 81 |
| <i>nisoldipine er</i> | 41 | <i>nystatin-triamcinolone</i> | 68 | <i>paricalcitol</i> | 76 |
| <i>nitazoxanide</i> | 105 | NYSTOP | 68 | <i>paroxetine hcl</i> | 58 |
| <i>nitisinone</i> | 82 | O | | <i>paroxetine hcl er</i> | 57, 58 |
| <i>nitrofurantoin macrocrystal</i> . | 105 | OCTAGAM..... | 94 | <i>paroxetine mesylate</i> | 58 |
| <i>nitrofurantoin monohyd macro</i> | | <i>octreotide acetate</i> | 88 | PAXLOVID (150/100)..... | 105 |
| | 105 | ODEFSEY | 105 | PAXLOVID (300/100)..... | 105 |
| <i>nitroglycerin</i> | 41, 68 | ODOMZO | 29 | <i>pazopanib hcl</i> | 29 |
| <i>nizatidine</i> | 81 | OFEV..... | 116 | PEDIARIX | 95 |
| NORA-BE..... | 87 | <i>ofloxacin</i> | 105, 111, 113 | PEDVAX HIB | 95 |
| NORDITROPIN FLEXPRO .. | 87 | OGSIVEO | 29 | <i>peg 3350-kcl-na bicarb-nacl</i> .. | 81 |

| | | | | | |
|--|---------|--|---------|---------------------------------------|-----|
| <i>peg-3350/electrolytes</i> | 81 | <i>potassium chloride</i> | 71 | <i>propranolol hcl</i> | 41 |
| PEGASYS | 95 | <i>potassium chloride crys er</i> | 71 | <i>propranolol hcl er</i> | 41 |
| PEMAZYRE | 29 | <i>potassium chloride er</i> | 71 | <i>propylthiouracil</i> | 89 |
| PENBRAYA | 95 | <i>potassium chloride in nacl</i> | 71 | PROQUAD..... | 95 |
| <i>penicillamine</i> | 83 | <i>potassium citrate er</i> | 83 | PROSOL..... | 71 |
| <i>penicillin g potassium</i> | 105 | <i>potassium cl in dextrose 5%</i> ...71 | | <i>protriptyline hcl</i> | 59 |
| <i>penicillin g sodium</i> | 105 | <i>pramipexole dihydrochloride</i> .58 | | PROVENTIL HFA..... | 116 |
| <i>penicillin v potassium</i> | 105 | <i>pramipexole dihydrochloride er</i> | | PULMOZYME..... | 116 |
| PENTACEL | 95 | | 58 | PURIXAN | 30 |
| <i>pentamidine isethionate</i> | 105 | <i>prasugrel hcl</i> | 35 | <i>pyrazinamide</i> | 106 |
| <i>pentazocine-naloxone hcl</i> | 24 | <i>pravastatin sodium</i> | 41 | <i>pyridostigmine bromide</i> | 59 |
| <i>pentoxifylline er</i> | 35 | <i>praziquantel</i> | 106 | <i>pyridostigmine bromide er</i> | 59 |
| <i>perindopril erbumine</i> | 41 | <i>prazosin hcl</i> | 41 | <i>pyrimethamine</i> | 106 |
| PERIOGARD | 68 | <i>prednicarbate</i> | 88 | Q | |
| <i>permethrin</i> | 68 | <i>prednisolone</i> | 88 | QINLOCK | 30 |
| <i>perphenazine</i> | 58 | <i>prednisolone acetate</i> | 111 | QUADRACEL | 95 |
| <i>perphenazine-amitriptyline</i> | 58 | <i>prednisolone sodium phosphate</i> | | <i>quetiapine fumarate</i> | 59 |
| PERSERIS..... | 58 | | 89, 111 | <i>quetiapine fumarate er</i> | 59 |
| PFIZERPEN | 106 | <i>prednisone</i> | 89 | <i>quinapril hcl</i> | 41 |
| <i>phenelzine sulfate</i> | 58 | <i>pregabalin</i> | 58, 59 | <i>quinapril-hydrochlorothiazide</i> | 42 |
| <i>phenobarbital</i> | 58 | PREHEVBRIO | 95 | <i>quinidine gluconate er</i> | 42 |
| <i>phenytoin</i> | 58 | PREMARIN | 89 | <i>quinidine sulfate</i> | 42 |
| PHENYTOIN INFATABS | 58 | PREMASOL..... | 71 | <i>quinine sulfate</i> | 106 |
| <i>phenytoin sodium extended</i> | 58 | <i>prevalite</i> | 41 | R | |
| PHESGO | 29 | PREVYMIS..... | 106 | RABAVERT..... | 95 |
| PIFELTRO | 106 | PREZCOBIX..... | 106 | <i>raloxifene hcl</i> | 89 |
| <i>pilocarpine hcl</i> | 68, 111 | PREZISTA | 106 | <i>ramelteon</i> | 59 |
| <i>pimecrolimus</i> | 68 | PRIFTIN..... | 106 | <i>ramipril</i> | 42 |
| <i>pimozide</i> | 58 | <i>primaquine phosphate</i> | 106 | <i>ranolazine er</i> | 42 |
| PIMTREA | 88 | <i>primidone</i> | 59 | <i>rasagiline mesylate</i> | 59 |
| <i>pindolol</i> | 41 | PRIORIX | 95 | RECLIPSEN..... | 89 |
| <i>pioglitazone hcl</i> | 76 | PRIVIGEN | 95 | RECOMBIVAX HB..... | 95 |
| <i>pioglitazone hcl-glimepiride</i> .. | 76 | <i>probenecid</i> | 24 | REGANEX | 68 |
| <i>pioglitazone hcl-metformin hcl</i> | | <i>prochlorperazine</i> | 81 | RELENZA DISKHALER | 106 |
| | 76 | <i>prochlorperazine maleate</i> | 81 | <i>repaglinide</i> | 76 |
| <i>piperacillin sod-tazobactam</i> . | 106 | PROCRIT | 35 | REPATHA..... | 42 |
| PIQRAY (200 MG DAILY | | PROCTO-MED HC | 68 | REPATHA PUSHTRONEX | |
| DOSE)..... | 29 | PROCTOSOL HC | 68 | SYSTEM | 42 |
| PIQRAY (250 MG DAILY | | PROCTOZONE-HC..... | 68 | REPATHA SURECLICK | 42 |
| DOSE)..... | 29 | <i>progesterone</i> | 89 | RESTASIS..... | 112 |
| PIQRAY (300 MG DAILY | | PROGRAF..... | 95 | RESTASIS MULTIDOSE.... | 112 |
| DOSE)..... | 29 | PROLASTIN-C | 82 | RETACRIT..... | 35 |
| <i>pirfenidone</i> | 116 | PROLIA..... | 76 | RETEVMO..... | 30 |
| <i>piroxicam</i> | 24 | PROMACTA..... | 35 | RETROVIR | 106 |
| <i>pitavastatin calcium</i> | 41 | <i>promethazine hcl</i> | 81 | REXULTI..... | 59 |
| PLENAMINE..... | 71 | <i>promethazine vc/codeine</i> | 109 | REYATAZ | 106 |
| <i>podofilox</i> | 68 | <i>promethazine-codeine</i> | 109 | REZLIDHIA..... | 30 |
| POLYCIN..... | 111 | <i>promethazine-phenylephrine</i> 116 | | REZUROCK..... | 95 |
| <i>polymyxin b-trimethoprim</i> | 111 | PROMETHEGAN..... | 81 | RHOPRESSA..... | 112 |
| POMALYST | 29 | <i>propafenone hcl</i> | 41 | RIABNI | 30 |
| PORTIA-28 | 88 | <i>propafenone hcl er</i> | 41 | <i>ribavirin</i> | 106 |
| <i>posaconazole</i> | 106 | <i>proparacaine hcl</i> | 112 | <i>rifabutin</i> | 106 |

| | | | | | |
|--|---------|---------------------------------------|---------|---|--------|
| <i>rifampin</i> | 106 | SIMLIYA | 89 | SUNLENCA..... | 107 |
| <i>riluzole</i> | 59 | <i>simvastatin</i> | 42 | SYMDEKO | 116 |
| <i>rimantadine hcl</i> | 106 | <i>sirolimus</i> | 95 | SYMLINPEN 120 | 77 |
| RINVOQ | 95 | SIRTIURO..... | 107 | SYMLINPEN 60 | 77 |
| RINVOQ LQ..... | 95 | SKYLA..... | 89 | SYMPAZAN | 61 |
| <i>risedronate sodium</i> | 76, 77 | SKYRIZI | 95, 96 | SYMTUZA..... | 107 |
| <i>risperidone</i> | 59, 60 | SKYRIZI PEN..... | 95 | SYNAREL..... | 89 |
| <i>risperidone microspheres er</i> ... | 59 | SOAANZ..... | 42 | SYNDROS | 81 |
| <i>ritonavir</i> | 107 | <i>sodium chloride</i> | 71, 109 | SYNJARDY | 77 |
| RITUXAN..... | 30 | <i>sodium fluoride</i> | 71 | SYNJARDY XR..... | 77 |
| <i>rivastigmine</i> | 60 | <i>sodium oxybate</i> | 60 | SYNTHROID | 89 |
| <i>rivastigmine tartrate</i> | 60 | <i>sodium phenylbutyrate</i> | 82 | T | |
| ROCKLATAN | 112 | <i>sodium polystyrene sulfonate</i> . | 77 | TABLOID..... | 30 |
| <i>roflumilast</i> | 116 | <i>sofosbuvir-velpatasvir</i> | 107 | TABRECTA | 30 |
| <i>ropinirole hcl</i> | 60 | <i>solifenacin succinate</i> | 83 | <i>tacrolimus</i> | 69, 96 |
| <i>rosuvastatin calcium</i> | 42 | SOLQUA | 77 | <i>tadalafil</i> | 83 |
| ROTARIX | 95 | SOLTAMOX..... | 30 | TAFINLAR | 31 |
| ROTATEQ | 95 | SOMATULINE DEPOT | 89 | TAGRISO..... | 31 |
| ROWEEPRA..... | 60 | SOMAVERT | 89 | TAKHZYRO | 35 |
| ROZLYTREK | 30 | <i>sorafenib tosylate</i> | 30 | TALZENNA..... | 31 |
| RUBRACA..... | 30 | SORINE..... | 42 | <i>tamoxifen citrate</i> | 31 |
| <i>rufinamide</i> | 60 | <i>sotalol hcl</i> | 42 | <i>tamsulosin hcl</i> | 83 |
| RUKOBIA..... | 107 | <i>sotalol hcl (af)</i> | 42 | TARINA FE 1/20 EQ..... | 89 |
| RYBELSUS | 77 | SPIRIVA HANDIHALER .. | 116 | TASIGNA..... | 31 |
| RYBREVANT | 30 | SPIRIVA RESPIMAT..... | 116 | <i>tazarotene</i> | 69 |
| RYDAPT | 30 | <i>spironolactone</i> | 42 | TAZICEF..... | 107 |
| RYLAZE | 30 | <i>spironolactone-hctz</i> | 42 | TAZORAC | 69 |
| RYTARY | 60 | SPRAVATO (56 MG DOSE) 60 | | TAZVERIK | 31 |
| S | | SPRAVATO (84 MG DOSE) 60 | | TDVAX | 96 |
| SAJAZIR..... | 35 | SPRINTEC 28 | 89 | TECENTRIQ..... | 31 |
| SANTYL | 68 | SPRITAM..... | 61 | TECVAYLI | 31 |
| <i>sapropterin dihydrochloride</i> .. | 82 | SPRYCEL | 30 | TEFLARO | 107 |
| SARCLISA..... | 30 | SPS | 77 | TEGLUTIK | 61 |
| SAVELLA..... | 60 | SSD (SILVER | | TEGSEDI | 42 |
| SAVELLA TITRATION PACK | | SULFADIAZINE)..... | 69 | <i>telmisartan</i> | 42 |
| | 60 | STELARA..... | 96 | <i>telmisartan-amlodipine</i> | 42 |
| SCEMBLIX..... | 30 | STIOLTO RESPIMAT..... | 116 | <i>telmisartan-hctz</i> | 42 |
| <i>scopolamine</i> | 81 | STIVARGA..... | 30 | <i>temazepam</i> | 61 |
| SECUADO | 60 | <i>streptomycin sulfate</i> | 107 | TENIVAC..... | 96 |
| <i>selegiline hcl</i> | 60 | STRIBILD | 107 | <i>tenofovir disoproxil fumarate</i> | |
| <i>selenium sulfide</i> | 68 | SUBVENITE..... | 61 | | 107 |
| SELZENTRY | 107 | <i>sucralfate</i> | 81 | TEPMETKO..... | 31 |
| SEREVENT DISKUS | 116 | <i>sulfacetamide sodium</i> | 112 | <i>terazosin hcl</i> | 42 |
| <i>sertraline hcl</i> | 60 | <i>sulfacetamide sodium (acne)</i> .. | 69 | <i>terbinafine hcl</i> | 107 |
| <i>sevelamer carbonate</i> | 77 | <i>sulfacetamide-prednisolone</i> .. | 112 | <i>terconazole</i> | 83 |
| SHAROBEL..... | 89 | <i>sulfadiazine</i> | 107 | <i>teriflunomide</i> | 61 |
| SHINGRIX..... | 95 | <i>sulfamethoxazole-trimethoprim</i> | | <i>teriparatide</i> | 77 |
| SIGNIFOR | 89 | | 107 | <i>teriparatide (recombinant)</i> | 77 |
| <i>sildenafil citrate</i> | 83, 116 | <i>sulfasalazine</i> | 81 | <i>testosterone</i> | 90 |
| <i>silodosin</i> | 83 | <i>sulindac</i> | 24 | <i>testosterone cypionate</i> | 89 |
| <i>silver sulfadiazine</i> | 68 | <i>sumatriptan succinate</i> | 61 | <i>testosterone enanthate</i> | 89 |
| SIMBRINZA | 112 | <i>sunitinib malate</i> | 30 | <i>tetrabenazine</i> | 61 |

| | | | | | |
|--|----------|--------------------------------------|-----|--|--------|
| <i>tetracycline hcl</i> | 107 | TRI FEMYNOR | 90 | UPTRAVI..... | 117 |
| THALOMID..... | 31 | <i>triamcinolone acetonide</i> | 69 | UPTRAVI TITRATION | 117 |
| <i>theophylline</i> | 117 | <i>triamterene-hctz</i> | 43 | <i>ursodiol</i> | 81 |
| <i>theophylline er</i> | 117 | <i>triazolam</i> | 61 | V | |
| <i>thioridazine hcl</i> | 61 | TRIDERM..... | 69 | <i>valacyclovir hcl</i> | 108 |
| <i>thiothixene</i> | 61 | <i>trientine hcl</i> | 78 | VALCHLOR | 69 |
| TIADYLT ER | 42 | TRI-ESTARYLLA | 90 | <i>valganciclovir hcl</i> | 108 |
| <i>tiagabine hcl</i> | 61 | <i>trifluoperazine hcl</i> | 61 | <i>valproic acid</i> | 62 |
| TIBSOVO..... | 31 | <i>trifluridine</i> | 108 | <i>valsartan</i> | 43 |
| TICOVAC | 96 | <i>trihexyphenidyl hcl</i> | 62 | <i>valsartan-hydrochlorothiazide</i> | |
| <i>tigecycline</i> | 107 | TRIJARDY XR | 78 | | 43 |
| TIGLUTIK | 61 | TRIKAFTA | 117 | VALTOCO 10 MG DOSE | 62 |
| <i>timolol maleate</i> | 42, 112 | TRI-LINYAH..... | 90 | VALTOCO 15 MG DOSE | 62 |
| <i>timolol maleate (once-daily)</i> | 112 | TRI-LO-ESTARYLLA | 90 | VALTOCO 20 MG DOSE | 62 |
| <i>tinidazole</i> | 107 | TRI-LO-MARZIA..... | 90 | VALTOCO 5 MG DOSE | 62 |
| TIVICAY | 107 | TRI-LO-MILI..... | 90 | <i>vancomycin hcl</i> | 108 |
| TIVICAY PD | 107 | TRI-LO-SPRINTEC..... | 90 | VANDAZOLE | 83 |
| <i>tizanidine hcl</i> | 61 | <i>trimethoprim</i> | 108 | VANFLYTA..... | 31 |
| TOBRADEX | 112 | TRI-MILI..... | 90 | VAQTA | 96 |
| TOBRADEX ST | 112 | <i>trimipramine maleate</i> | 62 | <i>varenicline tartrate</i> | 62 |
| <i>tobramycin</i> | 112, 117 | TRINTELLIX..... | 62 | <i>varenicline tartrate (starter)</i> .. | 62 |
| <i>tobramycin sulfate</i> | 108 | TRI-NYMYO | 90 | <i>varenicline tartrate(continue)</i> .. | 62 |
| <i>tobramycin-dexamethasone</i> .. | 112 | TRI-SPRINTEC | 90 | VARIVAX..... | 96 |
| TOBREX..... | 112 | TRIUMEQ..... | 108 | VARIZIG..... | 96 |
| <i>tolcapone</i> | 61 | TRIUMEQ PD..... | 108 | VARUBI (180 MG DOSE) | 81 |
| <i>tolmetin sodium</i> | 24 | TRI-VYLIBRA | 90 | VASCEPA | 43 |
| <i>tolterodine tartrate er</i> | 83 | TRI-VYLIBRA LO | 90 | VAXCHORA | 96 |
| <i>tolvaptan</i> | 77 | TRIZIVIR..... | 108 | VELPHORO..... | 78 |
| <i>topiramate</i> | 61 | TRODELVY | 31 | VELTASSA..... | 78 |
| <i>toremifene citrate</i> | 31 | TROPHAMINE..... | 71 | VENCLEXTA | 32 |
| <i>torseimide</i> | 42 | TRULICITY | 78 | VENCLEXTA STARTING | |
| TOUJEO MAX SOLOSTAR..... | 77 | TRUMENBA..... | 96 | PACK | 32 |
| TOUJEO SOLOSTAR..... | 77 | TRUQAP..... | 31 | <i>venlafaxine besylate er</i> | 62 |
| TPN ELECTROLYTES..... | 71 | TRUSELTIQ (100MG DAILY | | <i>venlafaxine hcl</i> | 62 |
| TRADJENTA..... | 77 | DOSE)..... | 31 | <i>venlafaxine hcl er</i> | 62, 63 |
| <i>tramadol hcl</i> | 24 | TRUSELTIQ (125MG DAILY | | <i>verapamil hcl</i> | 43 |
| <i>tramadol hcl (er biphasic)</i> | 24 | DOSE)..... | 31 | <i>verapamil hcl er</i> | 43 |
| <i>tramadol hcl er</i> | 24 | TRUSELTIQ (50MG DAILY | | VERQUOVO..... | 43 |
| <i>tramadol-acetaminophen</i> | 24 | DOSE)..... | 31 | VERSACLOZ..... | 63 |
| <i>trandolapril</i> | 43 | TRUSELTIQ (75MG DAILY | | VERZENIO | 32 |
| <i>trandolapril-verapamil hcl er</i> | 43 | DOSE)..... | 31 | <i>vigabatrin</i> | 63 |
| <i>tranexamic acid</i> | 35 | TUKYSA..... | 31 | VIGADRONE | 63 |
| <i>tranylcypromine sulfate</i> | 61 | TURALIO | 31 | VIGPODER | 63 |
| TRAVASOL..... | 71 | TURQOZ..... | 90 | <i>vilazodone hcl</i> | 63 |
| <i>travoprost (bak free)</i> | 112 | TWINRIX..... | 96 | <i>viorele</i> | 90 |
| <i>trazodone hcl</i> | 61 | TYBOST | 108 | VIRACEPT..... | 108 |
| TRECTOR..... | 108 | TYMLOS..... | 78 | VIREAD | 108 |
| TRELEGY ELLIPTA | 117 | TYPHIM VI | 96 | <i>vitamin d (ergocalciferol)</i> | 78 |
| TRELSTAR MIXJECT..... | 31 | U | | VITRAKVI..... | 32 |
| TRESIBA | 77 | UBRELVY | 62 | VIZIMPRO..... | 32 |
| TRESIBA FLEXTOUCH | 78 | UDENYCA | 35 | VOLNEA..... | 90 |
| <i>tretinoin</i> | 31, 69 | UNITHROID..... | 90 | VONJO..... | 32 |

| | |
|---------------------------|----------|
| <i>voriconazole</i> | 108, 109 |
| VOWST | 81 |
| VRAYLAR | 63 |
| VYLIBRA | 90 |
| VYZULTA | 112 |

W

| | |
|------------------------------|-----|
| <i>warfarin sodium</i> | 35 |
| WELIREG | 32 |
| <i>wixela inhub</i> | 117 |
| WYMZYA FE | 90 |

X

| | |
|-------------------------------------|--------|
| XALKORI | 32 |
| XARELTO | 35, 36 |
| XARELTO STARTER PACK | 36 |
| XATMEP | 96 |
| XCOPRI | 63 |
| XCOPRI (250 MG DAILY DOSE) | 63 |
| XCOPRI (350 MG DAILY DOSE) | 63 |
| XDEMVEY | 112 |
| XERMELO | 81 |
| XGEVA | 78 |
| XIFAXAN | 109 |

| | |
|--------------------------------------|--------|
| XIGDUO XR | 78 |
| XIIDRA | 112 |
| XOLAIR | 117 |
| XOSPATA | 32 |
| XPOVIO (100 MG ONCE WEEKLY) | 32 |
| XPOVIO (40 MG ONCE WEEKLY) | 32 |
| XPOVIO (40 MG TWICE WEEKLY) | 32 |
| XPOVIO (60 MG ONCE WEEKLY) | 32 |
| XPOVIO (60 MG TWICE WEEKLY) | 32 |
| XPOVIO (80 MG ONCE WEEKLY) | 32 |
| XPOVIO (80 MG TWICE WEEKLY) | 32 |
| XTANDI | 32, 33 |
| XURIDEN | 82 |

Y

| | |
|----------------------|----|
| YARGESA | 82 |
| YF-VAX | 96 |
| <i>yuvafem</i> | 90 |

Z

| | |
|-----------------------------------|-----|
| <i>zafirlukast</i> | 117 |
| <i>zaleplon</i> | 63 |
| ZARXIO | 36 |
| ZEJULA | 33 |
| ZELBORAF | 33 |
| ZENATANE | 69 |
| ZENPEP | 82 |
| ZENZEDI | 63 |
| ZEPZELCA | 33 |
| <i>zidovudine</i> | 109 |
| <i>ziprasidone hcl</i> | 63 |
| <i>ziprasidone mesylate</i> | 63 |
| ZIRGAN | 109 |
| ZOLINZA | 33 |
| <i>zolpidem tartrate</i> | 63 |
| <i>zolpidem tartrate er</i> | 63 |
| ZONISADE | 64 |
| <i>zonisamide</i> | 64 |
| ZTALMY | 64 |
| ZURZUVAE | 64 |
| ZYDELIG | 33 |
| ZYKADIA | 33 |
| ZYLET | 112 |
| ZYPREXA RELPREVV | 64 |



1-877-336-2069 / TTY: 711 | Fax: 305-448-5783

11430 NW 20th Street, Suite 300, Miami, FL 33172

HealthSun.com

MedicareRx
Prescription Drug Coverage

PLEASE READ: THIS DOCUMENT CONTAINS INFORMATION ABOUT THE DRUGS WE COVER IN THIS PLAN. TANPRI LI: DOKIMAN SA A GENYEN ENFÒMASYON SOU MEDIKAMAN NOU KOUVRI NAN PLAN SA A.

HPMS Approved Formulary ID 25102, Version 10

This formulary was updated on 9/23/2024. For more recent information or other questions, please contact our HealthSun Health Plans Member Services at 1-877-336-2069 / TTY: 711, Monday through Friday from 8 a.m. to 8 p.m. (EST), or visit www.healthsun.com. From October 1 through March 31, we are open seven days a week from 8 a.m. to 8 p.m. (our office will be closed on Thanksgiving and Christmas Day). From April 1 through September 30, we are available Monday through Friday from 8 a.m. to 8 p.m. (our office will be closed on federal holidays). Fòmilè sa a te fè mizajou nan dat 9/23/2024. Pou enfòmasyon ki pi resan oswa lòt kesyon, tanpri kontakte Sèvis Manm HealthSun Health Plans nou an nan 1-877-336-2069 / TTY: 711, Lendi jiska Vandredi soti 8 am jiska 8 pm (LÈS), oswa vizite www.healthsun.com. Soti 1ye oktòb jiska 31 mas, nou ouvri sèt jou pa semèn soti 8 am jiska 8 pm (biwo nou an ap fèmen jou Aksyon de Gras ak Jou Nwèl). Soti 1ye avril jiska 30 septanm, nou disponib Lendi jiska Vandredi de 8 am jiska 8 pm (biwo nou an ap fèmen nan jou ferye federal yo).